|
Phase II
Jerusalem, Israel
CDX-1307 Celldex Therapeutics first-line bladder cancer Phase II
Needham, MA (781) 433-0771
chemophase™ Halozyme Therapeutics superficial bladder cancer Phase I/II completed
hyaluronidase San Diego, CA (858) 794-8889
EN3348 Endo Pharmaceuticals (Fast Track) Phase III
Chadds Ford, PA (610) 558-9800
erbitux® Bristol-Myers Squibb (see also breast, head/neck, lung) Phase II
cetuximab Princeton, NJ (212) 546-4000
Eli Lilly (800) 545-5979
Indianapolis, IN (212) 645-1405
ImClone Systems
New York, NY
eribulin (E7389) Eisai (see also lung, prostate, sarcoma) Phase II
Woodcliff Lake, NJ (888) 422-4743
folotyn® Allos Therapeutics (see also breast, lung, lymphoma) Phase II
pralatrexate Westminster, CO (303) 426-6262
(orphan drug)
OGX-427 Oncogenex (see also breast, lung, ovarian, Phase I
Pharmaceuticals prostate) (425) 686-1500
Bothell, WA
tarceva® Genentech (see also brain, breast, colorectal, Phase II
erlotinib South San Francisco, CA head/neck, leukemia, liver, lung, (650) 224-1000
OSI Pharmaceuticals other) (800) 572-1932
Melville, NY
tesetaxel Genta advanced bladder cancer Phase II
Berkeley Heights, NJ (see also breast, prostate, skin, (908) 286-9800
stomach)
VB4-845 Viventia Biotechnologies (see also head/neck) Phase II
Mississauga, Canada (905) 362-2973
* For more information about a specific medicine in this report, please call the telephone number listed.
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 3
B r a i n c a n c e r
product name sponsor indication development status
8H9 mAb United Therapeutics (see also sarcoma, other) Phase I
Silver Spring, MD (301) 608-9292
ABT-888 Abbott Laboratories (see also breast, colorectal, Phase I
(veliparib) Abbott Park, IL ovarian, prostate, skin, other) (847) 937-6100
AC480 Ambit Biosciences glioma Phase I
San Diego, CA (see also solid tumors) (858) 334-2100
AEE788 Novartis Pharmaceuticals glioblastoma multiforme Phase I/II
East Hanover, NJ (888) 669-6682
antineoplaston- Burzynski Research glioma Phase II
AS2-1 IV Institute (713) 335-5697
(orphan drug) Houston, TX
APN301 Apeiron Biologics neuroblastoma Phase II completed
(hu14.18-IL2) Vienna, Austria (see also skin)
AR-67 Arno Therapeutics glioblastoma Phase I
Parsippany, NJ (see also other) (862) 703-7170
ARC-100 Archer Biosciences glioblastoma, medulloblastoma, Phase II
New York, NY neuroblastoma (616) 747-9090
(see also pancreatic, prostate, skin)
AT-101 Ascenta Therapeutics gliobastoma Phase II
Malvern, PA (see also leukemia, lung, lymphoma, (610) 408-0313
prostate, stomach)
AV-299 AVEO Pharmaceuticals recurrent gliobastoma Phase I
(ficlatuzumab) Cambridge, MA (see also lymphoma, multiple (617) 299-5000
myeloma, solid tumors)
avastin® Genentech first-line glioblastoma multiforme Phase III
bevacizumab South San Francisco, CA (see also breast, colorectal, lung, (650) 225-1000
ovarian, other)
azedra™ Molecular Insight neuroblastoma in children Phase II completed
iodine-labeled Pharmaceuticals (Fast Track) (617) 492-5554
metaiodobenzyl- Cambridge, MA (see also other)
guanidine
azixa™ Myrexis glioblastoma, metastatic brain cancer Phase II
verubulin Salt Lake City, UT (Fast Track) (801) 214-7800
(see also skin)
berubicin Reata Pharmaceuticals brain metastases, recurrent primary Phase II
(orphan drug) Dallas, TX brain cancer (972) 865-2200
--------------------------------------------------------------------------------------
glioma Phase I
(972) 865-2200
BIBW 2992 Boehringer Ingelheim glioblastoma Phase I/II
(afatinib) Pharmaceuticals (see also breast, head/neck, lung) (800) 243-0127
Ridgefield, CT
BMS-844203 Bristol-Myers Squibb recurrent glioblastoma Phase II
(VEGF R-2 Princeton, NJ (see also colorectal, lung) (212) 546-4000
adnectin)
--------------------------------------------------------------------------------------
newly-diagnosed glioblastoma Phase I
(212) 546-4000
4 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
B r a i n c a n c e r
product name sponsor indication development status
ch14.18 mAb United Therapeutics neuroblastoma in children Phase III
Silver Spring, MD (301) 608-9292
cilengitide EMD Serono newly diagnosed glioblastoma Phase III
(orphan drug) Rockland, MA (see also lymphoma, prostate) (800) 283-8088
--------------------------------------------------------------------------------------
recurrent glioblastoma Phase II
(800) 283-8088
cintredekin NeoPharm glioma (Fast Track) Phase I
besudotox Lake Bluff, IL (847) 887-0800
(orphan drug)
cotara® Peregrine Pharmaceuticals recurrent glioblastoma Phase II
mAb TNT-1 Tustin, CA (Fast Track) (714) 508-6000
(orphan drug)
CPP-1X Cancer Prevention neuroblastoma Phase I
(eflornithine) Pharmaceuticals (520) 908-7774
Tucson, AZ
dcvax®-Brain® Northwest Biotherapeutics glioblastoma Phase II
brain cancer Bothell, WA (425) 608-3000
vaccine
(orphan drug)
dendritic cell TriMed Biotech glioblastoma Phase II
cancer vaccine Vienna, Austria
Gliatak™ Advantagene Phase I/II
gene therapy Auburndale, MA (617) 916-5445
(orphan drug)
GRN 1005 Geron glioma, metastatic brain cancer Phase I/II
Menlo Park, CA (650) 473-7700
Hiltonol® Oncovir anaplastic astrocytoma, glioblastoma Phase II
poly-ICIC Washington, DC in adolescents and children
(orphan drug)
Hycamtin® GlaxoSmithKline metastatic brain cancer Phase III
topotecan Rsch. Triangle Park, NC (888) 825-5249
ICT-107 ImmunoCellular glioblastoma Phase II
(cancer vaccine) Therapeutics (818) 992-2907
(orphan drug) Woodland Hills, CA
lenvatinib Eisai glioma Phase II
(E7080) Woodcliff Lake, NJ (see also kidney, liver, ovarian, (888) 422-4743
skin, other)
levulan® Kerastick® DUSA Pharmaceuticals (see also skin) Phase II
aminolevulinic acid Wilmington, MA (978) 657-7500
lucanix® NovaRx glioma Phase I
belagenpumatucel-L San Diego, CA (see also lung) (858) 552-8600
motexafin Pharmacyclics glioblastoma (combination therapy) Phase II
gadolinium Sunnyvale, CA (408) 774-0330
nimotuzumab YM Biosciences USA brain metastates from non-small-cell Phase II
(orphan drug) Lehigh Valley, PA lung cancer (NSCLC), recurrent glioma (610) 560-0600
(see also breast, prostate)
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 5
B r a i n c a n c e r
product name sponsor indication development status
patupilone Novartis Pharmaceuticals (see also liver) Phase II
(EPO906) East Hanover, NJ (888) 669-6682
PD-0332991 Pfizer recurrent Rb-positive glioblastoma Phase II
New York, NY (see also breast, lymphoma, (860) 732-5156
multiple myeloma, sarcoma)
perifosine AEterna Zentaris glioma Phase II
(KRX-0401) Montreal, Canada (see also colorectal, kidney, leukemia, (212) 531-5965
Keryx Biopharmaceuticals lymphoma, multiple myeloma,
New York, NY ovarian, sarcoma, stomach)
prophage Agenus glioma Phase II
(vitespen) Lexington, MA (see also kidney, skin) (781) 674-4400
(orphan drug)
reolysin® Oncolytics Biotech glioma Phase I/II
reovirus Calgary, Canada (see also colorectal, head/neck, (403) 670-7377
lung, pancreatic, sarcoma, skin)
rilotumumab Amgen recurrent glioma Phase II
Thousand Oaks, CA (see also colorectal, lung, prostate, (800) 772-6436
stomach)
rindopepimut Celldex Therapeutics newly diagnosed glioblastoma Phase II
(orphan drug) Needham, MA (Fast Track) (860) 732-5156
(see also solid tumors)
sagopilone Bayer HealthCare (see also breast, ovarian, prostate) Phase II
Pharmaceuticals (888) 842-2937
Wayne, NJ
SB-313-xTZ Sangamo Biosciences glioblastoma Phase I
Richmond, CA (510) 970-6000
SBG and Biotec Pharmacon neuroblastoma (pediatric) Phase I/II
cancer vaccine Tromsø, Norway
SL-701 Stemline Therapeutics Phase I/II completed
vaccine New York, NY (212) 831-1111
sprycel® Bristol-Myers Squibb glioblastoma Phase I/II
dasatinib Princeton, NJ (see also breast, colorectal, leukemia, (212) 546-4000
lung, lymphoma, multiple myeloma,
prostate, skin)
tandutinib Millennium Pharmaceuticals glioblastoma, glioma Phase II
(MLN518) Cambridge, MA (800) 390-5663
tarceva® Genentech ependymoma, glioblastoma, late-stage Phase II
erlotinib South San Francisco, CA brain metastases (650) 225-1000
(orphan drug) OSI Pharmaceuticals (see also bladder, breast, colorectal, (800) 572-1932
Melville, NY head/neck, leukemia, liver, lung,
other)
terameprocol Erimos Pharmaceuticals glioma Phase I/II
(intravenous) Houston, TX (see also cervical, head/neck, (713) 541-2000
solid tumors, other)
Toca-511 Tocagen glioblastoma Phase I/II
(cytosine deaminase San Diego, CA (858) 412-8400
gene therapy)
6 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
B r a i n c a n c e r
product name sponsor indication development status
trisenox® Cephalon glioma Phase I
arsenic trioxide Frazer, PA (see also leukemia, multiple myeloma) (610) 344-0200
VB-111 VBL Therapeutics glioblastoma Phase I/II
Or Yehuda, Israel (see also other)
Xeloda® Roche newly-diagnosed glioma Phase I
capecitabine Nutley, NJ (973) 235-5000
B r e a s t c a n c e r
product name sponsor indication development status
18F-fluorothymidine Merck diagnosis of breast cancer Phase II
Whitehouse Station, NJ (800) 672-6372
abiraterone acetate Cougar Biotechnology (see also prostate) Phase I/II
(CB7630) Raritan, NJ (800) 817-5286
ABT-869 Abbott Laboratories (see also colorectal, kidney, Phase II
(linifarib) Abbott Park, IL liver, lung) (847) 937-6100
ABT-888 Abbott Laboratories (see also brain, colorectal, ovarian, Phase II
(veliparib) Abbott Park, IL prostate, skin, other) (847) 937-6100
acolbifene EndoCeutics prevention of breast cancer Phase II
Quebec City, Canada (418) 653-0033
aderbasib Incyte Phase II
(INCB7839) Wilmington, DE (302) 498-6700
AE-37 Antigen Express (see also ovarian) Phase II
Worcester, MA (508) 852-8783
afimoxifene ASCEND Therapeutics breast cancer prevention Phase II
Herndon, VA (703) 471-4744
afinitor® Novartis Pharmaceuticals (see also kidney, liver, lymphoma, Phase III
everolimus East Hanover, NJ stomach, other) (888) 669-6682
AMG 386 Amgen (see also colorectal, kidney, liver, Phase II
Thousand Oaks, CA ovarian, stomach, other) (800) 772-6436
AMG 479 Amgen (see also colorectal, lung, Phase II
(ganitumab) Thousand Oaks, CA pancreatic, sarcoma, other) (800) 772-6436
anti-CD3 TransTarget metastatic breast cancer Phase II
anti-HER/neu Hillsborough, CA
activated T-cells
ARRY-380 Array BioPharma Phase I
Boulder, CO (303) 381-6600
AUY922 Novartis Pharmaceuticals (see also colorectal, lung, Phase II
East Hanover, NJ multiple myeloma, stomach) (888) 669-6682
AV-951 AVEO Pharmaceuticals (see also kidney, lung, stomach) Phase I/II
(tivozanib) Cambridge, MA (617) 299-5000
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 7
B r e a s t c a n c e r
product name sponsor indication development status
avastin® Genentech first-line metastatic breast cancer Phase III
bevacizumab South San Francisco, CA (with Xeloda®) (650) 225-1000
(see also brain, colorectal,
lung, other)
--------------------------------------------------------------------------------------
HER2-positive breast cancer Phase III
(adjuvant therapy), (650) 225-1000
triple-negative breast cancer
(adjuvant therapy),
HER2-negative breast cancer
(adjuvant therapy)
--------------------------------------------------------------------------------------
first-line HER2-positive metastatic Phase III
breast cancer (650) 225-1000
(with Herceptin®)
AZD8931 AstraZeneca breast cancer Phase II
(erbB kinase Wilmington, DE (see also solid tumors) (800) 236-9933
inhibitor)
BIBW 2992 Boehringer Ingelheim metastatic breast cancer Phase III
(afatinib) Pharmaceuticals (see also brain, head/neck, lung) (800) 243-0127
Ridgefield, CT
BKM120 Novartis Pharmaceuticals (see also solid tumors) Phase I/II
East Hanover, NJ (888) 669-6682
BMS-690514 Bristol-Myers Squibb metastatic breast cancer Phase II
(HER/VEGFR2 Princeton, NJ (see also lung) (212) 546-4000
inhibitor)
BMS-754807 Bristol-Myers Squibb (see also solid tumors) Phase II
(IGF-1R antagonist) Princeton, NJ (212) 546-4000
breast cancer Quantum Immunologics Phase I/II
vaccine Tampa, FL (866) 213-4594
BTSCAN Molecular Targeting diagnosis of breast cancer Phase I
Technologies (610) 738-7938
West Chester, PA
BZL-101 Bionovo Phase I
Emeryville, CA (510) 601-2000
CDX-011 Celldex Therapeutics (Fast Track) Phase II
Needham, MA (see also skin) (781) 433-0771
CNF-2024 Biogen Idec (see also stomach) Phase II
Weston, MA (781) 464-2000
dalotuzumab Merck (see also colorectal, lung, Phase I/II
Whitehouse Station, NJ pancreatic, other) (800) 672-6372
dinaciclib Merck (see also leukemia, lung, lymphoma) Phase II
Whitehouse Station, NJ (800) 672-6372
DPX-0907 Immunovaccine (see also ovarian, prostate) Phase I
Halifax, Canada (902) 492-1819
8 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
B r e a s t c a n c e r
product name sponsor indication development status
erbitux® Bristol-Myers Squibb (see also bladder, head/neck, lung) Phase II
cetuximab Princeton, NJ (212) 546-4000
Eli Lilly (800) 545-5979
Indianapolis, IN (212) 645-1405
ImClone Systems
New York, NY
EVO 022 Evolve Oncology in clinical trials
New York, NY (646) 723-8941
EVO 033 Evolve Oncology in clinical trials
New York, NY (646) 723-8941
exelbine™ ADVENTRX (see also lung, lymphoma) application submitted
vinorelbine Pharmaceuticals (858) 552-0866
emulsion San Diego, CA
EZN-2208 Enzon Pharmaceuticals metastatic breast cancer Phase II
Bridgewater, NJ (see also colorectal, solid tumors) (908) 541-8600
folotyn® Allos Therapeutics (see also bladder, lung, lymphoma) Phase II
pralatrexate Westminster, CO (303) 426-6262
ganetespib Synta Pharmaceuticals (see also colorectal, lung, Phase II
Lexington, MA stomach, other) (781) 274-8200
GDC-0941 Genentech metastatic breast cancer Phase I
(PI3 kinase South San Francisco, CA (see also lung, lymphoma, solid (650) 224-1000
inhibitor) tumors)
GDC-0980 Genentech late-stage breast cancer Phase I
(PI3 kinase/mTOR South San Francisco, CA (see also lymphoma, solid tumors) (650) 224-1000
dual inhibitor)
GRN-163L Geron (see also leukemia, lung, Phase II
(imetelstat) Menlo Park, CA multiple myeloma) (650) 473-7700
GvaX® Breast BioSante Pharmaceuticals (see also colorectal, leukemia, Phase I
Lincolnshire, IL multiple myeloma, pancreatic) (847) 478-0500
Herceptin® sc Halozyme HER2-positive breast cancer Phase III
rHuPH20/ San Diego, CA (858) 794-8889
trastuzumab Roche (973) 235-5000
Nutley, NJ
IMT-1012 Immunotope (see also ovarian) Phase I
(immunotherapeutic Doylestown, PA (215) 253-4180
vaccine)
iniparib BiPar Sciences metastatic triple negative Phase III
(BSI-201) South San Francisco, CA breast cancer (800) 633-1810
sanofi-aventis (see also lung, ovarian)
Bridgewater, NJ
--------------------------------------------------------------------------------------
neoadjuvant breast cancer Phase II
(800) 633-1810
ixempra® Bristol-Myers Squibb early-stage breast cancer Phase II/III
ixabepilone Princeton, NJ (see also lung, stomach, other) (212) 546-4000
KW-2450 Kyowa Hakko Kirin Pharma Phase I/II
Princeton, NJ (609) 919-1100
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 9
B r e a s t c a n c e r
product name sponsor indication development status
LEP-ETU NeoPharm Phase II
Lake Bluff, IL (847) 887-0800
LOR-2040 Lorus Therapeutics metastatic breast cancer Phase II
Toronto, Canada (see also colorectal, kidney, (416) 798-1200
leukemia)
lymphoseek™ Neoprobe diagnosis of breast cancer Phase III
Dublin, OH (see also head/neck, skin) (800) 793-0079
MK-0752 Merck (see also solid tumors) Phase I
Whitehouse Station, NJ (800) 672-6372
MK-2206 Merck (see also colorectal, other) Phase I
Whitehouse Station, NJ (800) 672-6372
MM-111 Merrimack Pharmaceuticals (see also solid tumors) Phase I/II
Cambridge, MA (617) 441-1000
motesanib Amgen (see also lung) Phase II
(AMG 708) Thousand Oaks, CA (800) 772-6436
Millennium Pharmaceuticals (800) 390-5663
Cambridge, MA
Myocet™ Spherion Therapeutics (Fast Track) Phase III
doxorubicin Princeton, NJ (609) 986-2021
liposomal
neratinib Pfizer early-stage breast cancer, Phase III
(HKI272) New York, NY late-stage breast cancer (860) 732-5156
neuvax™ Apthera (see also prostate) Phase II
E75 cancer Scottsdale, AZ
vaccine
nexavar® Bayer HealthCare (see also colorectal, kidney, liver, Phase II
sorafenib Pharmaceuticals lung, ovarian, other) (888) 842-2937
Wayne, NJ (510) 597-6500
Onyx Pharmaceuticals
Emeryville, CA
nimotuzumab YM Biosciences USA (see also brain, prostate) Phase I completed
Lehigh Valley, PA (610) 560-0600
NK-012 Nippon Kayaku (see also lung) Phase II
Tokyo, Japan
NKTR-102 Nektar Therapeutics (see also colorectal, ovarian) Phase II
San Francisco, CA (415) 482-5300
NOV-002 Novelos Therapeutics early-stage breast cancer Phase II
Newton, MA (see also ovarian) (617) 244-1616
OBP-301 Oncolys Biopharma (see also head/neck, lung) Phase I
Tokyo, Japan
OGX-427 Oncogenex (see also bladder, lung, ovarian, Phase I
Pharmaceuticals prostate) (425) 686-1500
Bothell, WA
OPT-822/OPT-821 Optimer Pharmaceuticals Phase I
San Diego, CA (858) 909-0736
10 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
B r e a s t c a n c e r
product name sponsor indication development status
PD-0332991 Pfizer (see also brain, lymphoma, Phase I/II
New York, NY multiple myeloma, sarcoma) (860) 732-5156
pertuzumab Roche first-line metastatic HER2-positive Phase III
(RG 1273) Nutley, NJ breast cancer (973) 235-5000
--------------------------------------------------------------------------------------
early HER2-positive breast cancer, Phase II
metastatic breast cancer (973) 235-5000
PF-01367338 Pfizer (see also ovarian, skin) Phase II
New York, NY (860) 732-5156
pixuvri™ Cell Therapeutics metastatic breast cancer Phase II
pixantrone Seattle, WA (see also lymphoma) (800) 215-2355
PTC299 PTC Therapeutics (see also skin, solid tumors, other) Phase I/II
South Plainfield, NJ (908) 222-7000
PX-1032 BN ImmunoTherapeutics Phase I
(HER2 breast Mountain View, CA (650) 681-4660
cancer vaccine)
Quinamed® ChemGenex (see also ovarian, prostate) Phase II
amonafide Pharmaceuticals (650) 474-9800
Menlo Park, CA
ramucirumab Eli Lilly (see also colorectal, liver, lung, Phase III
(IMC-1121B) Indianapolis, IN stomach) (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
reximmune-c™ Epeius Biotechnologies Phase I/II
personalized San Marino, CA (626) 441-6695
cancer vaccine
rexin-G™ Epeius Biotechnologies recurrent, refractory metastatic Phase I/II
tumor-targeted San Marino, CA breast cancer (626) 441-6695
gene therapy (see also pancreatic, sarcoma)
ridaforolimus Merck (see also lung, sarcoma) Phase II
Whitehouse Station, NJ (800) 672-6372
sagopilone Bayer HealthCare (see also brain, ovarian, prostate) Phase II completed
Pharmaceuticals (888) 842-2937
Wayne, NJ
SAR256212 Merrimack Pharmaceuticals (see also ovarian, solid tumors) Phase II
(MM-121) Cambridge, MA (617) 441-1000
sanofi-aventis (800) 633-1810
Bridgewater, NJ
SF1 SonneMed advanced breast cancer Phase I/II
(sonodynamic Boston, MA
therapy)
SNDX-275 Syndax Pharmaceuticals (see also colorectal, leukemia, Phase II
(entinostat) Waltham, MA lymphoma, lung) (781) 419-1400
sprycel® Bristol-Myers Squibb (see also brain, colorectal, leukemia, Phase II
dasatinib Princeton, NJ lung, lymphoma, multiple myeloma, (212) 546-4000
prostate, skin)
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 11
B r e a s t c a n c e r
product name sponsor indication development status
tarceva® Genentech (see also bladder, brain, colorectal, Phase II
erlotinib South San Francisco, CA head/neck, leukemia, liver, (650) 224-1000
OSI Pharmaceuticals lung, other) (800) 572-1932
Melville, NY
TAS-108 Taiho Pharma USA Phase II
Princeton, NJ (609) 750-5300
tesetaxel Genta advanced breast cancer Phase II
Berkeley Heights, NJ (see also bladder, prostate, skin, (908) 286-9800
stomach)
thermodox® Celsion recurrent breast cancer Phase I/II
LTSDEL Columbia, MD (see also liver) (410) 290-5390
trabectedin Johnson & Johnson metastatic breast cancer Phase III
Pharmaceutical Research (see also ovarian, prostate, (800) 817-5286
& Development sarcoma)
Raritan, NJ
trastuzumab-DM1 Roche advanced metastatic HER2-positive Phase III
Nutley, NJ breast cancer, metastatic HER2- (973) 235-5000
positive breast cancer
--------------------------------------------------------------------------------------
early HER2-positive breast cancer Phase II
(973) 235-5000
tykerb® GlaxoSmithKline breast cancer (adjuvant therapy) Phase III
lapatinib Rsch. Triangle Park, NC (see also head/neck, stomach) (888) 825-5249
votrient® GlaxoSmithKline inflammatory breast cancer Phase III
pazopanib and Rsch. Triangle Park, NC (see also kidney, ovarian, sarcoma) (888) 825-5249
tykerb®
lapatinib
WX-671 Wilex metastatic breast cancer Phase II
Munich, Germany
YM-155 Astellas Pharma US (see also lymphoma) Phase II
Deerfield, IL (800) 727-7003
ZIO-301 ZIOPHARM Oncology late-stage breast cancer Phase I/II
(indibulin) New York, NY (646) 214-0700
Zolinza® Merck (see also multiple myeloma, other) Phase II
vorinostat Whitehouse Station, NJ (800) 672-6372
c e r v i c a l c a n c e r
product name sponsor indication development status
ADXS-11001 Advaxis cervical intraepithelial neoplasia Phase II
North Brunswick, NJ (732) 545-1590
interferon alpha-2b Helix BioPharma cervical dysplasia Phase II completed
topical Aurora, Canada (905) 841-2300
PM-00104 PharmaMar USA (see also other) Phase II
Cambridge, MA (617) 868-3797
12 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
c e r v i c a l c a n c e r
product name sponsor indication development status
PV701 Wellstat Biologics (see also colorectal) Phase II
Gaithersburg, MD (240) 631-2500
terameprocol Erimos Pharmaceuticals cervical intraepithelial neoplasia Phase II
(intravaginal) Houston, TX (see also brain, head/neck, solid tumors, (713) 541-2000
other)
TG4001 Transgene cervical intraepithelial neoplasia Phase II
Kensington, MD (301) 816-5404
V503 Merck cervical cancer prevention Phase III
Whitehouse Station, NJ (see also other) (800) 672-6372
V505 Merck cervical cancer prevention Phase II
Whitehouse Station, NJ (800) 672-6372
VGX-3100 Inovio Pharmaceuticals cervical intraepithelial neoplasia Phase II
Blue Bell, PA (267) 440-4200
c o l o r e c t a l c a n c e r
product name sponsor indication development status
ABT-869 Abbott Laboratories (see also breast, kidney, liver, Phase II
(linifanib) Abbott Park, IL lung) (847) 937-6100
ABT-888 Abbott Laboratories (see also brain, breast, Phase II
(veliparib) Abbott Park, IL ovarian, prostate, skin, other) (847) 937-6100
aflibercept sanofi-aventis second-line metastatic colorectal Phase III
(VEGF-trap) Bridgewater, NJ cancer (800) 633-1610
Regeneron Pharmaceuticals (see also lung, prostate) (914) 345-7400
Tarrytown, NY
--------------------------------------------------------------------------------------
first-line colorectal cancer Phase II
(800) 633-1610
(914) 345-7400
AMG 386 Amgen metastatic colorectal cancer Phase II
Thousand Oaks, CA (see also breast, kidney, liver, (800) 772-6436
ovarian, stomach, other)
AMG 479 Amgen (see also breast, lung, pancreatic, Phase II
(ganitumab) Thousand Oaks, CA sarcoma, other) (800) 772-6436
ARQ-197 ArQule (see also kidney, liver, lung, Phase II
Woburn, MA pancreatic, sarcoma, other) (781) 994-0300
Daiichi Sankyo (973) 944-2600
Parsippany, NJ
AUY922 Novartis Pharmaceuticals (see also breast, lung, multiple Phase I
East Hanover, NJ myeloma, stomach) (888) 669-6682
avastin® Genentech metastatic colorectal cancer Phase III
bevacizumab South San Francisco, CA (see also brain, lung, ovarian, other) (650) 225-1000
AVX701 AlphaVax colorectal cancer prevention in Phase I/II
Rsch. Triangle Park, NC patients with CEA-expressing (919) 595-0400
malignancies
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 13
c o l o r e c t a l c a n c e r
product name sponsor indication development status
BAY 73-4506 Bayer HealthCare metastatic colorectal cancer Phase III
(regorafenib) Pharmaceuticals (see also kidney, lung, stomach) (888) 842-2937
Wayne, NJ
BMS-844203 Bristol-Myers Squibb (see also brain, lung) Phase II
(VEGF R-2 Princeton, NJ (212) 546-4000
adnectin)
BMS-908662 Bristol-Myers Squibb (see also skin) Phase I/II
(RAF kinase Princeton, NJ (212) 546-4000
inhibitor) Exelixis
South San Francisco, CA
conatumumab Amgen (see also lung, pancreatic, sarcoma) Phase II
Thousand Oaks, CA (800) 772-6436
CPX-1 Celator Pharmaceuticals Phase II completed
Princeton, NJ (609) 243-0123
CS-7017 Daiichi Sankyo (see also lung, other) Phase II
(efatutazone) Parsippany, NJ (973) 944-2600
CT-011 CureTech (see also leukemia, lymphoma) Phase II
Yavne, Israel
dalotuzumab Merck (see also breast, lung, pancreatic, Phase II
Whitehouse Station, NJ other) (800) 672-6372
davanat® Pro-Pharmaceuticals (see also liver) Phase II
galactomannan C Newton, MA (617) 559-0033
dulanermin Amgen (see also lymphoma) Phase I
(rhApo2L/TRAIL) Thousand Oaks, CA (800) 772-6436
Genentech (650) 225-1000
South San Francisco, CA
E7820 Eisai Phase I/II
Woodcliff Lake, NJ (888) 422-4743
EMD 525797 EMD Serono Phase II
(DI17E6) Rockland, MA (800) 283-8088
encapsulated cell Rogosin Institute refractory metastatic colorectal Phase II
therapy New York, NY cancer (212) 746-1225
(macrobeads) (see also pancreatic, prostate)
ensituximab Neogenix Oncology metastatic colorectal cancer Phase I
Great Neck, NY (see also pancreatic) (516) 482-1200
EZN-2208 Enzon Pharmaceuticals metastatic colorectal cancer Phase II
Bridgewater, NJ (see also breast, solid tumors) (908) 541-8600
fusilev™ Spectrum Pharmaceuticals application submitted
levoleucovorin Irvine, CA (949) 788-6700
(ready-to-use
formulation)
ganetespib Synta Pharmaceuticals refractory metastatic colorectal cancer Phase II
Lexington, MA (see also breast, lung, stomach, (781) 274-8200
other)
GI-4000 GlobeImmune (see also lung, pancreatic) Phase I
Louisville, CO (303) 625-2700
14 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
c o l o r e c t a l c a n c e r
product name sponsor indication development status
GvaX® colorectal BioSante Pharmaceuticals (see also breast, leukemia, Phase I
Lincolnshire, IL multiple myeloma, pancreatic) (847) 478-0500
IMO-2055 EMD Serono (see also head/neck, lung) Phase I
(EMD-1201081) Rockland, MA (800) 283-8088
Idera Pharmaceuticals (617) 679-5500
Cambridge, MA
imprime pGG® Biothera (see also leukemia, lung, skin) Phase III
Eagen, MN (651) 675-0300
JX-594 Jennerex Biotherapeutics (see also liver) Phase II
San Francisco, CA (415) 281-8886
KRN-330 Kyowa Hakko Kirin Pharma Phase I/II
Princeton, NJ (609) 919-1100
litx™ Light Sciences Oncology metastatic colorectal cancer Phase III
talaporfin Bellevue, WA (425) 957-8900
LOR-2040 Lorus Therapeutics metastatic colorectal cancer Phase II
Toronto, Canada (see also breast, kidney, leukemia) (416) 798-1200
MK-2206 Merck (see also breast, other) Phase II
Whitehouse Station, NJ (800) 672-6372
nexavar® Bayer HealthCare (see also breast, kidney, liver, Phase II
sorafenib Pharmaceuticals lung, ovarian, other) (888) 842-2837
Wayne, NJ (510) 597-6500
Onyx Pharmaceuticals
Emeryville, CA
NKTR-102 Nektar Therapeutics (see also breast, ovarian) Phase II/III
San Francisco, CA (415) 482-5300
oncovaX® Vaccinogen stage II colorectal cancer Phase III
cancer vaccine Frederick, MD (Fast Track) (301) 668-8400
perifosine Aeterna Zentaris refractory, metastatic colorectal Phase III
(KRX-1401) Montreal, Canada cancer (Fast Track) (212) 531-5965
Keryx Biopharmaceuticals (see also brain, kidney, leukemia,
New York, NY lymphoma, multiple myeloma,
ovarian, sarcoma, stomach)
picoplatin Poniard Pharmaceuticals (see also lung, ovarian, prostate) Phase II
intravenous San Francisco, CA (650) 583-3774
polyclonal antibody Cancer Advances (see also pancreatic, stomach) Phase II
stimulator Durham, NC (919) 361-2162
PV701 Wellstat Biologics (see also cervical) Phase II
Gaithersburg, MD (240) 631-2500
ramucirumab Eli Lilly (see also breast, liver, lung, stomach) Phase III
(IMC-1121B) Indianapolis, IN (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
reolysin® Oncolytics Biotech (see also brain, head/neck, lung, Phase I
reovirus Calgary, Canada pancreatic, sarcoma, skin) (403) 670-7377
riGscan® cr49 Neoprobe diagnosis of metastatic colorectal application submitted
radiodiagnostic Dublin, OH cancer (800) 793-0079
agent
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 15
c o l o r e c t a l c a n c e r
product name sponsor indication development status
rilotumumab Amgen metastatic colorectal cancer Phase II
Thousand Oaks, CA (see also brain, lung, prostate, (800) 772-6436
stomach)
SNDX-275 Syndax Pharmaceuticals (see also breast, leukemia, Phase II
(entinostat) Waltham, MA lymphoma, lung) (781) 419-1400
sprycel® Bristol-Myers Squibb (see also brain, breast, leukemia, Phase I
dasatinib Princeton, NJ lung, lymphoma, multiple myeloma, (212) 546-4000
prostate, skin)
tarceva® Genentech (see also bladder, brain, breast, Phase II
erlotinib South San Francisco, CA head/neck, leukemia, liver, lung, (650) 224-1000
OSI Pharmaceuticals other) (800) 572-1932
Melville, NY
TAS-102 Taiho Pharma USA Phase II
Princeton, NJ (609) 750-5300
telatinib ACT Biotech (see also stomach) Phase I
San Francisco, CA (415) 230-3900
TF2 Immunomedics diagnosis of colorectal cancer Phase I
Morris Plains, NJ (973) 605-8200
tigatuzumab Daiichi Sankyo (see also liver, lymphoma, ovarian, Phase I
Parsippany, NJ pancreatic) (973) 359-2600
tnferade™ GenVec (see also head/neck, skin, stomach) Phase II
golnerminogene Gaithersburg, MD (877) 943-6832
pradenovec
vectibix® Amgen first-line colorectal cancer, Phase III
panitumumab Thousand Oaks, CA second-line colorectal cancer (800) 772-6436
(see also head/neck)
H e a d / n e c K c a n c e r
product name sponsor indication development status
alimta® Eli Lilly Phase III
pemetrexed Indianapolis, IN (800) 545-5979
BIBW 2992 Boehringer Ingelheim (see also brain, breast, lung) Phase II
(afatinib) Pharmaceuticals (800) 243-0127
Ridgefield, CT
erbitux® Bristol-Myers Squibb (see also bladder, breast, lung) Phase II
cetuximab Princeton, NJ (212) 546-4000
Eli Lilly (800) 545-5979
Indianapolis, IN (212) 645-1405
ImClone Systems
New York, NY
foretinib GlaxoSmithKline (see also kidney) Phase II
Rsch. Triangle Park, NC (888) 825-5249
HF10 Takara Bio Phase I
Shiga, Japan
16 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
H e a d / n e c K c a n c e r
product name sponsor indication development status
IMO-2055 EMD Serono (see also colorectal, lung) Phase II
(EMD-1201081) Rockland, MA (800) 283-8088
Idera Pharmaceuticals (617) 679-5500
Cambridge, MA
IRX-2 IRX Therapeutics (Fast Track) Phase II
New York, NY (212) 582-1199
lymphoseek™ Neoprobe diagnosis of head/neck cancer Phase III
Dublin, OH (see also breast, skin) (800) 793-0079
Multikine® CEL-SCI Phase III
leukocyte Vienna, VA (703) 506-9460
interleukin
OBP-301 Oncolys Biopharma (see also breast, lung) Phase I
Tokyo, Japan
OncoVEXGM-csf BioVex (see also skin) Phase III
Woburn, MA (781) 376-4900
prolindac™ Access Pharmaceuticals Phase II
polymer-DACH Dallas, TX (214) 905-5100
platinum conjugate
reolysin® Oncolytics Biotech (see also brain, colorectal, lung, Phase III
reovirus Calgary, Canada pancreatic, sarcoma, skin) (403) 670-7377
tarceva® Genentech (see also bladder, brain, breast, Phase II
erlotinib South San Francisco, CA colorectal, leukemia, liver, lung, (650) 224-1000
OSI Pharmaceuticals other) (800) 572-1932
Melville, NY
TAS-106 Taiho Pharma USA Phase II
Princeton, NJ (609) 750-5300
terameprocol Erimos Pharmaceuticals (see also brain, cervical, solid tumors, Phase I
(intravaginal) Houston, TX other) (713) 541-2000
tnferade™ GenVec (see also colorectal, pancreatic, skin, Phase I/II
Gaithersburg, MD stomach) (240) 632-0740
tykerb® GlaxoSmithKline (see also brain, stomach) Phase III
lapatinib Rsch. Triangle Park, NC (888) 825-5249
VB4-845 Viventia Biotechnologies (Fast Track) Phase II
(orphan drug) Mississauga, Canada (see also bladder) (905) 362-2973
vectibix® Amgen locally advanced head/neck Phase II
panitumumab Thousand Oaks, CA cancer (800) 772-6436
(see also colorectal)
zalutumumab Genmab (Fast Track) Phase II
Princeton, NJ (609) 430-2481
K i d n e y c a n c e r
product name sponsor indication development status
ABT-869 Abbott Laboratories (see also breast, colorectal, Phase II
(linifarib) Abbott Park, IL liver, lung) (847) 937-6100
(650) 225-1000
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 17
K i d n e y c a n c e r
product name sponsor indication development status
afinitor® Novartis Pharmaceuticals tuberous sclerosis complex Phase II
everolimus East Hanover, NJ angiomyolipomas (888) 669-6682
(see also breast, liver, lymphoma,
stomach, other)
AGS-003 Argos Therapeutics Phase II
Durham, NC (919) 287-6300
AGS-16M8F Agensys Phase I
Santa Monica, CA (800) 695-4321
Astellas Pharma US
Deerfield, IL
AMG 386 Amgen (see also breast, colorectal, liver, Phase II
Thousand Oaks, CA ovarian, stomach, other) (800) 772-6436
ARQ-197 ArQule (see also colorectal, liver, lung, Phase II
Woburn, MA pancreatic, sarcoma, other) (781) 994-0300
Daiichi Sankyo (973) 944-2600
Parsippany, NJ
AV-951 AVEO Pharmaceuticals (see also breast, lung, stomach) Phase III
(tivozanib) Cambridge, MA (617) 299-5000
axitinib Pfizer (see also lung, other) Phase III
New York, NY (860) 732-5156
BAY 73-4506 Bayer HealthCare (see also colorectal, lung, stomach) Phase II
(regorafenib) Pharmaceuticals (888) 842-2937
Wayne, NJ
BNC 105 Bionomics Phase II
Thebarton, Australia
CA9-SCAN Wilex diagnosis of kidney cancer Phase III completed
Munich, Germany
CYT-107 Cytheris (see also leukemia, skin, Phase I
Rockville, MD solid tumors) (301) 231-0450
EC-17 Endocyte Phase II
West Lafayette, IN (765) 463-7175
foretinib GlaxoSmithKline papillary renal cell carcinoma Phase II
Rsch. Triangle Park, NC (see also head/neck) (888) 825-5249
GC-1008 Genzyme (see also skin) Phase I
(fresolimumab) Cambridge, MA (617) 252-7000
lenvatinib Eisai renal cell carcinoma Phase I/II
(E7080) Woodcliff Lake, NJ (see also brain, liver, ovarian, (888) 422-4743
skin, other)
LOR-2040 Lorus Therapeutics metastatic kidney cancer Phase II
(orphan drug) Toronto, Canada (see also breast, colorectal, leukemia) (416) 798-1200
MDX-1203 Bristol-Myers Squibb (see also lymphoma) Phase I
(anti-CD70 ADC) Princeton, NJ (212) 546-4000
naptumomab Active Biotech (see also lung, pancreatic) Phase I completed
estafenatox Lund, Sweden
18 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
K i d n e y c a n c e r
product name sponsor indication development status
nexavar® Bayer HealthCare adjuvant therapy Phase III
sorafenib Pharmaceuticals (see also breast, colorectal, liver, (888) 842-2837
Wayne, NJ lung, ovarian, other) (510) 597-6500
Onyx Pharmaceuticals
Emeryville, CA
OSI-027 OSI Pharmaceuticals (see also lymphoma) Phase II
Melville, NY (800) 572-1932
perifosine AEterna Zentaris (see also brain, colorectal, leukemia, Phase II
(KRX-0401) Montreal, Canada lymphoma, multiple myeloma, (212) 531-5965
Keryx Biopharmaceuticals ovarian, sarcoma, stomach)
New York, NY
prophage Agenus (Fast Track) Phase II
(vitespen) Lexington, MA (see also brain, skin) (781) 674-4400
(orphan drug)
rencarex® Wilex non-metastatic, clear cell renal Phase III
girentuximab Munich, Germany cell carcinoma
(orphan drug)
SGN-75 Seattle Genetics renal cell carcinoma Phase I
Bothell, WA (see also lymphoma) (425) 527-4000
sutent® Pfizer adjuvant therapy Phase III
sunitinib New York, NY (see also pancreatic) (860) 732-5156
talactoferrin Agennix (Fast Track) Phase II
(orphan drug) Houston, TX (see also lung) (713) 552-1091
torisel® Pfizer combination therapy Phase III
temsirolimus New York, NY (860) 732-5156
(orphan drug)
tremelimumab Pfizer (see also pancreatic, skin, stomach, Phase II
(CP-675206) New York, NY other) (860) 732-5156
veglin VasGene Therapeutics (see also lung, skin) Phase I
(VEGF antisense) Los Angeles, CA (323) 221-7818
votrient® GlaxoSmithKline (see also breast, ovarian, sarcoma) Phase III
pazopanib Rsch. Triangle Park, NC (888) 825-5249
l e u K e M i a
product name sponsor indication development status
ABIO05/01 Abiogen Pharma chronic myeloid leukemia (CML) Phase II
(TALL-104) Pisa, Italy
AC430 Ambit Biosciences Phase I
San Diego, CA (858) 334-2100
AEG-35156 Aegera Therapeutics acute myeloid leukemia (AML) Phase II
Montreal, Canada (see also lymphoma) (514) 288-5532
--------------------------------------------------------------------------------------
chronic lymphocytic leukemia (CLL) Phase I/II
(514) 288-5532
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 19
l e u K e M i a
product name sponsor indication development status
aezea® Eleos AML Phase II completed
cenersen Omaha, NE (402) 393-3034
(orphan drug)
afutuzumab Biogen Idec CLL Phase III
(GA101/RG7159) Cambridge, MA (see also lymphoma) (617) 679-2000
Roche (973) 235-5000
Nutley, NJ
AFX-9154 Afecta Pharmaceuticals in clinical trials
Irvine, CA (949) 253-4688
ALD-151 Aldagen Phase I
Durham, NC (919) 484-2571
ALXN-6000 Alexion Pharmaceuticals CLL Phase I/II
(samalizumab) Cheshire, CT (see also multiple myeloma) (203) 272-2596
aminopterin Syntrix Biosystems acute lymphoblastic leukemia (ALL) Phase II completed
Auburn, WA (253) 833-8009
anti-CD22 ADC Genentech recurrent CLL Phase I
South San Francisco, CA (see also lymphoma) (650) 225-1000
anti-CD22/CD19 Abiogen Pharma ALL Phase I
mAb-toxin Pisa, Italy
conjugate University of Texas
Southwestern Medical
Center
Dallas, TX
AR-42 Arno Therapeutics CLL Phase I/II
Parsippany, NJ (see also lymphoma, multiple (862) 703-7170
myeloma)
ARRY-520 Array BioPharma AML Phase I/II
Boulder, CO (see also multiple myeloma, (303) 381-6600
solid tumors)
ARRY-614 Array BioPharma myelodysplastic syndromes Phase I
Boulder, CO (303) 381-6600
arzerra® GlaxoSmithKline first-line CLL Phase III
ofatumumab Rsch. Triangle Park, NC (see also lymphoma) (888) 825-5249
(orphan drug)
AS-1411 Antisoma AML Phase II
Cambridge, MA (617) 252-6100
AT-101 Ascenta Therapeutics CLL Phase II completed
Malvern, PA (see also brain, lung, lymphoma, (610) 408-0313
prostate, stomach)
AT9283 Astex Therapeutics AML Phase I/II
Cambridge, United Kingdom (see also solid tumors)
com
bafetinib CytRx CLL Phase II
(orphan drug) Los Angeles, CA (see also prostate) (310) 826-5648
--------------------------------------------------------------------------------------
ALL, CML Phase I
(310) 826-5648
20 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l e u K e M i a
product name sponsor indication development status
BI 811283 Boehringer Ingelheim AML Phase II
Pharmaceuticals (see also solid tumors) (800) 243-0127
Ridgefield, CT
blinatumomab Micromet ALL Phase II
Bethesda, MD (see also lymphoma) (240) 752-1420
BMS-936564 Bristol-Myers Squibb AML Phase I
(anti-CXCR4) Princeton, NJ (212) 546-4000
bosutinib Pfizer CML Phase III
New York, NY (860) 732-5156
CAL-101 Calistoga Pharmaceuticals CLL Phase II
Seattle, WA (see also lymphoma, multiple myeloma) (206) 728-4700
--------------------------------------------------------------------------------------
AML Phase I
(206) 728-4700
campath® Genzyme CLL combination therapy Phase III
alemtuzumab Cambridge, MA (see also cancer/chemotherapy) (617) 252-7500
(intravenous)
(orphan drug)
campath® Genzyme CLL Phase II
alemtuzumab Cambridge, MA (617) 252-7500
(subcutaneous)
cell permeation MaxCyte CLL Phase I/II
therapeutic vaccine Gaithersburg, MD (301) 944-1700
ceplene™ EpiCept AML application submitted
histamine Tarrytown, NY (914) 606-3500
dehydrochloride
injection
(orphan drug)
clolar® Genzyme AML in elderly (monotherapy) application submitted
clofarabine Cambridge, MA (617) 252-7500
--------------------------------------------------------------------------------------
AML in elderly (combination therapy) Phase III
(617) 252-7500
--------------------------------------------------------------------------------------
AML in children, Phase II
myelodysplastic syndromes (617) 252-7500
CNDO-109 Coronado Biosciences AML Phase I/II
New York, NY (212) 332-1665
CPX-351 Celator Pharmaceuticals AML Phase II
Princeton, NJ (609) 243-0123
CST-101 ConKwest AML Phase I
Del Mar, CA (see also lung, lymphoma, skin) (858) 380-1999
CT-011 CureTech AML Phase II
Yavne, Israel (see also colorectal, lymphoma)
CYT-107 Cytheris myeloid leukemia Phase I
Rockville, MD (see also kidney, skin, solid tumors) (301) 231-0450
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 21
l e u K e M i a
product name sponsor indication development status
dacetuzumab Seattle Genetics CLL Phase I/II
(anti-CD40) Bothell, WA (see also lymphoma, (425) 527-4000
(orphan drug) multiple myeloma)
danusertib Nerviano Medical Sciences CML Phase II
Nerviano, Italy
DCC-2036 Deciphera Pharmaceuticals ALL, CML Phase I/II
Lawrence, KS (785) 838-3767
dinaciclib Merck (see also breast, lung, lymphoma) Phase II
Whitehouse Station, NJ (800) 672-6372
elacyt™ Clavis Pharma AML (Fast Track) Phase III
elacytarabine Oslo, Norway
(orphan drug)
elesclomol Synta Pharmaceuticals AML Phase I
Lexington, MA (781) 274-8200
epratuzumab Immunomedics ALL in children Phase II
(orphan drug) Morris Plains, NJ (see also lymphoma) (973) 605-8200
erwinaze® EUSA Pharma ALL (Fast Track) application submitted
crisantaspase Langhorne, PA (800) 833-3533
(orphan drug)
EZN-3042 Enzon Pharmaceuticals ALL in children Phase I
Bridgewater, NJ (see also lymphoma, solid tumors) (908) 541-8600
fodosine™ BioCryst Pharmaceuticals CLL Phase II
forodesine Birmingham, AL (see also lymphoma) (205) 444-4600
Genasense® Genta CLL (Fast Track) application submitted
oblimersen Berkeley Heights, NJ (see also lymphoma, skin) (908) 286-9800
(orphan drug)
GNKG-68 SBI Biotech CLL Phase I
Tokyo, Japan
GRN-163L Geron CLL Phase I/II
(imetelstat) Menlo Park, CA (see also breast, lung, (650) 473-7700
multiple myeloma)
GRNVAC1 Geron AML Phase II
Menlo Park, CA (see also prostate) (650) 473-7700
GvaX® leukemia BioSante Pharmaceuticals AML, CML Phase II
(orphan drug) Lincolnshire, IL (see also breast, colorectal, (847) 478-0500
multiple myeloma, pancreatic)
HuM195-Ac-225 Actinium Pharmaceuticals AML Phase I
Newark, NJ (973) 344-6500
HuM195-Bi-213 Actinium Pharmaceuticals AML Phase I/II
Newark, NJ (973) 344-6500
HuM195/rGel Targa Therapeutics AML, CML, myelodysplastic Phase I
(lintuzumab-gelonin San Diego, CA syndromes (858) 483-6600
conjugate)
imprime pGG® Biothera CLL Phase I/II
Eagen, MN (see also colorectal, lung, skin) (651) 675-0300
22 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l e u K e M i a
product name sponsor indication development status
ISF35 Memgen CLL Phase II
Dallas, TX (see also lymphoma) (214) 731-3141
JNJ-26481585 Johnson & Johnson refractory metastatic leukemia, Phase I
Pharmaceutical Research refractory metastatic (800) 817-5286
& Development myelodysplastic syndromes
Raritan, NJ
JVRS-100 Juvaris BioTherapeutics Phase I
immunotherapeutic Burlingame, CA (650) 259-1800
L-annamycin Callisto Pharmaceuticals ALL, AML Phase I/II
(liposomal New York, NY (212) 297-0010
annamycin)
(orphan drug)
LC-1 Leuchemix AML Phase I
Redwood City, CA (650) 851-9925
lestaurtinib Cephalon AML Phase II
Frazer, PA (610) 344-0200
LG740 Lentigen ALL, B-cell prolymphocytic Phase I
Gaithersburg, MD leukemia, CLL (301) 527-4200
University of Pennsylvania (see also lymphoma)
Philadelphia, PA
LOR-2040 Lorus Therapeutics AML Phase II
(orphan drug) Toronto, Canada (see also breast, colorectal, kidney) (416) 798-1200
--------------------------------------------------------------------------------------
CML, myelodysplastic Phase I
syndromes (416) 798-1200
Marqibo® Talon Therapeutics ALL (Fast Track) Phase II
vincristine South San Francisco, CA (see also skin) (650) 588-6404
liposomal
(orphan drug)
masitinib AB Science USA mastocytosis Phase III
Short Hills, NJ (see also pancreatic, stomach) (973) 218-2437
MGCD-0103 MethylGene CLL Phase II completed
Montreal, Canada (see also lymphoma, solid tumors) (514) 337-3333
midostaurin Novartis Pharmaceuticals AML Phase III
(PKC412) East Hanover, NJ (888) 669-6682
(orphan drug)
--------------------------------------------------------------------------------------
aggressive systemic mastocytosis Phase II
(888) 669-6682
milatuzumab Immunomedics CLL Phase I/II
(IMMU-115) Morris Plains, NJ (see lymphoma, multiple myeloma) (973) 605-8200
(orphan drug)
Mozobil™ Genzyme AML, CLL Phase I/II
plerixafor Cambridge, MA (617) 252-7500
navitoclax Abbott Laboratories CLL Phase II
(ABT-263/RG7433) Abbott Park, IL (see also lung, lymphoma) (847) 937-6100
Genentech (650) 225-1000
South San Francisco, CA
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 23
l e u K e M i a
product name sponsor indication development status
nplate™ Amgen myelodysplastic syndromes Phase II
romiplostim Thousand Oaks, CA (see also cancer/chemotherapy) (800) 772-6436
obatoclax Gemin X Biotechnologies CLL Phase I/II completed
(orphan drug) Montreal, Canada (see also lung, lymphoma, (514) 281-8989
multiple myeloma)
omapro™ ChemGenex second-line CML application submitted
omacetaxine Pharmaceuticals (Fast Track) (650) 474-9800
mepesuccinate Menlo Park, CA
--------------------------------------------------------------------------------------
(orphan drug) AML, CML, Phase II
myelodysplastic syndromes (650) 474-9800
ON-01910 Onconova Therapeutics myelodysplastic syndromes Phase III
(orphan drug) Princeton, NJ (see also lymphoma, ovarian, (609) 844-7735
solid tumors)
--------------------------------------------------------------------------------------
AML, CLL Phase II
(609) 844-7735
ON-013105 Onconova Therapeutics ALL Phase I
Princeton, NJ (see also lymphoma) (609) 844-7735
OXi4503 OXiGENE AML Phase I
South San Francisco, CA (see also solid tumors) (650) 635-7000
PCI-32765 Pharmacyclics CLL Phase I
(BTK inhibitor) Sunnyvale, CA (see also lymphoma) (408) 774-0330
perifosine Aeterna Zentaris refractory metastatic CLL Phase II
(KRX-1401) Montreal, Canada (see also brain, colorectal, kidney, (212) 531-5965
Keryx Biopharmaceuticals lymphoma, multiple myeloma,
New York, NY ovarian, sarcoma, stomach)
polyphenon E Polyphenon Pharma CLL Phase I/II
(orphan drug) New York, NY (see also prostate) (212) 661-0578
ponatinib ARIAD Pharmaceuticals ALL, CML Phase II
(AP24534) Cambridge, MA (617) 494-0400
PR1 cancer Vaccine Company AML Phase III
vaccine South San Francisco, CA (650) 244-4100
--------------------------------------------------------------------------------------
CML, myelodysplastic syndromes Phase II
(650) 244-4100
PR104 Proacta Therapeutics AML Phase I/II
San Diego, CA (858) 642-0386
quizartinib Ambit Biosciences AML Phase II
San Diego, CA (see also solid tumors) (858) 334-2100
Astellas Pharma US (800) 727-7003
Deerfield, IL
sapacitabine Cyclacel Pharmaceuticals AML in elderly patients Phase III
Short Hills, NJ (see also lung) (973) 847-5955
SAR103168 sanofi-aventis AML Phase I
(multikinase Bridgewater, NJ (800) 633-1810
inhibitor)
SB939 S*Bio AML Phase II
Redwood City, CA (see also solid tumors) (650) 730-2860
24 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l e u K e M i a
product name sponsor indication development status
SB1518 S*Bio myeloid leukemia Phase I/II
Redwood City, CA (see also lymphoma) (650) 730-2860
SCH-900776 Merck (see also lymphoma) Phase I
Whitehouse Station, NJ (800) 672-6372
SF1126 Semafore Pharmaceuticals CLL Phase I
(orphan drug) Indianapolis, IN (see also multiple myeloma, (317) 876-3075
solid tumors)
SGI-110 SuperGen AML Phase I/II
Dublin, CA (925) 560-0100
SL-401 Stemline Therapeutics AML Phase I/II
New York, NY (212) 831-1111
SNDX-275 Syndax Pharmaceuticals (see also breast, leukemia, lung, Phase II
(entinostat) Waltham, MA lymphoma) (781) 419-1400
sprycel® Bristol-Myers Squibb myelodysplastic syndromes Phase II
dasatinib Princeton, NJ (see also brain, breast, colorectal, (212) 546-4000
lung, lymphoma, multiple myeloma,
prostate, skin)
tamibarotene CytRx acute promyelocytic leukemia (APL) Phase II
(orphan drug) Los Angeles, CA (Fast Track) (310) 826-5648
(see also lung)
tarceva® Genentech myelodysplastic syndromes Phase II
erlotinib South San Francisco, CA (see also bladder, brain, breast, (650) 224-1000
OSI Pharmaceuticals colorectal, head/neck, liver, lung, (800) 572-1932
Melville, NY other)
tasigna® Novartis Pharmaceuticals CML in adolescents and children Phase II
nilotinib East Hanover, NJ (see also skin, stomach) (888) 669-6682
(orphan drug)
telintra® Telik myelodysplastic syndromes Phase II
ezatiostat Palo Alto, CA (650) 845-7700
temodar® Merck AML Phase II
temozolomide Whitehouse Station, NJ (see also lung, skin) (800) 672-6372
TH-302 Threshold Pharmaceuticals advanced leukemia Phase I
Redwood City, CA (see also pancreatic, sarcoma, (650) 474-8200
solid tumors)
thiarabine Access Pharmaceuticals (see also lymphoma) Phase I/II
Dallas, TX (214) 905-5100
tosedostat Chroma Therapeutics AML Phase II
(orphan drug) Oxford, United Kingdom
therapeutics.com
treosulfan medac ALL, AML, myelodysplastic Phase II
Wedel, Germany syndromes
trisenox® Cephalon AML in elderly patients Phase III
arsenic trioxide Frazer, PA (see also brain, multiple myeloma) (610) 344-0200
TRU-016 Emergent Biosolutions CLL Phase I/II
(anti-CD37) Rockville, MD (see also lymphoma) (301) 795-1800
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 25
l e u K e M i a
product name sponsor indication development status
veltuzumab Immunomedics CLL Phase I/II completed
(IMMU-106) Morris Plains, NJ (see also lymphoma) (973) 605-8200
vidaza® Celgene AML Phase III
azacitidine Summit, NJ (908) 673-9000
(orphan drug)
vosaroxin Sunesis Pharmaceuticals AML (Fast Track) Phase III
(SNS-595) South San Francisco, CA (see also ovarian) (650) 266-3500
(orphan drug)
--------------------------------------------------------------------------------------
AML in the elderly Phase II
(650) 266-3500
WT1 recombinant GlaxoSmithKline AML Phase II
vaccine Rsch. Triangle Park, NC (888) 825-5249
(antigen specific
cancer
immunotherapy)
XmAb®5574 Xencor CLL Phase I
(MOR-208) Monrovia, CA (626) 305-5900
MorphoSys
Munich, Germany
zosuquidar Kanisa Pharmaceuticals newly-diagnosed AML in elderly Phase I/II
(orphan drug) San Diego, CA patients (858) 436-1800
l i v e r c a n c e r
product name sponsor indication development status
ABT-869 Abbott Laboratories (see also breast, colorectal, Phase III
(linifarib) Abbott Park, IL kidney, lung) (847) 937-6100
ADI-PEG 20 Polaris Pharmaceuticals (see also lung, skin) Phase II
(orphan drug) San Diego, CA (858) 452-6688
afinitor® Novartis Pharmaceuticals advanced hepatocellular carcinoma Phase III
everolimus East Hanover, NJ (see also breast, liver, lymphoma, (888) 669-6682
stomach, other)
ALN-VSP Alnylam Pharmaceuticals Phase I
Cambridge, MA (617) 551-8200
AMG 386 Amgen (see also breast, colorectal, kidney, Phase II
Thousand Oaks, CA ovarian, stomach, other) (800) 772-6436
ARQ-197 ArQule hepatocellular carcinoma Phase II
Woburn, MA (see also colorectal, kidney, lung, (781) 994-0300
Daiichi Sankyo pancreatic, sarcoma, solid tumors, (973) 944-2600
Parsippany, NJ other)
bavituximab Peregrine Pharmaceuticals (see also breast, pancreatic) Phase I/II
Tustin, CA (714) 508-6000
BAY 86-9766 Bayer HealthCare Phase II
Pharmaceuticals (888) 842-2937
Wayne, NJ
26 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l i v e r c a n c e r
product name sponsor indication development status
BIIB 022 Biogen Idec (see also lung) Phase I
Cambridge, MA (617) 679-2000
brivanib Bristol-Myers Squibb hepatocellular carcinoma Phase III
(VEGFR/FGFR Princeton, NJ (see also stomach) (212) 546-4000
kinase inhibitor)
CRS-100 Aduro BioTech Phase I
Berkeley, CA (510) 848-4400
darinaparsin ZIOPHARM Oncology (see also lymphoma, Phase II completed
(ZIO-101) New York, NY multiple myeloma, solid tumors) (646) 214-0700
davanat™ Pro-Pharmaceuticals biliary cancer Phase II
galactomannan C Newton, MA (see also colorectal) (617) 559-0033
E7050 Eisai hepatocellular carcinoma Phase I/II
Woodcliff Lake, NJ (see also stomach, other) (888) 422-4743
GC-33/RG7686 Chugai Pharma USA Phase I
Berkeley Heights, NJ (908) 516-1350
Roche (973) 235-5000
Nutley, NJ
irinotecan Biocompatibles liver metastases from Phase II
eluting beads International colorectal cancer
Surrey, United Kingdom
JX-594 Jennerex Biotherapeutics (see also colorectal) Phase II
San Francisco, CA (415) 281-8886
lenvatinib Eisai hepatocellular carcinoma Phase I/II
(E7080) Woodcliff Lake, NJ (see also brain, kidney, ovarian, (888) 422-4743
skin, other)
mapatumumab Human Genome Sciences (see also lung, multiple myeloma) Phase I/II
Rockville, MD (301) 309-8504
MB-07133 Ligand Pharmaceuticals inoperable, unresectable Phase I/II completed
(orphan drug) La Jolla, CA liver cancer (858) 550-7500
melphalan drug Delcath Systems secondary liver cancer arising from application submitted
delivery system New York, NY metastatic ocular or cutaneous (212) 489-2100
melanoma
muparfostat Progen Pharmaceuticals (Fast Track) Phase III
(PI-88) Redwood City, CA (see also skin) (650) 610-7080
nexavar® Bayer HealthCare adjuvant therapy Phase III
sorafenib Pharmaceuticals (see also breast, colorectal, kidney, (888) 842-2837
Wayne, NJ lung, ovarian, other) (510) 597-6500
Onyx Pharmaceuticals
Emeryville, CA
NV1020 Catherex Phase I/II completed
Arlington, VA (703) 786-3790
patupilone Novartis Pharmaceuticals (see also brain) Phase II
(EPO906) East Hanover, NJ (888) 669-6682
prevonco™ Apricus Biosciences Phase II
lansoprazole San Diego, CA (858) 222-8041
(orphan drug)
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 27
l i v e r c a n c e r
product name sponsor indication development status
PV-10 Provectis Pharmaceuticals liver metastases Phase I
Knoxville, TN (see also skin) (866) 594-5999
ramucirumab Eli Lilly (see also breast, colorectal, Phase III
(IMC-1121B) Indianapolis, IN lung, stomach) (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
tarceva® Genentech inoperable, unresectable liver cancer Phase III
erlotinib South San Francisco, CA (see also bladder, brain, breast, (650) 224-1000
OSI Pharmaceuticals colorectal, head/neck, leukemia, (800) 572-1932
Melville, NY lung, other)
thermodox® Celsion inoperable, unresectable liver cancer Phase III
LTSDEL Columbia, MD (Fast Track) (410) 290-5390
(orphan drug) (see also breast)
tigatuzumab Daiichi Sankyo (see also colorectal, lymphoma, Phase II
Parsippany, NJ ovarian, pancreatic) (973) 359-2600
l u n G c a n c e r
product name sponsor indication development status
abraxane® Celgene advanced non-small-cell lung cancer Phase III
albumin-bound Summit, NJ (NSCLC) (908) 673-9000
paclitaxel (see also bladder, ovarian,
pancreatic, skin)
ABT-869 Abbott Laboratories NSCLC Phase II
(linifarib) Abbott Park, IL (see also breast, kidney, liver) (847) 937-6100
ADI-PEG 20 Polaris Pharmaceuticals small-cell lung cancer (SCLC) Phase II
(orphan drug) San Diego, CA (see also liver, skin) (858) 452-6688
--------------------------------------------------------------------------------------
mesothelioma Phase I
(858) 452-6688
aflibercept sanofi-aventis second-line NSCLC Phase III
(VEGF-trap) Bridgewater, NJ (see also colorectal, prostate) (800) 633-1610
Regeneron Pharmaceuticals (914) 345-7400
Tarrytown, NY
AMG 479 Amgen SCLC Phase I/II
(gunitumab) Thousand Oaks, CA (see also breast, colorectal, (800) 772-6436
pancreatic, sarcoma, other)
amrubicin Celgene second-line SCLC Phase III
(orphan drug) Summit, NJ (Fast Track) (908) 673-9000
--------------------------------------------------------------------------------------
first-line SCLC Phase II
(908) 673-9000
apricoxib Tragara Pharmaceuticals NSCLC Phase II
San Diego, CA (see also pancreatic) (858) 350-6900
28 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l u n G c a n c e r
product name sponsor indication development status
ARQ-197 ArQule NSCLC Phase III
Woburn, MA (see also colorectal, kidney, liver, (781) 994-0300
Daiichi Sankyo pancreatic, sarcoma, solid tumors, (973) 944-2600
Parsippany, NJ other)
AT-101 Ascenta Therapeutics NSCLC, SCLC Phase II
Malvern, PA (see also leukemia, lymphoma, (610) 408-0301
prostate, stomach)
AUY922 Novartis Pharmaceuticals NSCLC Phase II
East Hanover, NJ (see also breast, colorectal, multiple (888) 669-6682
myeloma, stomach)
AV-951 AVEO Pharmaceuticals NSCLC Phase I/II
(tivozanib) Cambridge, MA (see also breast, kidney, stomach) (617) 299-5000
avastin® Genentech NSCLC (adjuvant therapy) Phase III
bevacizumab South San Francisco, CA (see also brain, breast, colorectal, (650) 225-1000
ovarian, other)
axitinib Pfizer NSCLC Phase II
New York, NY (see also kidney, other) (860) 732-5156
bavituximab Peregrine Pharmaceuticals NSCLC Phase II
Tustin, CA (see also liver, pancreatic) (714) 508-6000
BAY 73-4506 Bayer HealthCare NSCLC Phase I
(regorafenib) Pharmaceuticals (see also colorectal, kidney, stomach) (888) 842-2937
Wayne, NJ
belinostat Spectrum Pharmaceuticals NSCLC Phase I/II
Irvine, CA (see also lymphoma, other) (949) 788-6700
TopoTarget USA (973) 895-6900
Rockaway, NJ
BI 2536 Boehringer Ingelheim SCLC Phase II completed
Pharmaceuticals (see also lymphoma) (800) 243-0127
Ridgefield, CT
BIBF 1120 Boehringer Ingelheim NSCLC Phase III
(intedanib) Pharmaceuticals (800) 243-0127
Ridgefield, CT
BIBW 2992 Boehringer Ingelheim NSCLC Phase III
(afatinib) Pharmaceuticals (Fast Track) (800) 243-0127
Ridgefield, CT (see also brain, breast, head/neck)
BIIB 022 Biogen Idec NSCLC Phase I
Cambridge, MA (see also liver) (617) 679-2000
BMS-690514 Bristol-Myers Squibb NSCLC Phase II
(HER/VEGFR2 Princeton, NJ (see also breast) (212) 546-4000
inhibitor)
BMS-844203 Bristol-Myers Squibb NSCLC Phase II
(VEGF R-2 Princeton, NJ (see also brain, colorectal) (212) 546-4000
adnectin)
cabozantinib Exelixis NSCLC Phase I/II
(XL-184) South San Francisco, CA (see also other) (650) 837-7000
CBP501 CanBas mesothelioma, NSCLC Phase II
Shizuoka, Japan
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 29
l u n G c a n c e r
product name sponsor indication development status
conatumumab Amgen NSCLC Phase I/II
Thousand Oaks, CA (see also colorectal, pancreatic, (800) 772-6436
sarcoma)
crizotinib Pfizer NSCLC (Fast Track) Phase III
New York, NY (860) 732-5156
CS-7017 Daiichi Sankyo NSCLC Phase II
(efatutazone) Parsippany, NJ (see also colorectal, other) (973) 944-2600
CST-101 ConKwest NSCLC, SCLC Phase I
Del Mar, CA (see also leukemia, lymphoma, skin) (858) 380-1999
dalotuzumab Merck NSCLC Phase I/II
Whitehouse Station, NJ (see also breast, colorectal, (800) 672-6372
pancreatic, other)
dinaciclib Merck NSCLC Phase II
Whitehouse Station, NJ (see also breast, leukemia, lymphoma) (800) 672-6372
EC-145 Endocyte late-stage NSCLC Phase II
West Lafayette, IN (see also ovarian, other) (765) 463-7175
erbitux® Bristol-Myers Squibb NSCLC Phase III
cetuximab Princeton, NJ (see also bladder, breast, head/neck) (212) 546-4000
Eli Lilly (800) 545-5979
Indianapolis, IN (212) 645-1405
ImClone Systems
New York, NY
eribulin Eisai NSCLC Phase I/II
(E7389) Woodcliff Lake, NJ (see also bladder, prostate, sarcoma) (888) 422-4743
exelbine™ ADVENTRX NSCLC application submitted
vinorelbine Pharmaceuticals (see also breast, lymphoma) (858) 552-0866
emulsion San Diego, CA
farletuzumab Eisai NSCLC Phase II
(MORAb-003) Woodcliff Lake, NJ (see also ovarian) (888) 422-4743
folotyn® Allos Therapeutics NSCLC Phase II
pralatrexate Westminster, CO (see also bladder, breast, lymphoma) (303) 426-6262
ganetespib Synta Pharmaceuticals NSCLC Phase II
Lexington, MA (see also breast, colorectal, (781) 274-8200
stomach, other)
GDC-0941 Genentech metastatic NSCLC Phase I
(PI3 kinase inhibitor) South San Francisco, CA (see also breast, lymphoma, solid (650) 224-1000
tumors)
GI-4000 GlobeImmune NSCLC Phase I
Louisville, CO (see also colorectal, pancreatic) (303) 625-2700
GRN-163L Geron NSCLC Phase II
(imetelstat) Menlo Park, CA (see also breast, leukemia, (650) 473-7700
multiple myeloma)
GSK2302032A GlaxoSmithKline resectable NSCLC Phase I
(PRAME Rsch. Triangle Park, NC (see also skin) (888) 825-5249
immunotherapeutic
recombinant
vaccine)
30 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l u n G c a n c e r
product name sponsor indication development status
HS-L1 Heat Biologics NSCLC Phase I
Miami Beach, FL (305) 432-4684
Hyperacute® lung NewLink Genetics NSCLC Phase I/II
lung cancer Ames, IA (515) 296-5555
vaccine
IMGN-901 ImmunoGen SCLC Phase I/II
(orphan drug) Cambridge, MA (see also multiple myeloma) (617) 995-2500
IMO-2055 EMD Serono NSCLC Phase I
(EMD-1201081) Rockland, MA (see also colorectal, kidney) (800) 283-8088
Idera Pharmaceuticals (617) 679-5500
Cambridge, MA
imprime pGG® Biothera NSCLC Phase II
Eagen, MN (see also colorectal, leukemia, skin) (651) 675-0300
iniparib BiPar Sciences squamous lung cancer Phase III
(BSI-201) South San Francisco, CA (see also breast, ovarian) (650) 615-7000
sanofi-aventis (800) 633-1810
Bridgewater, NJ
--------------------------------------------------------------------------------------
non-squamous NSCLC Phase II
(650) 615-7000
(800) 633-1810
ipilimumab Bristol-Myers Squibb NSCLC Phase II
Princeton, NJ (see also prostate, skin) (212) 546-4000
ixempra® Bristol-Myers Squibb NSCLC Phase II
ixabepilone Princeton, NJ (see also breast, stomach, other) (212) 546-4000
JNJ-26854165 Johnson & Johnson NSCLC Phase I
Pharmaceutical Research (see also prostate, solid tumors) (800) 817-5286
& Development
Raritan, NJ
lucanix® NovaRx NSCLC (Fast Track) Phase III
belagenpumatucel-L San Diego, CA (see also brain) (858) 552-8600
MAGE-A3 GlaxoSmithKline NSCLC Phase III
recombinant vaccine Rsch. Triangle Park, NC (see also skin) (888) 825-5249
(antigen-specific
cancer
immunotherapeutic)
mapatumumab Human Genome Sciences NSCLC Phase II
Rockville, MD (see also liver, multiple myeloma) (301) 309-8504
MetmAb Genentech NSCLC Phase II
(RG 3638) South San Francisco, CA (650) 225-1000
MGCD-265 MethylGene NSCLC Phase II
Montreal, Canada (see also solid tumors) (514) 337-3333
MORAb-009 Eisai mesothelioma Phase II
Woodcliff Lake, NJ (888) 422-4743
motesanib Amgen NSCLC Phase III
(AMG 706) Thousand Oaks, CA (see also breast) (800) 772-6436
Millennium Pharmaceuticals (800) 390-5663
Cambridge, MA
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 31
l u n G c a n c e r
product name sponsor indication development status
naptumomab Active Biotech NSCLC (Fast Track) Phase I completed
estafenatox Lund, Sweden (see also kidney, pancreatic)
navitoclax Abbott Laboratories SCLC Phase II
(ABT-263/RG7433) Abbott Park, IL (see also leukemia, lymphoma) (847) 937-6100
Genentech (650) 225-1000
South San Francisco, CA
necitumumab Bristol-Myers Squibb NSCLC Phase III
(IMC-11F8) Princeton, NJ (212) 546-4000
Eli Lilly (800) 545-5979
Indianapolis, IN (212) 645-1405
ImClone Systems
New York, NY
nexavar® Bayer HealthCare NSCLC Phase III
sorafenib Pharmaceuticals (see also breast, colorectal, kidney, (888) 842-2837
Wayne, NJ liver, ovarian, other) (510) 597-6500
Onyx Pharmaceuticals
Emeryville, CA
NK-012 Nippon Kayaku SCLC Phase II
Tokyo, Japan (see also breast)
NTX-10 Neotropix SCLC Phase II
Malvern, PA (see also other) (617) 460-1200
obatoclax Gemin X Biotechnologies SCLC Phase I/II
Montreal, Canada (see also leukemia, lymphoma, (514) 281-8989
multiple myeloma)
OBP-301 Oncolys Biopharma mesothelioma Phase I
Tokyo, Japan (see also breast, head/neck)
OGX-427 Oncogenex NSCLC Phase I
Pharmaceuticals (see also bladder, breast, ovarian, (425) 686-1500
Bothell, WA prostate)
onconase® Tamir Biotechnology NSCLC Phase II
ranpirnase Monmouth Junction, NJ (732) 823-1003
opaxio™ Cell Therapeutics NSCLC Phase III
paclitaxel Seattle, WA (see also ovarian, other) (800) 215-2355
poliglumex Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
OSI-906 OSI Pharmaceuticals NSCLC Phase II
(linsitinib) Melville, NY (see also ovarian, other) (631) 962-2000
P2045 Bryan Oncor NSCLC, SCLC Phase I
Somerville, MA (617) 273-2466
palifosfamide ZIOPHARM Oncology SCLC Phase I
(ZIO-201) New York, NY (see also sarcoma) (212) 214-0700
PF-00299804 Pfizer NSCLC Phase III
New York, NY (860) 732-5156
picoplatin Poniard Pharmaceuticals SCLC (Fast Track) Phase II
intravenous San Francisco, CA (see also colorectal, ovarian, prostate) (650) 583-3774
(orphan drug)
32 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l u n G c a n c e r
product name sponsor indication development status
plinabulin Nereus Pharmaceuticals NSCLC Phase II
(NPI-2358) San Diego, CA (858) 587-4090
PM-02734 Pharmamar USA NSCLC Phase II
(elisidepsin) New York, NY
ramucirumab Eli Lilly NSCLC Phase III
(IMC-1121B) Indianapolis, IN (see also breast, colorectal, (800) 545-5979
ImClone Systems liver, stomach) (212) 645-1405
New York, NY
rencentin™ AstraZeneca NSCLC Phase II
cediranib Wilmington, DE (800) 236-9933
reolysin® Oncolytics Biotech NSCLC Phase II
reovirus Calgary, Canada (see also brain, colorectal, head/neck, (403) 670-7377
pancreatic, sarcoma, skin)
retaspimycin Infinity Pharmaceuticals NSCLC Phase II
(IPI-504) Cambridge, MA (see also solid tumors) (617) 453-1000
ridaforolimus Merck NSCLC Phase II
Whitehouse Station, NJ (see also breast, sarcoma) (800) 672-6372
rilotumumab Amgen SCLC Phase II
Thousand Oaks, CA (see also brain, colorectal, prostate, (800) 772-6436
stomach)
salirasib Concordia Pharmaceuticals NSCLC Phase II
Ft. Lauderdale, FL (see also pancreatic)
sapacitabine Cyclacel Pharmaceuticals NSCLC Phase II
Short Hills, NJ (see also leukemia) (973) 847-5955
SNDX-275 Syndax Pharmaceuticals NSCLC Phase I/II
(entinostat) Waltham, MA (see also breast, colorectal, leukemia, (781) 419-1400
lymphoma)
sprycel® Bristol-Myers Squibb NSCLC Phase II
dasatinib Princeton, NJ (see also brain, breast, colorectal, (212) 546-4000
leukemia, lymphoma, multiple
myeloma, prostate, skin)
--------------------------------------------------------------------------------------
mesothelioma Phase I
(212) 546-4000
stimuvax® EMD Serono NSCLC (Fast Track) Phase III
emepepimut-S Rockland, MA (800) 283-8088
(BLP25 liposomal Oncothyreon (425) 450-0370
cancer vaccine) Bellevue, WA
talactoferrin Agennix NSCLC (Fast Track) Phase III
(orphan drug) Houston, TX (see also kidney) (713) 552-1091
tamibarotene CytRx NSCLC Phase II
Los Angeles, CA (see also leukemia) (310) 826-5648
tarceva® Roche NSCLC Phase III
erlotinib Nutley, NJ (see also bladder, brain, breast, (973) 235-5000
OSI Pharmaceuticals colorectal, head/neck, leukemia, (800) 572-1932
Melville, NY liver, other)
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 33
l u n G c a n c e r
product name sponsor indication development status
tavocept™ BioNumerik Pharmaceuticals (see also cancer/chemotherapy) Phase III
dimesna San Antonio, TX (210) 614-1701
telcyta® Telik NSCLC Phase III completed
canfosfimide Palo Alto, CA (see also lymphoma, ovarian) (650) 845-7700
temodar® Merck SCLC Phase II
temozolomide Whitehouse Station, NJ (see also leukemia, skin) (800) 672-6372
topotecan Talon Therapeutics SCLC Phase I
liposomal South San Francisco, CA (see also ovarian) (650) 588-6404
TV-1011/OGX-011 Teva Pharmaceutical NSCLC Phase I/II
(custiren) Tikva, Israel (see also prostate) (425) 686-1500
Oncogenex
Pharmaceuticals
Bothell, WA
veglin VasGene Therapeutics mesothelioma Phase I
(VEGF antisense) Los Angeles, CA (see also kidney, skin) (323) 221-7818
volociximab Biogen Idec NSCLC Phase II
Cambridge, MA (see also ovarian) (617) 679-2000
Facet Biotech (650) 454-1000
Redwood City, CA
XL647 Symphony Evolution NSCLC Phase II
Rockville, MD
evolution.com
Zybrestat™ OXiGENE first-line NSCLC Phase II
fosbretabulin South San Francisco, CA (see also ovarian, other) (650) 635-7000
l y M p H o M a
product name sponsor indication development status
AEG-35156 Aegera Therapeutics B-cell lymphoma Phase I/II
Montreal, Canada (see also leukemia) (514) 288-5532
AEZS-112 AEterna-Zentaris (see also solid tumors) Phase I
Warren, NJ (908) 626-5428
afinitor® Novartis Pharmaceuticals diffuse large B-cell lymphoma Phase III
everolimus East Hanover, NJ (see also breast, kidney, liver, (888) 669-6682
stomach, other)
--------------------------------------------------------------------------------------
mantle-cell lymphoma Phase II
(888) 669-6682
AFM13 Affimed Therapeutics Hodgkin’s lymphoma Phase I
Heidelberg, Germany
afutuzumab Biogen Idec indolent non-Hodgkin’s lymphoma Phase III
(GA101/RG7159) Cambridge, MA (see also leukemia) (617) 679-2000
Roche (973) 235-5000
Nutley, NJ --------------------------------------------------------------------------------------
aggressive non-Hodgkin’s lymphoma Phase II
(617) 679-2000
(973) 235-5000
34 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l y M p H o M a
product name sponsor indication development status
AME133 MENTRIK Biotech non-Hodgkin’s lymphoma Phase II completed
(anti-CD20mAb) Dallas, TX (214) 594-0002
amuvatinib SuperGen (see also solid tumors) Phase I
Dublin, CA (925) 560-0100
anti-CD22 ADC Genentech recurrent non-Hodgkin’s lymphoma Phase I
South San Francisco, CA (see also leukemia) (650) 225-1000
anti-CD22 mAb- Abiogen Pharma B-cell lymphoma Phase I
toxin conjugate Pisa, Italy
University of Texas
Southwestern Medical
Center
Dallas, TX
aplidin® PharmaMar USA (see also multiple myeloma, Phase I
plitidepsin Cambridge, MA solid tumors) (617) 868-3797
AR-12 Arno Therapeutics (see also solid tumors) Phase I
Parsippany, NJ (862) 703-7170
AR-42 Arno Therapeutics (see also leukemia, multiple Phase I/II
Parsippany, NJ myeloma) (862) 703-7170
arzerra® GlaxoSmithKline follicular lymphoma, Phase III
ofatumumab Rsch. Triangle Park, NC diffuse large B-cell lymphoma (888) 825-5249
(see also leukemia)
ASP-3026 Astellas Pharma US late-stage non-Hodgkin’s lymphoma Phase I
Deerfield, IL (800) 477-6472
AT-101 Ascenta Therapeutics non-Hodgkin’s lymphoma Phase II completed
Malvern, PA (see also brain, leukemia, lung, (610) 408-0301
prostate, stomach)
AT-406 Ascenta Therapeutics lymphoma Phase I
Malvern, PA (see also solid tumors) (610) 408-0313
AV-299 AVEO Pharmaceuticals (see also brain, multiple myeloma, Phase I
(ficlatuzumab) Cambridge, MA solid tumors) (617) 299-5000
belinostat Spectrum Pharmaceuticals peripheral T-cell lymphoma Phase II
Irvine, CA (see also lung, other) (949) 788-6700
TopoTarget USA (973) 895-6900
Rockaway, NJ
Bexxar® GlaxoSmithKline mantle-cell lymphoma Phase II
tositumomab Rsch. Triangle Park, NC (888) 825-5249
BI 2536 Boehringer Ingelheim non-Hodgkin’s lymphoma Phase I
Pharmaceuticals (see also lung) (800) 243-0127
Ridgefield, CT
Biovaxid® Biovest follicular lymphoma Phase III
B-cell lymphoma International (Fast Track) (813) 864-2554
vaccine Tampa, FL --------------------------------------------------------------------------------------
mantle-cell lymphoma Phase II
(813) 864-2554
blinatumomab Micromet non-Hodgkin’s lymphoma Phase I
Bethesda, MD (see also leukemia) (240) 752-1420
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 35
l y M p H o M a
product name sponsor indication development status
CAL-101 Calistoga Pharmaceuticals non-Hodgkin’s lymphoma Phase I
Seattle, WA (see also leukemia, (206) 728-4700
multiple myeloma)
cancer vaccine Bayer Innovation follicular lymphoma Phase I
Dusseldorf, Germany (prevention of relapse) (805) 488-2147
Stellar Biotechnologies
Port Hueneme, CA
CC-223 Celgene non-Hodgkin’s lymphoma Phase I/II
Summit, NJ (see also leukemia, solid tumors) (908) 673-9000
cilengitide EMD Serono late-stage lymphoma Phase I completed
Rockland, MA (see also brain, prostate) (800) 283-8088
CST-101 ConKwest (see also leukemia, lung, skin) Phase I
Del Mar, CA (858) 380-1999
CT-011 CureTech diffuse large B-cell lymphoma, Phase II
Yavne, Israel follicular lymphoma
(see also colorectal, leukemia)
dacetuzumab Seattle Genetics non-Hodgkin’s lymphoma Phase I
(anti-CD40) Bothell, WA (see also leukemia, (425) 527-4000
multiple myeloma)
darinaparsin ZIOPHARM Oncology (see also liver, multiple myeloma, Phase II
(ZIO-101) New York, NY solid tumors) (646) 214-0700
DI-Leu16-IL2 Provenance non-Hodgkin’s lymphoma Phase I
(antibody-cytokine Biopharmaceuticals (781) 497-9888
fusion protein) Waltham, MA
dinaciclib Merck mantle-cell lymphoma Phase II
Whitehouse Station, NJ (see also breast, leukemia, lung) (800) 672-6371
dulanermin Amgen non-Hodgkin’s lymphoma Phase I/II
(rhApo2L/TRAIL) Thousand Oaks, CA (see also colorectal) (800) 772-6436
Genentech (650) 225-1000
South San Francisco, CA
enzastaurin Eli Lilly diffuse large B-cell lymphoma Phase III
Indianapolis, IN (800) 545-5979
epratuzumab Immunomedics diffuse large B-cell lymphoma, Phase II
(orphan drug) Morris Plains, NJ follicular lymphoma (973) 605-8200
(see also leukemia)
epratuzumab Y-90 Immunomedics recurrent non-Hodgkin’s lymphoma Phase I/II
Morris Plains, NJ (973) 605-8200
exelbine™ ADVENTRX non-Hodgkin's lymphoma application submitted
vinorelbine Pharmaceuticals (see also breast, lung) (858) 552-0866
emulsion San Diego, CA
EZN-2968 Enzon Pharmaceuticals (see also solid tumors) Phase I
Bridgewater, NJ (908) 541-8600
EZN-3042 Enzon Pharmaceuticals (see also leukemia, solid tumors) Phase I
Bridgewater, NJ (908) 541-8600
fodosine™ BioCryst Pharmaceuticals cutaneous T-cell lymphoma Phase II
forodesine Birmingham, AL (see also leukemia) (205) 444-4600
36 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l y M p H o M a
product name sponsor indication development status
folotyn® Allos Therapeutics B-cell lymphoma Phase II
pralatrexate Westminster, CO (see also bladder, breast, lung) (303) 426-6262
(orphan drug) --------------------------------------------------------------------------------------
Hodgkin’s disease, non-Hodgkin’s Phase I/II
lymphoma (303) 426-6262
--------------------------------------------------------------------------------------
cutaneous T-cell lymphoma Phase I
(303) 426-6262
GDC-0917 Genentech (see also solid tumors) Phase I
(IAP antagonist) South San Francisco, CA (650) 224-1000
GDC-0941 Genentech non-Hodgkin’s lymphoma Phase I
(PI3 kinase inhibitor) South San Francisco, CA (see also breast, lung, solid tumors) (650) 224-1000
GDC-0980 Genentech non-Hodgkin’s lymphoma Phase I
(PI3 kinase/mTOR South San Francisco, CA (see also breast, solid tumors) (650) 224-1000
dual inhibitor)
Genasense® Genta non-Hodgkin’s lymphoma Phase II
oblimersen Berkeley Heights, NJ (see also leukemia, skin) (908) 286-9800
GSK2141795 GlaxoSmithKline (see also solid tumors) Phase I
(AKT protein kinase Rsch. Triangle Park, NC (888) 825-5249
inhibitor)
HGS-1029 Human Genome Sciences (see also solid tumors) Phase I
Rockville, MD (301) 309-8504
INK128 Intellikine Waldenström’s macroglobulinemia Phase I
(TORC1/2 inhibitor) La Jolla, CA (see also multiple myeloma, (858) 768-6500
solid tumors)
inotuzumab UCB aggressive non-Hodgkin’s lymphoma Phase III
ozogamicin Smyrna, GA (770) 970-7500
(CMC-544) Pfizer (860) 732-5156
New York, NY --------------------------------------------------------------------------------------
indolent non-Hodgkin’s lymphoma Phase II
(770) 970-7500
(860) 732-5156
ISF35 Memgen diffuse large-cell lymphoma, Phase II
Dallas, TX follicular lymphoma, (214) 731-3141
small lymphocytic lymphoma
istodax® Celgene peripheral T-cell lymphoma application submitted
romidepsin Summit, NJ (Fast Track) (908) 673-9000
(orphan drug)
LEE011 Novartis Pharmaceuticals (see also solid tumors) Phase I
East Hanover, NJ (888) 669-6682
LG740 Lentigen diffuse large B-cell lymphoma, Phase I
Gaithersburg, MD follicular lymphoma, (301) 527-4200
University of Pennsylvania mantle-cell lymphoma
Philadelphia, PA (see also leukemia)
lucatumumab Novartis Pharmaceuticals Phase I/II
(HCD122) East Hanover, NJ (888) 669-6682
XOMA (510) 204-7200
Berkeley, CA
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 37
l y M p H o M a
product name sponsor indication development status
Mabthera® sc/ Halozyme follicular lymphoma Phase III
rHuPH20/ San Diego, CA (858) 794-8889
rituximab Roche (973) 235-5000
Nutley, NJ
MDX-1203 Bristol-Myers Squibb non-Hodgkin’s lymphoma Phase I
(anti-CD70 ADC) Princeton, NJ (see also kidney) (212) 546-4000
mechlorethamine Yaupon Therapeutics cutaneous T-cell lymphoma Phase III
gel Radnor, PA (Fast Track) (610) 975-9290
(orphan drug)
MGCD-0103 MethylGene diffuse large B-cell lymphoma, Phase II
Montreal, Canada follicular lymphoma (514) 337-3333
(see also leukemia, solid tumors)
milatuzumab Immunomedics non-Hodgkin’s lymphoma Phase I/II
(IMMU-115) Morris Plains, NJ (see also leukemia, multiple (973) 605-8200
myeloma)
mogamulizumab Kyowa Hakko T-cell lymphoma Phase II
Kirin Pharma (609) 919-1100
Princeton, NJ
navitoclax Abbott Laboratories relapsed or refractory lymphoid Phase I/II
(ABT-263/RG7433) Abbott Park, IL malignancies (847) 937-6100
Genentech (see also leukemia, lung) (650) 225-1000
South San Francisco, CA
NPI-0052 Nereus Pharmaceuticals (see also multiple myeloma, Phase I
(marizomib) San Diego, CA solid tumors) (858) 587-4090
obatoclax Gemin X Biotechnologies follicular lymphoma Phase II
Montreal, Canada (see also leukemia, lung, (514) 281-8989
multiple myeloma)
--------------------------------------------------------------------------------------
mantle-cell lymphoma Phase I/II
(514) 281-8989
ON-01910 Onconova Therapeutics (see also leukemia, ovarian, Phase II
Princeton, NJ solid tumors) (609) 844-7735
ON-013105 Onconova Therapeutics (see also leukemia) Phase I
Princeton, NJ (609) 844-7735
OSI-027 OSI Pharmaceuticals (see also kidney) Phase I
Melville, NY (800) 572-1932
P276 Piramal Life Sciences mantle-cell lymphoma Phase II
Mumbai, India
panobinostat Novartis Pharmaceuticals Hodgkin’s lymphoma application submitted
(LBH589) East Hanover, NJ (see also multiple myeloma, (888) 669-6682
other)
PCI-24781 Pharmacyclics (see also sarcoma) Phase II
(HDAC inhibitor) Sunnyvale, CA (408) 774-0330
PCI-32765 Pharmacyclics mantle-cell lymphoma Phase II
(BTK inhibitor) Sunnyvale, CA (see also leukemia) (408) 774-0330
38 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l y M p H o M a
product name sponsor indication development status
PD-0332991 Pfizer mantle-cell lymphoma Phase I
New York, NY (see also brain, breast, multiple (860) 732-5156
myeloma, sarcoma)
perifosine AEterna Zentaris recurrent lymphoma, Waldenström’s Phase II
(KRX-0401) Montreal, Canada macroglobulinemia (212) 531-5965
Keryx Biopharmaceuticals (see also brain, colorectal, kidney,
New York, NY leukemia, multiple myeloma, ovarian,
sarcoma, stomach)
pixuvri™ Cell Therapeutics non-Hodgkin’s lymphoma application submitted
pixantrone Seattle, WA (Fast Track) (800) 215-2355
(see also breast)
--------------------------------------------------------------------------------------
diffuse large B-cell lymphoma Phase II
(800) 215-2355
PLX3397 Plexxikon recurrent or refractory Phase II
Berkeley, CA Hodgkin’s disease (510) 647-4000
(see also solid tumors)
PX-478 Oncothyreon (see also solid tumors) Phase I completed
Seattle, WA (206) 801-2100
rituxan® Biogen Idec non-Hodgkin’s lymphoma Phase III
rituxumab Cambridge, MA (subcutaneous) (617) 679-2000
Roche (973) 235-5000
Nutley, NJ --------------------------------------------------------------------------------------
non-Hodgkin’s lymphoma Phase III
(fast fusion) (617) 679-2000
(973) 235-5000
SAR3419 sanofi-aventis non-Hodgkin’s lymphoma Phase I
Bridgewater, NJ (800) 633-1610
SB1518 S*Bio late-stage lymphoma Phase II
Redwood City, CA (see also leukemia) (650) 730-2860
SCH-900776 Merck (see also leukemia) Phase I
Whitehouse Station, NJ (800) 672-6372
SGN-35 Millennium Pharmaceuticals Hodgkin’s disease (combination application submitted
(brentuximab Cambridge, MA therapy), recurrent non-Hodgkin’s (800) 390-5663
vedotin) Seattle Genetics lymphoma (425) 527-4000
(orphan drug) Bothell, WA --------------------------------------------------------------------------------------
non-Hodgkin’s lymphoma Phase II
(monotherapy) (800) 390-5663
(Fast Track) (425) 527-4000
SGN-75 Seattle Genetics non-Hodgkin’s lymphoma Phase I
Bothell, WA (see also kidney) (425) 527-4000
SNDX-275 Syndax Pharmaceuticals Hodgkin’s disease Phase II
(entinostat) Waltham, MA (see also breast, colorectal, (781) 419-1400
leukemia, lung)
sprycel® Bristol-Myers Squibb non-Hodgkin’s lymphoma Phase I/II
dasatinib Princeton, NJ (see also brain, breast, colorectal, (212) 546-4000
leukemia, lung, multiple myeloma,
prostate, skin)
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 39
l y M p H o M a
product name sponsor indication development status
stem cell therapy Benitec AIDS-related lymphoma Phase I
Melbourne, Australia
City of Hope
Medical Center
Duarte, CA
telcyta® Telik diffuse large B-cell lymphoma, Phase II
canfosfamide Palo Alto, CA mantle-cell lymphoma (650) 845-7700
non-Hodgkin’s lymphoma
(see also lung, ovarian)
thiarabine Access Pharmaceuticals (see also leukemia) Phase I/II
Dallas, TX (214) 905-5100
tigatuzumab Daiichi Sankyo (see also colorectal, liver, ovarian, Phase I completed
Parsippany, NJ pancreatic) (973) 359-2600
TKM-PLK1 Tekmira Pharmaceuticals (see also solid tumors) Phase I
Vancouver, Canada (604) 419-3200
treanda® Cephalon first-line non-Hodgkin’s lymphoma Phase III
bendamustine Frazer, PA (610) 344-0200
--------------------------------------------------------------------------------------
mantle-cell lymphoma Phase II
(610) 344-0200
TRU-016 Emergent Biosolutions recurrent non-Hodgkin’s lymphoma Phase I
(anti-CD37) Rockville, MD (see also leukemia) (301) 795-1800
UNBS-5162 Drais Pharmaceuticals (see also solid tumors) Phase I
Bridgewater, NJ (908) 895-1200
velcade® Millennium Pharmaceuticals relapsed or refractory follicular Phase III
bortezomib Cambridge, MA lymphoma, first-line mantle-cell (800) 390-5663
lymphoma
(see also multiple myeloma)
--------------------------------------------------------------------------------------
diffuse large B-cell lymphoma Phase II
(800) 390-5663
veltuzumab Immunomedics non-Hodgkin’s lymphoma Phase I/II
(IMMU-106) Morris Plains, NJ (see also leukemia) (973) 605-8200
vinorelbine Talon Therapeutics non-Hodgkin’s lymphoma Phase I
liposomal South San Francisco, CA (see also solid tumors) (650) 588-6404
XmAb 2513 Xencor Hodgkin’s disease, Phase I
Monrovia, CA T-cell lymphoma (626) 305-5900
YM-155 Astellas Pharma US non-Hodgkin’s lymphoma Phase II
Deerfield, IL (see also breast) (800) 727-7003
zanolimumab TenX Biopharma cutaneous T-cell lymphoma Phase III
Philadelphia, PA (Fast Track) (215) 774-1176
--------------------------------------------------------------------------------------
peripheral T-cell lymphoma Phase II completed
(215) 774-1176
40 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
M u l t i p l e M y e l o M a
product name sponsor indication development status
ACE-041 Acceleron Pharma (see also solid tumors) Phase I
Cambridge, MA (617) 649-9200
actimid™ Celgene recurrent multiple myeloma Phase II
pomalidomide Summit, NJ (908) 673-9000
ALXN-6000 Alexion Pharmaceuticals (see also leukemia) Phase I/II
(samalizumab) Cheshire, CT (203) 272-2596
anti-FGFR3 mAb Genentech refractory, metastatic Phase I
(RG7444) South San Francisco, CA multiple myeloma (650) 224-1000
aplidin® PharmaMar USA (see also lymphoma, solid tumors) Phase III
plitidepsin Cambridge, MA (617) 868-3797
(orphan drug)
AR-42 Arno Therapeutics (see also leukemia, lymphoma) Phase I/II
Parsippany, NJ (862) 703-7170
ARRY-520 Array BioPharma (see also leukemia, solid tumors) Phase II
Boulder, CO (303) 381-6600
AT7519 Astex Therapeutics (see also solid tumors) Phase I/II
Cambridge, United Kingdom
com
ATN-224 Tactic Pharma (see also prostate, skin) Phase I/II
Evanston, IL (847) 733-0940
AUY922 Novartis Pharmaceuticals (see also breast, colorectal, Phase I/II
East Hanover, NJ lung, stomach) (888) 669-6682
AV-299 AVEO Pharmaceuticals (see also brain, lymphoma, Phase I
(ficlatuzumab) Cambridge, MA solid tumors) (617) 299-5000
BHQ880 Novartis Pharmaceuticals (see also solid tumors) Phase II
East Hanover, NJ (888) 669-6682
BI-505 BioInvent International late-stage multiple myeloma Phase I
Lund, Sweden
BIW-8962 BioWa Phase I/II
Princeton, NJ (609) 580-7500
BT-062 Biotest Phase I/II
(orphan drug) Dreieich, Germany
CAL-101 Calistoga Pharmaceuticals (see also leukemia, lymphoma) Phase I
Seattle, WA (206) 728-4700
carfilzomib Onyx Pharmaceuticals (Fast Track) application submitted
(orphan drug) Emeryville, CA (see also solid tumors) (510) 597-6500
CB3304 Cougar Biotechnology Phase I/II
Los Angeles, CA (310) 943-8040
CC-223 Celgene (see also lymphoma, solid tumors) Phase I/II
Summit, NJ (908) 673-9000
CEP-18770 Cephalon Phase II
(proteasome Frazer, PA (610) 344-0200
inhibitor)
CNTO 328 Centocor Ortho Biotech (see also prostate, other) Phase II
(siltuximab) Horsham, PA (800) 457-6399
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 41
M u l t i p l e M y e l o M a
product name sponsor indication development status
CX-4945 Cylene Pharmaceuticals (see also solid tumors, other) Phase I
San Diego, CA (858) 875-5100
dacetuzumab Seattle Genetics (see also leukemia, lymphoma) Phase I
(anti-CD40) Bothell, WA (425) 527-4000
(orphan drug)
darinaparsin Ziopharm Oncology (see also liver, lymphoma, Phase II completed
(ZIO-101) New York, NY solid tumors) (646) 214-0700
elotuzumab Bristol-Myers Squibb Phase I/II
(BMS-901608) Princeton, NJ (212) 546-4000
Facet Biotech (650) 454-1000
Redwood City, CA
ENMD-2076 EntreMed relapsed or refractory multiple Phase I
Rockville, MD myeloma (240) 864-2600
(see also ovarian, other)
GRN-163L Geron (see also breast, leukemia, lung) Phase II
(imetelstat) Menlo Park, CA (650) 473-7700
GvaX® Multiple BioSante Pharmaceuticals (see also breast, colorectal, Phase II
Myeloma Lincolnshire, IL leukemia, pancreatic) (847) 478-0500
IMGN-901 ImmunoGen (see also lung) Phase I
Cambridge, MA (617) 995-2500
INK128 Intellikine (see also lymphoma, solid tumors) Phase I
(TORC1/2 inhibitor) La Jolla, CA (858) 768-6500
IPH-2101 Innate Pharma Phase II
Marseille, France
KW-2478 Kyowa Hakko Kirin Pharma Phase I/II
Princeton, NJ (609) 919-1100
LY2127399 Applied Molecular Evolution Phase I
(BAFF antibody) San Diego, CA (800) 545-5979
Eli Lilly
Indianapolis, IN
mapatumumab Human Genome Sciences (see also liver, lung) Phase II
Rockville, MD (301) 309-8504
melphalan CyDex Pharmaceuticals Phase II
intravenous Lenexa, KS (888) 436-6910
(orphan drug)
milatuzumab Immunomedics (see also leukemia, lymphoma) Phase I/II
(IMMU-115) Morris Plains, NJ (973) 605-8200
(orphan drug)
NPI-0052 Nereus Pharmaceuticals (see also lymphoma, solid tumors) Phase I
(marizomib) San Diego, CA (858) 587-4090
obatoclax Gemin X Biotechnologies (see also leukemia, lung, lymphoma) Phase I
Montreal, Canada (514) 281-8989
panobinostat Novartis Pharmaceuticals (see also lymphoma, other) Phase III
(LBH589) East Hanover, NJ (888) 669-6682
PD-0332991 Pfizer (see also brain, breast, lymphoma, Phase I/II
New York, NY sarcoma) (860) 732-5156
42 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
M u l t i p l e M y e l o M a
product name sponsor indication development status
perifosine AEterna Zentaris recurrent multiple myeloma Phase III
(KRX-0401) Montreal, Canada (Fast Track) (212) 531-5965
(orphan drug) Keryx Biopharmaceuticals (see also brain, colorectal, kidney,
New York, NY leukemia, lymphoma, ovarian,
sarcoma, stomach)
Quadramet® EUSA Pharma (see also prostate, sarcoma, Phase I/II completed
samarium sm-153 Langhorne, PA other) (800) 833-3533
lexidronam
injection
SF1126 Semafore Pharmaceuticals (see also multiple myeloma, Phase I
Indianapolis, IN solid tumors) (317) 876-3075
sprycel® Bristol-Myers Squibb (see also brain, breast, colorectal, Phase I
dasatinib Princeton, NJ leukemia, lung, lymphoma, (212) 546-4000
prostate, skin)
treanda® Cephalon (see also lymphoma) Phase II
bendamustine Frazer, PA (610) 344-0200
trisenox® Cephalon combination therapy Phase II
arsenic trioxide Frazer, PA (see also brain, leukemia) (610) 344-0200
VEL-0230 Velcura Therapeutics Phase I completed
Ann Arbor, MI (734) 973-1000
velcade® Millennium Pharmaceuticals (see also lymphoma) Phase III
bortezomib Cambridge, MA (800) 390-5663
(subcutaneous)
Zolinza® Merck (see also breast, other) Phase III
vorinostat Whitehouse Station, NJ (800) 672-6372
(orphan drug)
o v a r i a n c a n c e r
product name sponsor indication development status
A° 6 Angstrom Pharmaceuticals (see also other) Phase II
Solana Beach, CA (858) 314-2356
abagovomab Menarini Phase II/III
(anti-idiotype Florence, Italy
ovarian cancer
vaccine)
(orphan drug)
abraxane® Celgene (see also bladder, lung, pancreatic, Phase II
albumin-bound Summit, NJ skin) (908) 673-9000
paclitaxel
ABT-888 Abbott Laboratories (see also brain, breast, Phase II
(veliparib) Abbott Park, IL colorectal, prostate, skin, other) (847) 937-6100
AE-37 Antigen Express (see also breast) Phase I
Worcester, MA (508) 852-8783
AMG 386 Amgen (see also breast, colorectal, kidney, Phase III
Thousand Oaks, CA liver, stomach, other) (800) 772-6436
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 43
o v a r i a n c a n c e r
product name sponsor indication development status
avastin® Genentech first-line metastatic ovarian cancer, Phase III
bevacizumab South San Francisco, CA recurrent platinum-sensitive ovarian (650) 225-1000
cancer
(see also brain, breast, colorectal,
lung, other)
BC-819 BioCancell Therapeutics (see also bladder, pancreatic) Phase I/II
Jerusalem, Israel
catumaxomab Fresenius Biotech (see also other) Phase II
North America
Waltham, MA
cvax™ Prima BioMed Phase II
MUC-2 Armadale, Australia
cancer vaccine biomed.com.au
dcvax®-l Northwest Biotherapeutics (see also other) Phase I/II
ovarian cancer Bothell, WA (425) 608-3000
vaccine
DPX-0907 Immunovaccine (see also breast, prostate) Phase I
Halifax, Canada (902) 492-1819
EC-145 Endocyte (see also lung, other) Phase II
West Lafayette, IN (765) 463-7175
EGEN 001 EGEN recurrent ovarian cancer Phase II
(orphan drug) Huntsville, AL (see also other) (256) 512-0077
--------------------------------------------------------------------------------------
refractory metastatic ovarian cancer Phase I
(256) 512-0077
ENMD-2076 EntreMed platinum-resistant ovarian cancer Phase II
Rockville, MD (see also multiple myeloma, other) (240) 864-2600
farletuzumab Eisai (see also lung) Phase III
(MORAb-003) Woodcliff Lake, NJ (888) 422-4743
iboctadekin GlaxoSmithKline Phase I
Rsch. Triangle Park, NC (888) 825-5249
IMT-1012 Immunotope (see also breast) Phase I
(immunotherapeutic Doylestown, PA (215) 253-4180
vaccine)
iniparib BiPar Sciences (see also breast, lung) Phase II
(BSI-201) South San Francisco, CA (800) 633-1810
sanofi-aventis
Bridgewater, NJ
Karenitecin® BioNumerik advanced epithelial ovarian cancer Phase III
cositecan Pharmaceuticals (210) 614-1701
San Antonio, TX
KHK-2866 Kyowa Hakko Kirin Pharma (see also solid tumors) Phase I
Princeton, NJ (609) 919-1100
lenvatinib Eisai (see also brain, kidney, liver, Phase I/II
(E7080) Woodcliff Lake, NJ skin, other) (888) 422-4743
44 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
o v a r i a n c a n c e r
product name sponsor indication development status
nexavar® Bayer HealthCare (see also breast, colorectal, kidney, Phase II
sorafenib Pharmaceuticals liver, lung, other) (888) 842-2837
Wayne, NJ (510) 597-6500
Onyx Pharmaceuticals
Emeryville, CA
NKTR-102 Nektar Therapeutics metastatic ovarian cancer Phase II
San Francisco, CA (see also breast, colorectal) (415) 482-5300
NOV-002 Novelos Therapeutics (see also breast) Phase II completed
Newton, MA (617) 244-1616
OGX-427 Oncogenex (see also bladder, breast, lung, Phase I
Pharmaceuticals prostate) (425) 686-1500
Bothell, WA
olaparib AstraZeneca serous ovarian cancer Phase II
Wilmington, DE (800) 236-9933
ON-01910 Onconova Therapeutics (see also leukemia, lymphoma, Phase II
Princeton, NJ solid tumors) (609) 844-7735
opaxio™ Cell Therapeutics (see also lung, other) Phase III
paclitaxel Seattle, WA (800) 215-2355
poliglumex Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
oregovomab Quest Pharmatech Phase I/II
Edmonton, Canada (780) 448-1400
OSI-906 OSI Pharmaceuticals (see also lung, other) Phase II
(linsitinib) Melville, NY (631) 962-2000
ovax® AVAX Technologies Phase I/II
ovarian cancer Philadelphia, PA (215) 241-9760
vaccine
(orphan drug)
perifosine AEterna Zentaris (see also brain, colorectal, kidney, Phase I
(KRX-0401) Montreal, Canada leukemia, lymphoma, multiple (212) 531-5965
Keryx Biopharmaceuticals myeloma, sarcoma, stomach)
New York, NY
PF-01367338 Pfizer (see also breast, skin) Phase II
New York, NY (860) 732-5156
phenoxodiol Marshall Edwards late-stage ovarian cancer Phase III
San Diego, CA (Fast Track) (858) 792-6300
(see also prostate, other)
picoplatin Poniard Pharmaceuticals (see also colorectal, lung, prostate) Phase II
intravenous San Francisco, CA (650) 583-3774
Quinamed® ChemGenex (see also breast, prostate) Phase II
amonafide Pharmaceuticals (650) 474-9800
Menlo Park, CA
sagopilone Bayer HealthCare (see also brain, breast, prostate) Phase II
Pharmaceuticals (888) 842-2937
Wayne, NJ
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 45
o v a r i a n c a n c e r
product name sponsor indication development status
SAR256212 Merrimack Pharmaceuticals (see also breast, solid tumors) Phase I
(MM-121) Cambridge, MA (617) 441-1000
sanofi-aventis (800) 633-1810
Bridgewater, NJ
SG2000 Spirogen Phase II
London, United Kingdom
squalamine OHR Pharmaceuticals resistant ovarian cancer Phase II
New York, NY (212) 682-8452
telcyta® Telik (see also lung, lymphoma) Phase III completed
canfosfimide Palo Alto, CA (650) 845-7700
tigatuzumab Daiichi Sankyo (see also colorectal, liver, lymphoma, Phase II
Parsippany, NJ pancreatic) (973) 359-2600
topotecan Talon Therapeutics (see also lung) Phase I
liposomal South San Francisco, CA (650) 588-6404
trabectedin Johnson & Johnson (see also breast, prostate, sarcoma) application submitted
(orphan drug) Pharmaceutical Research (800) 817-5286
& Development
Raritan, NJ
volociximab Biogen Idec (see also lung) Phase II
Cambridge, MA (617) 679-2000
Facet Biotech (650) 454-1000
Redwood City, CA
vosaroxin Sunesis Pharmaceuticals platinum-resistant ovarian cancer Phase II
(SNS-595) South San Francisco, CA (see also leukemia) (650) 266-3500
votrient® GlaxoSmithKline (see also breast, kidney, sarcoma) Phase III
pazopanib Rsch. Triangle Park, NC (888) 825-5249
Zybrestat™ OXiGENE (see also lung, other) Phase II
fosbretabulin South San Francisco, CA (650) 635-7000
(orphan drug)
p a n c r e a t i c c a n c e r
product name sponsor indication development status
abraxane® Celgene (see also bladder, lung, Phase III
albumin-bound Summit, NJ ovarian, skin) (908) 673-9000
paclitaxel
(orphan drug)
AGS-1C4D4 Agensys Phase II
Santa Monica, CA (310) 820-8029
Astellas Pharma US (800) 477-6472
Deerfield, IL
AMG 479 Amgen (see also breast, colorectal, lung, Phase III
(ganitumab) Thousand Oaks, CA sarcoma, other) (800) 772-6436
anti-MUC1 mAb Quest PharmaTech Phase I/II
Edmonton, Canada (780) 448-1400
46 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
p a n c r e a t i c c a n c e r
product name sponsor indication development status
apricoxib Tragara Pharmaceuticals (see also lung) Phase II
San Diego, CA (858) 350-6900
ARC-100 Archer Biosciences (see also brain, prostate, skin) Phase II
New York, NY (646) 747-9090
ARQ-197 ArQule (see also colorectal, kidney, liver, Phase I
Woburn, MA lung, sarcoma, solid tumors, other) (781) 994-0300
Daiichi Sankyo (973) 944-2600
Parsippany, NJ
ASG-5ME Agensys metastatic pancreatic cancer Phase I
Santa Monica, CA (see also prostate) (301) 820-8029
Astellas Pharma US (800) 477-6472
Deerfield, IL
bavituximab Peregrine Pharmaceuticals (see also breast, liver) Phase II
Tustin, CA (714) 508-6000
BC-819 BioCancell Therapeutics inoperable/unresectable Phase I/II
Jerusalem, Israel pancreatic cancer
(see also bladder, ovarian)
CO-101/CP-4126 Clovis Oncology Phase II
(orphan drug) Boulder, CO (303) 625-5000
conatumumab Amgen (see also colorectal, lung, sarcoma) Phase I/II
Thousand Oaks, CA (800) 772-6436
CPI-613 Cornerstone (see also other) Phase I/II
(orphan drug) Pharmaceuticals (609) 409-7050
Cranbury, NJ
dalotuzumab Merck (see also breast, colorectal, Phase I/II
Whitehouse Station, NJ lung, other) (888) 669-6682
encapsulated cell Rogosin Institute refactory metastatic pancreatic Phase II
therapy New York, NY cancer (212) 746-1225
(macrobeads) (see also colorectal, prostate)
ensituximab Neogenix Oncology inoperable/unresectable, late-stage, Phase I
Great Neck, NY metastatic pancreatic cancer (516) 482-1200
(see also colorectal)
FG-3019 Fibrogen Phase II
San Francisco, CA (415) 978-1200
GI-4000 GlobeImmune (see also colorectal, lung) Phase II
Louisville, CO (303) 625-2700
glufosfamide Eleison Pharmaceuticals (Fast Track) Phase III completed
(orphan drug) Princeton, NJ (215) 416-7620
GSK1120212 GlaxoSmithKline (see also skin, solid tumors) Phase II
(MEK inhibitor) Rsch. Triangle Park, NC (888) 825-5249
GvaX® pancreatic BioSante Pharmaceuticals (see also breast, colorectal, Phase II
(orphan drug) Lincolnshire, IL leukemia, multiple myeloma) (847) 478-0500
Hyperacute® NewLink Genetics (Fast Track) Phase III
pancreas Ames, IA (515) 296-5555
algenpantucel-L
(orphan drug)
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 47
p a n c r e a t i c c a n c e r
product name sponsor indication development status
IPI-926 Infinity Pharmaceuticals (see also sarcoma, solid tumors) Phase I/II
Cambridge, MA (617) 453-1000
JX-929 Jenerex Biotherapeutics Phase I
San Francisco, CA (415) 281-8886
LE-DT NeoPharm late-stage, metastatic pancreatic Phase II
Lake Bluff, IL cancer (847) 887-0800
(see also prostate)
masitinib AB Science USA (see also leukemia, stomach) Phase III
Short Hills, NJ (973) 218-2437
MM-398 Merrimack Pharmaceuticals metastatic pancreatic cancer Phase II
Cambridge, MA (617) 441-1000
naptumomab Active Biotech (see also kidney, lung) Phase I completed
estafenatox Lund, Sweden
pancatak™ Advantagene Phase I
gene therapy Auburndale, MA (617) 916-5445
PCI-27483 Pharmacyclics Phase II
(factor VIIa Sunnyvale, CA (408) 774-0330
inhibitor)
polyclonal antibody Cancer Advances (see also colorectal, stomach) Phase III
stimulator Durham, NC (919) 361-2162
(orphan drug)
reolysin® Oncolytics Biotech (see also brain, colorectal, head/neck, Phase II
reovirus Calgary, Canada lung, sarcoma, skin) (403) 670-7377
rexin-G™ Epeius Biotechnologies recurrent, refractory metastatic Phase I/II
tumor-targeted San Marino, CA pancreatic cancer (Fast Track) (626) 441-6695
gene therapy (see also breast, sarcoma)
(orphan drug)
RX-0201 Rexahn Pharmaceuticals Phase II
(orphan drug) Rockville, MD (240) 268-5300
salirasib Concordia Pharmaceuticals (see also lung) Phase I/II
(orphan drug) Ft. Lauderdale, FL
sutent® Pfizer pancreatic islet cell tumors application submitted
sunitinib New York, NY (see also kidney) (860) 732-5156
TH-302 Threshold Pharmaceuticals (see also leukemia, sarcoma, Phase II
Redwood City, CA solid tumors) (650) 474-8200
tigatuzumab Daiichi Sankyo (see also colorectal, liver, Phase II completed
Parsippany, NJ lymphoma, ovarian) (973) 359-2600
tremelimumab Pfizer (see also kidney, skin, stomach, other) Phase II
(CP-675206) New York, NY (860) 732-5156
virulizin Zor Pharmaceuticals Phase III
Wilmington, NC (919) 946-4457
Y-90 hPAM4 Immunomedics Phase I/II
(IMMU-107) Morris Plains, NJ (973) 605-8200
(orphan drug)
48 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
p r o s t a t e c a n c e r
product name sponsor indication development status
ABI-008 Celgene hormone-refractory prostate cancer Phase II
(nab®-docetaxel) Summit, NJ (908) 673-9000
abiraterone acetate Cougar Biotechnology metastatic advanced prostate cancer application submitted
(CB7630) Raritan, NJ (see also breast) (800) 817-5286
ABR-215050 Active Biotech Phase III
(tasquinimod) Lund, Sweden
ABT-888 Abbott Laboratories (see also brain, breast, Phase I
(veliparib) Abbott Park, IL colorectal ovarian, skin, other) (847) 937-6100
acapodene® GTx prostatic intraepithelial neoplasia Phase III
toremifene Memphis, TN (prevention) (901) 523-9700
(see also cancer/chemotherapy)
AEZS-108 AEterna-Zentaris (see also bladder) Phase I/II
Warren, NJ (908) 626-5428
aflibercept sanofi-aventis first-line metastatic prostate Phase III
(VEGF-trap) Bridgewater, NJ cancer (800) 633-1610
Regeneron Pharmaceuticals (see also colorectal, lung) (714) 345-7400
Tarrytown, NY
androgen receptor Endo Pharmaceuticals Phase I
antagonist Chadds Ford, PA (800) 462-3636
Orion
Espoo, Finland
ARC-100 Archer Biosciences (see also brain, pancreatic, skin) Phase II
New York, NY (646) 747-9090
ARN-509 Aragon Pharmaceuticals Phase I/II
San Diego, CA (858) 369-7600
ASG-5ME Agensys castration-resistant prostate cancer Phase I
Santa Monica, CA (see also pancreatic) (301) 820-8029
Astellas Pharma US (800) 477-6472
Deerfield, IL
AT-101 Ascenta Therapeutics (see also brain, leukemia, lung, Phase II
Malvern, PA lymphoma, stomach) (618) 408-0301
ATN-224 Tactic Pharma (see also multiple myeloma, skin) Phase II
Evanston, IL (847) 733-0940
avodart® GlaxoSmithKline prostate cancer prevention, application submitted
dutasteride Rsch. Triangle Park, NC prostatic intraepithelial neoplasia (888) 825-5249
AZD3514 AstraZeneca Phase I
(androgen receptor Wilmington, DE (800) 236-9933
down regulator)
bafetinib CytRx hormone-refractory prostate cancer Phase II
Los Angeles, CA (see also leukemia) (310) 826-5648
BPX-101 Bellicum Pharmaceuticals Phase I/II
(BP-GMAX-CD1) Houston, TX (713) 341-6472
carlumab Centocor Ortho Biotech metastatic prostate cancer Phase II
Horsham, PA (see also solid tumors) (800) 457-6399
cilengitide EMD Serono (see also brain, lymphoma) Phase II
Rockland, MA (800) 283-8088
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 49
p r o s t a t e c a n c e r
product name sponsor indication development status
CNTO 95 Centocor Ortho Biotech (see also skin, solid tumors) Phase II completed
Horsham, PA (800) 457-6399
CNTO 328 Centocor Ortho Biotech hormone-refractory prostate cancer Phase I
(siltuximab) Horsham, PA (see also multiple myeloma, other) (800) 457-6399
CV9103 Curevac Phase I/II
Tübingen, Germany
dcvax®-prostate Northwest Biotherapeutics Phase III
prostate cancer Bothell, WA (425) 608-3000
vaccine
DPX-0907 Immunovaccine (see also breast, ovarian) Phase I
Halifax, Canada (902) 492-1819
encapsulated cell Rogosin Institute refractory metastatic pancreatic Phase II
therapy New York, NY cancer (212) 746-1225
(macrobeads) (see also colorectal, pancreatic)
eribulin Eisai (see also bladder, lung, sarcoma) Phase II
(E7389) Woodcliff Lake, NJ (888) 422-4743
Gleevec® Novartis Pharmaceuticals Phase II/III
imatinib East Hanover, NJ (888) 669-6682
GRNVAC1 Geron (see also leukemia) Phase I/II
Menlo Park, CA (650) 473-7700
GTx-758 GTx Phase II completed
Memphis, TN (901) 523-9700
HE-3235 Harbor Biosciences hormone-resistant prostate cancer Phase II completed
San Diego, CA (858) 587-9333
Hyperacute® NewLink Genetics hormone-refractory prostate cancer Phase I/II completed
prostate Ames, IA (515) 296-5555
prostate cancer
vaccine
INSM-18 Triact Therapeutics Phase I/II
Palo Alto, CA
ipilimumab Bristol-Myers Squibb (see also lung, skin) Phase III
Princeton, NJ (212) 546-4000
irofulven Eisai Phase II
(E7850) Woodcliff Lake, NJ (888) 422-4743
irosustat Ipsen Phase I
Paris, France
JNJ-26854165 Johnson & Johnson (see also lung, solid tumors) Phase I
Pharmaceutical Research (800) 817-5286
& Development
Raritan, NJ
KX2-391 Kinex Pharmaceuticals Phase II
Buffalo, NY (716) 881-8984
LE-DT NeoPharm castration-resistant metastatic Phase II
Lake Bluff, IL prostate cancer (847) 887-0800
(see also pancreatic)
50 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
p r o s t a t e c a n c e r
product name sponsor indication development status
leupron depot® Abbott Pharmaceuticals application submitted
leuprorelin depot Abbott Park, IL (847) 937-6100
(6-month
formulation)
MDV-3100 Astellas Pharma US hormone-refractory prostate Phase III
Deerfield, IL cancer (800) 727-7003
Medivation (415) 543-3470
San Francisco, CA
mepacrine Incuron hormone-refractory prostate Phase II completed
(CBLC102) Buffalo, NY cancer (716) 849-6810
MER-104 Merrion Pharmaceuticals Phase I
Wilmington, NC (910) 799-1847
MIP1095 Molecular Insight diagnosis of prostate cancer Phase I
Pharmaceuticals (617) 492-5554
Cambridge, MA
MVA-5T4 Oxford BioMedica Phase II
Oxford, United Kingdom
co.uk
Mva-Bn®-pro BN ImmunoTherapeutics Phase I/II
Mountain View, CA (650) 681-4660
neuvax™ Apthera (see also breast) Phase I/II
E75 cancer Scottsdale, AZ
vaccine
nimotuzumab YM Biosciences USA (see also brain, breast) Phase II
Lehigh Valley, PA (610) 560-0600
OGX-427 Oncogenex hormone-refractory prostate cancer Phase II
Pharmaceuticals (see also bladder, breast, lung, (425) 686-1500
Bothell, WA ovarian)
onyvax-p VaxOnco Phase II
anti-idiotype Seoul, South Korea
cancer vaccine
105AD7
ozarelix Spectrum Pharmaceuticals Phase II
Irvine, CA (949) 788-6700
phenoxodiol Marshall Edwards (Fast Track) Phase II completed
San Diego, CA (see also ovarian, other) (858) 792-6300
picoplatin Poniard Pharmaceuticals (see also colorectal, lung, ovarian) Phase II
intravenous San Francisco, CA (650) 583-3774
polyphenon E Polyphenon Pharma prostatic intraepithelial neoplasia Phase II
New York, NY (see also leukemia) (212) 661-0578
proscar® Merck prevention of prostate cancer Phase III completed
finasteride Whitehouse Station, NJ (800) 673-6372
prostatak™ Advantagene Phase II completed
gene therapy Auburndale, MA (617) 916-5445
prostvac®-vf BN ImmunoTherapeutics metastatic prostate cancer Phase II
prostate Mountain View, CA (Fast Track) (650) 681-4660
cancer vaccine
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 51
p r o s t a t e c a n c e r
product name sponsor indication development status
provenge® Dendreon androgen-dependent recurrent Phase III
sipuleucel-T Seattle, WA prostate cancer (877) 256-4545
--------------------------------------------------------------------------------------
early-stage prostate cancer Phase II
(neoadjuvant therapy) (877) 256-4545
PRX302 Protox Therapeutics Phase II
Vancouver, Canada (604) 688-0199
PSMA ADC Progenics Pharmaceuticals Phase I
Tarrytown, NY (914) 789-2800
PSMA subunit Progenics Phase I
vaccine Tarrytown, NY (914) 789-2800
PSMA VRP Progenics Pharmaceuticals Phase I
Tarrytown, NY (914) 789-2800
Quadramet® EUSA Pharma (see also multiple myeloma, Phase II
samarium SM-153 Langhorne, PA sarcoma, other) (800) 833-3533
lexidronam
injection
Quinamed® ChemGenex (see also breast, ovarian) Phase II
amonafide Pharmaceuticals (650) 474-9800
Menlo Park, CA
REIC gene therapy Momotaro-Gene Phase I
Okayama, Japan
revlimid® Celgene Phase III
lenalidomide Summit, NJ (908) 673-9000
rilotumumab Amgen (see also brain, colorectal, lung, Phase II
Thousand Oaks, CA stomach) (800) 772-6436
sagopilone Bayer HealthCare (see also brain, breast, ovarian) Phase II
Pharmaceuticals (888) 842-2937
Wayne, NJ
seocalcitol Cougar Biotechnology Phase I
(CB1089) Los Angeles, CA (310) 943-8040
SL052 Quest PharmaTech Phase I/II
Edmonton, Canada (780) 448-1400
sprycel® Bristol-Myers Squibb (see also brain, breast, colorectal, Phase II/III
dasatinib Princeton, NJ leukemia, lung, lymphoma, (212) 546-4000
multiple myeloma, skin)
TAK-448 Millennium Pharmaceuticals Phase I/II
Cambridge, MA (800) 390-5663
TAK-700 Millennium Pharmaceuticals metastatic hormone-refractory Phase III
(orteronel) Cambridge, MA prostate cancer (800) 390-5663
tesetaxel Genta advanced prostate cancer Phase II
Berkeley Heights, NJ (see also bladder, breast, skin, (908) 286-9800
stomach)
tigapotide Kotinos Pharmaceuticals Phase II
New York, NY
52 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
p r o s t a t e c a n c e r
product name sponsor indication development status
TOK-01 Tokai Pharmaceuticals Phase I/II
Cambridge, MA (617) 225-4305
trabectedin Johnson & Johnson (see also breast, ovarian, Phase II
Pharmaceutical Research sarcoma) (800) 817-5286
& Development
Raritan, NJ
TRC105 TRACON Pharmaceuticals metastatic prostate cancer Phase I/II
San Diego, CA (see also solid tumors) (858) 550-0780
trofex™ Molecular Insight diagnosis of prostate cancer Phase I
radiolabelled Pharmaceuticals (617) 492-5554
diagnostic Cambridge, MA
TV-1001/OCX-011 OncoGenex metastatic prostate cancer Phase III
(custiren) Pharmaceuticals (Fast Track) (425) 686-1500
Bothell, WA (see also lung)
Teva Pharmaceutical
Tikva, Israel
zibotentan AstraZeneca castration-resistant prostate cancer Phase III
Wilmington, DE (Fast Track) (800) 236-9933
s a r c o M a
product name sponsor indication development status
8H9 mAb United Therapeutics soft tissue sarcoma Phase I
Silver Spring, MD (see also brain, other) (301) 608-9292
AMG 479 Amgen (see also breast, colorectal, lung, Phase II
(ganitumab) Thousand Oaks, CA pancreatic, other) (800) 772-6436
ARQ-197 ArQule soft tissue sarcoma Phase II
Woburn, MA (see also colorectal, liver, lung, (781) 994-0300
Daiichi Sankyo pancreatic, sarcoma, other) (973) 944-2600
Parsippany, NJ
cancer vaccine MabVax Therapeutics Phase II
San Diego, CA (858) 259-9405
conatumumab Amgen (see also colorectal, lung, Phase I/II
Thousand Oaks, CA pancreatic) (800) 772-6436
eribulin Eisai (see also bladder, lung, prostate) Phase II
(E7389) Woodcliff Lake, NJ (888) 422-4743
IPI-926 Infinity Pharmaceuticals inoperable/unresectable Phase I
Cambridge, MA chondrosarcoma (617) 453-1000
mifamurtide Millennium Pharmaceuticals osteosarcoma Phase III
Cambridge, MA (800) 390-5663
ombrabulin sanofi-aventis Phase III
(AVE8062) Bridgewater, NJ (800) 633-1610
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 53
s a r c o M a
product name sponsor indication development status
palifosfamide ZIOPHARM Oncology soft-tissue sarcoma (first-line therapy) Phase III
(ZIO-201) New York, NY (see also lung) (212) 214-0700
(orphan drug) --------------------------------------------------------------------------------------
soft-tissue sarcoma Phase I/II
(second-line therapy) (212) 214-0700
PCI-24781 Pharmacyclics (see also lymphoma) Phase I
(HDAC inhibitor) Sunnyvale, CA (408) 774-0330
PD-0332991 Pfizer late-stage liposarcoma Phase II
New York, NY (see also brain, breast, lymphoma) (860) 732-5156
perifosine AEterna Zentaris (see also brain, colorectal, kidney, Phase II
(KRX-0401) Montreal, Canada leukemia, lymphoma, multiple (212) 531-5965
Keryx Biopharmaceuticals myeloma, ovarian, stomach)
New York, NY
Quadramet® EUSA Pharma osteosarcoma Phase I/II
samarium sm-153 Langhorne, PA (see also multiple myeloma, (800) 833-3533
lexidronam prostate, other)
injection
reolysin® Oncolytics Biotech (see also brain, colorectal, Phase II
reovirus Calgary, Canada head/neck, lung, pancreatic, skin) (403) 670-7377
rexin-G™ Epeius Biotechnologies osteosarcoma Phase II
tumor-targeted San Marino, CA (see also breast, pancreatic) (626) 441-6695
gene therapy --------------------------------------------------------------------------------------
(orphan drug) soft tissue sarcoma Phase I/II
(626) 441-6695
ridaforolimus Merck oral formulation (Fast Track) Phase III
(orphan drug) Whitehouse Station, NJ (see also breast, lung) (800) 672-6372
--------------------------------------------------------------------------------------
intravenous formulation Phase II
(800) 672-6372
robatumumab Merck osteosarcoma, sarcoma Phase II
Whitehouse Station, NJ (see also solid tumors) (800) 672-6372
TH-302 Threshold soft tissue sarcoma Phase I/II
Pharmaceuticals (see also leukemia, pancreatic, (650) 474-8200
Redwood City, CA solid tumors)
trabectedin Johnson & Johnson soft tissue sarcoma Phase III
(orphan drug) Pharmaceutical Research (see also breast, ovarian, prostate, (800) 817-5286
& Development other)
Raritan, NJ --------------------------------------------------------------------------------------
soft tissue sarcoma in adolescents Phase II
and children (800) 817-5286
votrient® GlaxoSmithKline (see also breast, kidney, ovarian) Phase III
pazopanib Rsch. Triangle Park, NC (888) 669-6682
54 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s K i n c a n c e r
product name sponsor indication development status
abraxane® Celgene malignant melanoma Phase III
albumin-bound Summit, NJ (see also bladder, lung, ovarian, (908) 673-9000
paclitaxel pancreatic)
(orphan drug)
ABT-888 Abbott Laboratories malignant melanoma Phase II
(veliparib) Abbott Park, IL (see also brain, breast, colorectal, (847) 937-6100
ovarian, prostate, other)
AD-1001 Intrexon late-stage malignant melanoma Phase I
Germantown, MD (646) 214-0700
ZIOPHARM Oncology
New York, NY
ADI-PEG 20 Polaris Pharmaceuticals malignant melanoma Phase II
(orphan drug) San Diego, CA (see also liver, lung) (858) 452-6688
allovectin-7® Vical malignant melanoma Phase III
velimogene San Diego, CA (Fast Track) (858) 646-1100
aliplasmid
(immunotherapeutic
vaccine)
(orphan drug)
ALS-357 Advanced Life Sciences malignant melanoma Phase I
(betulinic topical) Woodridge, IL (630) 739-6744
ALT-801 Altor BioScience malignant melanoma Phase I/II
Miramar, FL (954) 443-8600
APN301 Apeiron Biologics malignant melanoma Phase II
(hu14.18-IL2) Vienna, Austria (see also brain)
com
ARC-100 Archer Biosciences malignant melanoma Phase II
New York, NY (see also brain, pancreatic, prostate) (646) 747-9090
ATN-224 Tactic Pharma malignant melanoma Phase II
Evanston, IL (see also multiple myeloma, prostate) (847) 733-0940
azixa™ Myrexis malignant melanoma Phase II
(verubulin) Salt Lake City, UT (see also brain) (801) 214-7800
BMS-908662 Bristol-Myers Squibb malignant melanoma Phase I
(RAF kinase Princeton, NJ (see also colorectal) (212) 546-4000
inhibitor) Exelixis
South San Francisco, CA
BMS-936558 Bristol-Myers Squibb inoperable/unresectable malignant Phase I
(anti-PD1) Princeton, NJ melanoma (212) 546-4000
(see also solid tumors)
CDX-011 Celldex Therapeutics malignant melanoma Phase II
Needham, MA (see also breast) (781) 433-0771
CNTO 95 Centocor Ortho Biotech malignant melonoma Phase I/II
Horsham, PA (see also prostate, solid tumors) (800) 457-6399
CST-101 ConKwest stage IV malignant melanoma Phase I
Del Mar, CA (see also leukemia, lung, lymphoma) (858) 380-1999
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 55
s K i n c a n c e r
product name sponsor indication development status
CYT-107 Cytheris malignant melanoma Phase I
Rockville, MD (see also kidney, leukemia, (301) 231-0450
solid tumors)
denenicokin Bristol-Myers Squibb malignant melanoma Phase II
(IL-21) Princeton, NJ (212) 546-5000
(orphan drug)
E7272 Eisai melanoma Phase II
Woodcliff Lake, NJ (888) 422-4743
ecromeximab Life Sciences malignant melanoma Phase II
Pharmaceuticals (203) 656-2500
Darien, CT
GC-1008 Genzyme malignant melanoma Phase I
(fresolimumab) Cambridge, MA (see also kidney) (617) 252-7000
Genasense® Genta malignant melanoma Phase III
oblimersen Berkeley Heights, NJ (Fast Track) (908) 286-9800
(orphan drug) (see also leukemia, lymphoma)
GMX-1777 Gemin X Biotechnologies malignant melanoma Phase I completed
(teglarinad) Montreal, Canada (514) 281-8989
GSK1120212 GlaxoSmithKline malignant melanoma Phase III
(MEK inhibitor) Rsch. Triangle Park, NC (see also pancreatic, solid tumors) (888) 825-5249
--------------------------------------------------------------------------------------
combination therapy Phase II
(888) 825-5249
GSK2118436 GlaxoSmithKline metastatic malignant melanoma Phase III
(BRaf protein kinase Rsch. Triangle Park, NC (see also lung) (888) 825-5249
inhibitor)
GSK2302032A GlaxoSmithKline metastatic melanoma Phase I
(PRAME Rsch. Triangle Park, NC (888) 825-5249
immunotherapeutic
recombinant
vaccine)
GSK2401502 GlaxoSmithKline malignant melanoma Phase I
Rsch. Triangle Park, NC (888) 825-5249
Lipotek
Acton, Australia
Hyperacute® NewLink Genetics malignant melanoma Phase II
Melanoma Ames, IA (515) 296-5555
melanoma vaccine
IMC-20D7S Eli Lilly malignant melanoma Phase I
Indianapolis, IN (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
IMC-gp100 Immunocore malignant melanoma Phase 0
Oxon, United Kingdom
imprime pGG® Biothera malignant melanoma Phase I/II
Eagen, MN (see also colorectal, leukemia, lung) (651) 675-0300
56 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s K i n c a n c e r
product name sponsor indication development status
ioflubenzamide Molecular Insight malignant melanoma Phase I
I-131 Pharmaceuticals (617) 492-5554
Cambridge, MA
ipilimumab Bristol-Myers Squibb metastatic melanoma, combination Phase III
(orphan drug) Princeton, NJ therapy, first-line therapy (212) 546-4000
(Fast Track)
(see also lung, prostate)
lenvatinib Eisai melanoma Phase I/II
(E7080) Woodcliff Lake, NJ (see also brain, kidney, liver, other) (888) 422-4743
levulan® Kerastick® DUSA Pharmaceuticals prevention of skin cancer in solid Phase II
aminolevulinic acid Wilmington, MA organ transplant patients (978) 657-7500
lymphoseek™ Neoprobe diagnosis of malignant melanoma Phase III
Dublin, OH (see also breast, head/neck) (800) 793-0079
MAGE-A3 GlaxoSmithKline malignant melanoma Phase III
recombinant Rsch. Triangle Park, NC (see also lung) (888) 825-5249
vaccine (antigenspecific
cancer
immunotherapeutic)
Marqibo® Talon Therapeutics malignant melanoma Phase II
vincristine South San Francisco, CA (see also leukemia) (650) 588-6404
liposomal
(orphan drug)
melanoma Ichor Medical Systems malignant melanoma Phase I
vaccine San Diego, CA (858) 550-2022
Memorial Sloan-Kettering
Cancer Center
New York, NY
Metvixia® PhotoCure basal cell cancer Phase III
methyl Oslo, Norway
aminolevulinate
MKC1106-MT MannKind malignant melanoma Phase II
Valencia, CA (661) 775-5300
MORAb-028 Eisai malignant melanoma Phase I
Woodcliff Lake, NJ (888) 422-4743
muparfostat Progen Pharmaceuticals malignant melanoma Phase II
(PI-88) Redwood City, CA (see also liver) (650) 610-7080
(orphan drug)
OncoVEXGM-csf BioVex malignant melanoma Phase III
Woburn, MA (see also head/neck) (781) 376-4900
ontak® Eisai melanoma Phase II
denileukin diftitox Woodcliff Lake, NJ (888) 422-4743
PEP005 LEO Pharma non-melanoma skin cancer Phase II
Parsippany, NJ (877) 494-4536
PF-1367338 Pfizer malignant melanoma Phase II
New York, NY (see also breast, ovarian) (860) 732-5156
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 57
s K i n c a n c e r
product name sponsor indication development status
prophage Agenus malignant melanoma Phase III
(vitespen) Lexington, MA (Fast Track) (781) 674-4400
(orphan drug) (see also brain, kidney)
PTC299 PTC Therapeutics Kaposi’s sarcoma Phase I/II
South Plainfield, NJ (see also breast, solid tumors, other) (908) 222-7000
PTI-188 Pain Therapeutics malignant melanoma Phase I completed
San Mateo, CA (650) 624-8200
PV-10 Provectus Pharmaceuticals malignant melanoma Phase II
Knoxville, TN (see also liver) (866) 594-5999
RAF265 Novartis Pharmaceuticals malignant melanoma Phase I
East Hanover, NJ (888) 669-6682
reolysin® Oncolytics Biotech malignant melanoma Phase II
reovirus Calgary, Canada (see also brain, colorectal, head/neck, (403) 670-7377
lung, pancreatic, sarcoma)
RG3616 Curis basal cell carcinoma Phase II
(systemic hedgehog Lexington, MA (973) 235-5000
antagonist) Roche
Nutley, NJ
RG7204 Plexxikon first-line malignant melanoma Phase III
(BRAF kinase Berkeley, CA (510) 647-4000
inhibitor) Roche (973) 235-5000
Nutley, NJ --------------------------------------------------------------------------------------
second- and third-line malignant Phase II
melanoma (510) 647-4000
(973) 235-5000
RG7256 Roche BRAF-mutated malignant melanoma Phase I
Nutley, NJ (973) 235-5000
sprycel® Bristol-Myers Squibb malignant melanoma Phase I/II
dasatinib Princeton, NJ (see also brain, breast, colorectal, (212) 546-4000
leukemia, lung, lymphoma,
multiple myeloma, prostate)
tasigna® Novartis Pharmaceuticals malignant melanoma Phase III
nilotinib East Hanover, NJ (see also leukemia, stomach) (888) 669-6682
temodar® Merck malignant melanoma Phase I
temozolomide Whitehouse Station, NJ (see also leukemia, lung) (800) 672-6372
tesetaxel Genta advanced melanoma Phase II
(orphan drug) Berkeley Heights, NJ (see also bladder, breast, prostate, (908) 286-9800
stomach)
tnferade™ GenVec malignant melanoma Phase II completed
golnerminogene Gaithersburg, MD (see also colorectal, head/neck, (240) 632-0740
pradenovec stomach)
tremelimumab Pfizer malignant melanoma Phase II
(CP-675206) New York, NY (see also kidney, pancreatic, stomach, (860) 732-5156
other)
TRX518 Tolerx malignant melanoma Phase I
Cambridge, MA (617) 354-8100
58 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s K i n c a n c e r
product name sponsor indication development status
veglin VasGene Therapeutics Kaposi’s sarcoma Phase I
(VEGF antisense) Los Angeles, CA (see also kidney, lung) (323) 221-7818
Zadaxin® SciClone Pharmaceuticals malignant melanoma Phase II completed
thymalfasin Foster City, CA (650) 358-3456
(orphan drug)
s o l i d t u M o r s
product name sponsor indication development status
1MT NewLink Genetics metastatic disease Phase I
Ames, IA (515) 296-5555
ABI-009 Celgene Phase I
(nab®-rapamycin) Summit, NJ (908) 673-9000
ABI-101 Celgene Phase I
(nab®-17AAG) Summit, NJ (908) 673-9000
ABT-348 Abbott Laboratories late-stage disease Phase I
Abbott Park, IL (see also other) (847) 937-6100
ABT-806 Abbott Laboratories Phase I
Abbott Park, IL (847) 937-6100
AC480 Ambit Biosciences (see also brain) Phase II completed
San Diego, CA (858) 334-2100
--------------------------------------------------------------------------------------
solid tumors (combination therapy) Phase I
(858) 334-2100
ACE-041 Acceleron Pharma (see also multiple myeloma) Phase I
Cambridge, MA (617) 649-9200
AEW541 Novartis Pharmaceuticals (see also other) Phase I
East Hanover, NJ (888) 669-6682
AEZS-112 AEterna-Zentaris (see also lymphoma) Phase I
Warren, NJ (908) 626-5428
AFP-464 Tigris Pharmaceuticals Phase I
Bonita Springs, FL (239) 444-5400
AI-850 Acusphere Phase I
Watertown, MA (617) 648-8800
Cephalon (610) 344-0200
Frazer, PA
ALB 109564(a) AMRI Phase I
Albany, NY (518) 512-2000
AMG 208 Amgen Phase I
Thousand Oaks, CA (800) 772-6436
AMG 780 Amgen Phase I
Thousand Oaks, CA (800) 772-6436
AMG 820 Amgen Phase I
Thousand Oaks, CA (800) 772-6436
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 59
s o l i d t u M o r s
product name sponsor indication development status
AMG 888 Amgen Phase I
(U3-1287) Thousand Oaks, CA (800) 772-6436
AMG 900 Amgen Phase I
Thousand Oaks, CA (800) 772-6436
amplimexon® AmpliMed Phase I/II completed
imexon Tucson, AZ (520) 529-1000
amuvatinib SuperGen (see also lymphoma) Phase I
Dublin, CA (925) 560-0100
anti-EGFL7 mAb Genentech Phase I
(RG7414) South San Francisco, CA (650) 224-1000
anti-HER3/EGFR Genentech Phase I
DAF (RG7597) South San Francisco, CA (650) 224-1000
aplidin® PharmaMar USA (see also lymphoma, Phase I
plitidepsin Cambridge, MA multiple myeloma) (617) 868-3797
AR-12 Arno Therapeutics (see also lymphoma) Phase I
Parsippany, NJ (862) 703-7170
ARQ-621 ArQule late-stage solid tumors Phase I
Woburn, MA (781) 994-0300
ARQ-736 ArQule late-stage solid tumors Phase I
Woburn, MA (781) 994-0300
ARRY-520 Array BioPharma (see also leukemia, multiple Phase I
Boulder, CO myeloma) (303) 381-6600
ARRY-543 Array BioPharma Phase II
(varlitinib) Boulder, CO (303) 381-6600
AT-406 Ascenta Therapeutics (see also lymphoma) Phase I
Malvern, PA (610) 408-0313
AT7519 Astex Therapeutics (see also multiple myeloma) Phase I
Cambridge, United Kingdom
com
AT9283 Astex Therapeutics (see also leukemia) Phase I
Cambridge, United Kingdom
com
ATI-1123 Azaya Therapeutics Phase I
San Antonio, TX (210) 341-6600
AT13387 Astex Therapeutics Phase I
Cambridge, United Kingdom
com
ATN-161 Tactic Pharma Phase II
Evanston, IL (847) 733-0940
AV-299 AVEO Pharmaceuticals (see also glioblastoma, lymphoma, Phase I
(ficlatuzumab) Cambridge, MA multiple myeloma) (617) 299-5000
AZD1480 AstraZeneca (see also other) Phase I
(JAK2 inhibitor) Wilmington, DE (800) 236-9933
AZD2014 AstraZeneca Phase I
(TOR kinase Wilmington, DE (800) 236-9933
inhibitor)
60 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s o l i d t u M o r s
product name sponsor indication development status
AZD2461 AstraZeneca Phase I
(PARP inhibitor) Wilmington, DE (800) 236-9933
AZD4547 AstraZeneca Phase I/II
(FGFR tyrosine Wilmington, DE (800) 236-9933
kinase inhibitor)
AZD5363 AstraZeneca Phase I
(AKT inhibitor) Wilmington, DE (800) 236-9933
AZD7762 AstraZeneca Phase I
(CHK1 kinase Wilmington, DE (800) 236-9933
inhibitor)
AZD8055 AstraZeneca Phase I
(TOR kinase Wilmington, DE (800) 236-9933
inhibitor)
AZD8330 Array Bio Pharma Phase I
(ARRY-704) Boulder, CO (800) 236-9933
AstraZeneca
Wilmington, DE
AZD8931 AstraZeneca (see also breast) Phase II
(erbB kinase Wilmington, DE (800) 236-9933
inhibitor)
BAY 79-4620 Bayer HealthCare Phase I
Pharmaceuticals (888) 842-2937
Wayne, NJ
BAY 80-6946 Bayer HealthCare Phase I
Pharmaceuticals (888) 842-2937
Wayne, NJ
BAY 10-00394 Bayer HealthCare Phase I
Pharmaceuticals (888) 842-2937
Wayne, NJ
BBI608 Boston Biomedical Phase I
Norwood, MA (781) 278-0900
BEZ235 Novartis Pharmaceuticals late-stage solid tumors Phase I/II
East Hanover, NJ (888) 669-6682
BGJ398 Novartis Pharmaceuticals Phase I
East Hanover, NJ (888) 669-6682
BGT226 Novartis Pharmaceuticals Phase I/II
East Hanover, NJ (888) 669-6682
BHQ880 Novartis Pharmaceuticals (see also multiple myeloma) Phase I
East Hanover, NJ (888) 669-6682
BI 811283 Boehringer Ingelheim (see also leukemia) Phase I
Pharmaceuticals (800) 243-0127
Ridgefield, CT
BI 831266 Boehringer Ingelheim Phase I
Pharmaceuticals (800) 243-0127
Ridgefield, CT
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 61
s o l i d t u M o r s
product name sponsor indication development status
BIIB 015 Biogen Idec Phase I
Cambridge, MA (617) 679-2000
BKM120 Novartis Pharmaceuticals (see also breast) Phase I
East Hanover, NJ (888) 669-6682
BMN-673 BioMarin Pharmaceuticals Phase I/II
Novato, CA (415) 506-6700
BMS-247615 Bristol-Myers Squibb Phase I
(DNA topoisomerase Princeton, NJ (212) 546-4000
I and II inhibitor)
BMS-754807 Bristol-Myers Squibb (see also breast) Phase I/II
(IGF-1R antagonist) Princeton, NJ (212) 546-4000
BMS-777607 Bristol-Myers Squibb advanced solid tumors Phase I/II completed
(receptor protein- Princeton, NJ (212) 546-4000
tyrosine kinase
antagonists)
BMS-833923 Bristol-Myers Squibb Phase I
(SMO inhibitor) Princeton, NJ (212) 546-4000
BMS-936558 Bristol-Myers Squibb (see also skin) Phase I
(anti-PD1) Princeton, NJ (212) 546-4000
BMS-936559 Bristol-Myers Squibb Phase I
(anti-PDL-L1) Princeton, NJ (212) 546-4000
BQS481 Novartis Pharmaceuticals Phase I
East Hanover, NJ (888) 669-6682
BYL719 Novartis Pharmaceuticals late-stage solid tumors Phase I
East Hanover, NJ (888) 669-6682
c31510 Cytotech Labs Phase I
for injection Natick, MA
CALAA 01 Calando Pharmaceuticals Phase I
Pasadena, CA (626) 683-7200
carfilzomib Onyx Pharmaceuticals (see also multiple myeloma) Phase II
Emeryville, CA (510) 597-6500
carlumab Centocor Ortho Biotech (see also prostate) Phase I
Horsham, PA (800) 457-6399
CC-223 Celgene late-stage solid tmors Phase I/II
Summit, NJ (see also leukemia, lymphoma) (908) 673-9000
CDX-1401 Celldex Therapeutics Phase I/II
Needham, MA (781) 433-0771
CEP-9722 Cephalon Phase I
(PARP inhibitor) Frazer, PA (610) 344-0200
CEP-11981 Cephalon Phase I
(VEGF-R/TIE2 Frazer, PA (610) 344-0200
kinase inhibitor)
CG201 CG Therapeutics Phase II
Seattle, WA (206) 336-5604
62 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s o l i d t u M o r s
product name sponsor indication development status
CLR1404 Cellectar Phase I
Madison, WI (608) 441-8120
CNTO 95 Centocor Ortho Biotech (see also prostate, skin) Phase I completed
Horsham, PA (800) 457-6399
CRLX101 Cerulean Pharma late-stage solid tumors Phase I/II
Cambridge, MA (617) 551-9600
crolibulin EpiCept Phase I/II
Tarrytown, NY (914) 606-3500
CRS-207 Aduro BioTech Phase I
Berkeley, CA (510) 848-4400
CUDC-101 Curis Phase I
Cambridge, MA (617) 503-6500
CX-4945 Cylene Pharmaceuticals (see also multiple myeloma, other) Phase I
San Diego, CA (858) 875-5100
CYC-116 Cyclacel Pharmaceuticals Phase I
Berkeley Heights, NJ (908) 517-7330
CYT-107 Cytheris vaccine enhancer Phase I
Rockville, MD (see also kidney, leukemia, skin) (301) 231-0450
CYT 6091 CytImmune Sciences Phase I
Rockville, MD (301) 825-3041
darinaparsin oral ZIOPHARM Oncology (see also liver, lymphoma, Phase I
(ZIO-101) New York, NY multiple myeloma) (646) 214-0700
denibulin MediciNova Phase I
(MN-029) San Diego, CA (858) 373-1500
dovitinib Novartis Pharmaceuticals Phase II
(TKI258) East Hanover, NJ (888) 669-6682
EC-0489 Endocyte Phase I
West Lafayette, IN (765) 463-7175
elsamitrucin Spectrum advanced solid tumors Phase I
Pharmaceuticals (949) 788-6700
Irvine, CA
EMD-1204831 EMD Serono late-stage solid tumors Phase I
(c-Met kinase Rockland, MA (800) 283-8088
inhibitor)
EMD-1214063 EMD Serono Phase I
(c-Met kinase Rockland, MA (800) 283-8088
inhibitor)
EP-100 Esperance Pharmaceuticals Phase I
Baton Rouge, LA (225) 615-8944
ETBX-011 Etubics late-stage solid tumors Phase I
Seattle, WA (206) 838-5110
EZN-2208 Enzon Pharmaceuticals refractory metastatic solid tumors Phase I
Bridgewater, NJ (see also breast, colorectal) (908) 541-8600
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 63
s o l i d t u M o r s
product name sponsor indication development status
EZN-2968 Enzon Pharmaceuticals (see also lymphoma) Phase I
Bridgewater, NJ (908) 541-8600
EZN-3042 Enzon Pharmaceuticals (see also leukemia, lymphoma) Phase I
Bridgewater, NJ (908) 541-8600
fluciclatide F-18 GE Healthcare diagnosis of solid tumors Phase II
Waukesha, WI
FP-1039 Five Prime Therapeutics (see also other) Phase I
San Francisco, CA (415) 365-5600
G-202 GenSpera Phase I
San Antonio, TX (210) 479-8112
GDC-0068 Genentech Phase I
(Akt inhibitor) South San Francisco, CA (650) 224-1000
GDC-0623 Genentech Phase I
(MEK inhibitor) South San Francisco, CA (650) 224-1000
GDC-0917 Genentech (see also lymphoma) Phase I
(IAP antagonist) South San Francisco, CA (650) 224-1000
GDC-0941 Genentech (see also breast, lung, lymphoma) Phase I
(PI3 kinase South San Francisco, CA (650) 224-1000
inhibitor)
GDC-0973 Exelixis Phase I
(MEK inhibitor) South San Francisco, CA (650) 837-7000
Genentech
South San Francisco, CA
GDC-0980 Genentech (see also breast, lymphoma) Phase I
(PI3 kinase/mTOR South San Francisco, CA (650) 224-1000
dual inhibitor)
Genasense® Genta brief, high-dose IV-infusion Phase I/II
oblimersen Berkeley Heights, NJ (see also breast, leukemia, lung, (908) 286-9800
lymphoma, skin)
--------------------------------------------------------------------------------------
intermittent therapy Phase I
(908) 286-9800
Genz-644282 Genzyme Phase I
Cambridge, MA (617) 252-7500
GGTI-2418 Tigris Pharmaceuticals Phase I
Bonita Springs, FL (239) 444-5400
GL-ONC1 Genelux Phase I
San Diego, CA (858) 483-0024
GO-203-2c Genus Oncology advanced solid tumors Phase I
Vernon Hills, IL (847) 549-6500
GS 6624 Gilead Sciences Phase I
Foster City, CA (800) 445-3235
GSK1070916A GlaxoSmithKline Phase I
Rsch. Triangle Park, NC (888) 825-5249
GSK1120212 GlaxoSmithKline (see also pancreatic, skin) Phase I
(MEK inhibitor) Rsch. Triangle Park, NC (888) 825-5249
64 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s o l i d t u M o r s
product name sponsor indication development status
GSK2141795 GlaxoSmithKline (see also lymphoma) Phase I
(AKT protein kinase Rsch. Triangle Park, NC (888) 825-5249
inhibitor)
GSK2256098 GlaxoSmithKline Phase I
(FAK inhibitor) Rsch. Triangle Park, NC (888) 825-5249
HER2/neu receptor Dendreon Phase I
(active cellular Seattle, WA (877) 256-4545
immunotherapy)
HGS-1029 Human Genome Sciences (see also lymphoma) Phase I
Rockville, MD (301) 309-8504
HSP990 Novartis Pharmaceuticals Phase I
East Hanover, NJ (888) 669-6682
IMC-RON8 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
IMGN-388 ImmunoGen Phase I
Waltham, MA (781) 895-0600
INCB-18424 Incyte Phase I
(ruxolitinib) Wilmington, DE (302) 498-6700
INCB-24360 Incyte Phase I/II
(IDO inhibitor) Wilmington, DE (302) 498-6700
INCB-28060 Incyte Phase I/II
(c-MET inhibitor) Wilmington, DE (302) 498-6700
Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
INK128 Intellikine (see also lymphoma, multiple Phase I
(TORC1/2 inhibitor) La Jolla, CA myeloma) (858) 768-6500
INNO-206 CytRx Phase I completed
Los Angeles, CA (310) 826-5648
IPI-493 Infinity Pharmaceuticals advanced solid tumors Phase I
Cambridge, MA (see also other) (617) 453-1000
IPI-926 Infinity Pharmaceuticals (see also pancreatic, sarcoma) Phase I
Cambridge, MA (617) 453-1000
JI-101 Jubilant Innovation Phase I/II
Bedminster, NJ (215) 369-0965
JNJ-26854165 Johnson & Johnson late-stage solid tumors Phase I
Pharmaceutical Research (see also lung, prostate) (800) 817-5286
& Development
Raritan, NJ
JNJ-38877605 Johnson & Johnson Phase I/II
Pharmaceutical Research (800) 817-5286
& Development
Raritan, NJ
KHK-2866 Kyowa Hakko Kirin Pharma (see also ovarian) Phase I
Princeton, NJ (609) 919-1100
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 65
s o l i d t u M o r s
product name sponsor indication development status
LCL161 Novartis Pharmaceuticals Phase I
East Hanover, NJ (888) 669-6682
LDE225 Novartis Pharmaceuticals Phase II
East Hanover, NJ (888) 669-6682
LDK378 Novartis Pharmaceuticals Phase II
East Hanover, NJ (888) 669-6682
LEE011 Novartis Pharmaceuticals (see also lymphoma) Phase I
East Hanover, NJ (888) 669-6682
LEQ506 Novartis Pharmaceuticals Phase I
East Hanover, NJ (888) 669-6682
L-MDAM BioNumerik Phase I
Pharmaceuticals (210) 614-1701
San Antonio, TX
LOR-253 Lorus Therapeutics Phase I
Toronto, Canada (416) 798-1200
LP-261 Ansaris Phase I
Blue Bell, PA (215) 358-2000
MEDI-565 AstraZeneca Phase I
(anti-CEA BiTE) Wilmington, DE (800) 236-9933
MedImmune (301) 398-0000
Gaithersburg, MD
MEDI-573 AstraZeneca Phase I
(anti-IGF mAb) Wilmington, DE (800) 236-9933
MedImmune (301) 398-0000
Gaithersburg, MD
MEDI-575 AstraZeneca Phase II
Wilmington, DE (800) 236-9933
MedImmune (301) 398-0000
Gaithersburg, MD
MEDI-3617 AstraZeneca Phase I
(anti-ANG-2 mAb) Wilmington, DE (800) 236-9933
MedImmune (301) 398-0000
Gaithersburg, MD
MEK162/ Array BioPharma Phase I
ARRY-162 Boulder, CO (303) 381-6600
Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
MGAH22 Macrogenics Phase I
(anti-HER2) Rockville, MD (301) 251-5172
MGCD-265 MethylGene late-stage solid tumors Phase I
Montreal, Canada (see also lung) (514) 337-3333
MGCD-0103 MethylGene (see also leukemia, lymphoma) Phase I/II
Montreal, Canada (514) 337-3333
MINT-1526A Genentech advanced solid tumors Phase I
(anti-angiogenic) South San Francisco, CA (650) 224-1000
66 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s o l i d t u M o r s
product name sponsor indication development status
MK-0752 Merck (see also breast) Phase I
Whitehouse Station, NJ (800) 672-6372
MK-1496 Merck Phase I completed
Whitehouse Station, NJ (800) 672-6372
MK-1775 Merck Phase I
Whitehouse Station, NJ (800) 672-6372
MK-4827 Merck late-stage solid tumors Phase I
Whitehouse Station, NJ (800) 672-6372
MK-5108 Merck late-stage or refractory solid tumors Phase I
(VX-689) Whitehouse Station, NJ (800) 672-6372
Vertex Pharmaceuticals
Cambridge, MA
MKC1106-PP MannKind Phase I completed
Valencia, CA (661) 775-5300
MLN4924 Millennium Pharmaceuticals (see also other) Phase I
Cambridge, MA (800) 390-5663
MLN8237 Millennium Pharmaceuticals (see also other) Phase I/II
Cambridge, MA (800) 390-5663
MLN9708 Millennium Pharmaceuticals (see also other) Phase I/II
Cambridge, MA (800) 390-5663
MM-111 Merrimack Pharmaceuticals (see also breast) Phase I/II
Cambridge, MA (617) 441-1000
MN-201 Marillion advanced solid tumors Phase I
Pharmaceuticals (484) 875-3018
Exton, PA
MORAb-004 Eisai Phase I
Woodcliff Lake, NJ (888) 422-4743
MT-110 Micromet Phase I
Bethesda, MD (240) 752-1420
NB-1011 Kiadis Pharma Phase I/II
Amsterdam,
The Netherlands
NKTR-105 Nektar Therapeutics Phase I
(pegylated San Francisco, CA (415) 482-5300
docetaxel)
NMS-1116354 Nerviano Medical Sciences metastatic solid tumors Phase I
Milan, Italy
NMS-1286937 Nerviano Medical Sciences Phase I
Milan, Italy
NPI-0052 Nereus Pharmaceuticals (see also lymphoma, Phase I
(marizomib) San Diego, CA multiple myeloma) (858) 587-4090
OMP-21M18 GlaxoSmithKline Phase I
Rsch. Triangle Park, NC (888) 825-5249
OncoMed Pharmaceuticals (650) 995-8200
Redwood City, CA
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 67
s o l i d t u M o r s
product name sponsor indication development status
OMP-59R5 GlaxoSmithKline late-stage solid tumors Phase I
Rsch. Triangle Park, NC (888) 825-5249
OncoMed Pharmaceuticals (650) 995-8200
Redwood City, CA
omtriptolide Pharmagenesis Phase I
Redwood City, CA (650) 842-7060
Pierre Fabre (973) 898-1042
Pharmaceuticals
Parsippany, NJ
ON-01910 Onconova Therapeutics (see also leukemia, lymphoma, Phase I
Princeton, NJ ovarian) (609) 844-7735
ONX-0801 Onyx Pharmaceuticals Phase I
Emeryville, CA (510) 597-6500
ONX-0912 Onyx Pharmaceuticals late-stage solid tumors Phase I
Emeryville, CA (510) 597-6500
ortatexal Spectrum Pharmaceuticals taxane-refractory solid tumors Phase II
Irvine, CA (949) 788-6700
OSI-930 OSI Pharmaceuticals late-stage solid tumors Phase I
Melville, NY (631) 962-2000
OXi4503 OXiGENE (see also leukemia) Phase I/II
South San Francisco, CA (650) 635-7000
PA799 Chugai Pharma USA Phase I
Berkeley Heights, NJ (908) 516-1350
PDL-192 Facet Biotech Phase I
(enavatuzumab) Redwood City, CA (650) 454-1000
PEGPH20 Halozyme Phase I
(pegylated San Diego, CA (858) 794-8889
recombinant human
hyaluronidase)
PF-03446962 Pfizer late-stage solid tumors Phase I
New York, NY (860) 732-5156
PF-03758309 Pfizer Phase I
New York, NY (860) 732-5156
PF-04605412 Pfizer Phase I
New York, NY (860) 732-5156
PF-04691502 Pfizer Phase I
New York, NY (860) 732-5156
PF-04856884 Pfizer Phase I
(CVX060) New York, NY (860) 732-5156
PF-05057459 Pfizer Phase I
(CVX 241) New York, NY (860) 732-5156
PG11047 Progen Pharmaceuticals Phase I
Redwood City, CA (650) 610-7800
picoplatin Poniard Pharmaceuticals Phase I
oral San Francisco, CA (650) 583-3774
68 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s o l i d t u M o r s
product name sponsor indication development status
PLX3397 Plexxikon (see also lymphoma) Phase I
Berkeley, CA (510) 647-4000
PM-01183 PharmaMar USA Phase I completed
Cambridge, MA (617) 868-3797
PM-060184 PharmaMar USA Phase I
Cambridge, MA (617) 868-3797
PNT2258 ProNAi Therapeutics Phase I
Kalamazoo, MI (269) 815-8098
PRLX-93936 Prolexys Pharmaceuticals Phase I
Salt Lake City, UT (801) 303-1700
PTC299 PTC Therapeutics (see also breast, skin, other) Phase I
South Plainfield, NJ (908) 222-7000
purine nucleoside PNP Therapeutics Phase I
phosphorylase Birmingham, AL
gene therapy
PX-478 Oncothyreon (see also lymphoma) Phase I completed
Seattle, WA (206) 801-2100
PX-866 Oncothyreon Phase I/II
Seattle, WA (206) 801-2100
quizartinib Ambit Biosciences late-stage solid tumors Phase I
San Diego, CA (see also leukemia) (858) 334-2100
Astellas Pharma US (800) 727-7003
Deerfield, IL
retaspimycin Infinity Pharmaceuticals (see also lung) Phase I
(IPI 504) Cambridge, MA (617) 453-1000
RG7112 Roche (see also other) Phase I
Nutley, NJ (973) 235-5000
RG7160 Roche Phase I
(HumAb EGFR) Nutley, NJ (973) 235-5000
RG7167 Roche Phase I
Nutley, NJ (973) 235-5000
RG7304 Roche Phase I
(Raf/MEK dual Nutley, NJ (973) 235-5000
inhibitor)
RG7334 Roche Phase I
(anti-PLGF mAb) Nutley, NJ (973) 235-5000
RG7347 Genentech Phase I
South San Francisco, CA (650) 224-1000
RG7422 Genentech Phase I
(PI3 kinase inhibitor) South San Francisco, CA (650) 224-1000
RG7593 Genentech Phase I
South San Francisco, CA (650) 224-1000
RG7594 Genentech Phase I
South San Francisco, CA (650) 224-1000
rindopepimut Celldex Therapeutics (see also brain) Phase I
Needham, MA (860) 732-5156
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 69
s o l i d t u M o r s
product name sponsor indication development status
robatumumab Merck solid tumors Phase II
Whitehouse Station, NJ (see also sarcoma) (800) 672-6372
--------------------------------------------------------------------------------------
solid tumors in children Phase I
(800) 672-6372
SAR256212 Merrimack Pharmaceuticals (see also ovarian) Phase I
(MM-121) Cambridge, MA (617) 441-1000
sanofi-aventis (800) 633-1810
Bridgewater, NJ
SAR566658 sanofi-aventis Phase I
(maytansin-loaded Bridgewater, NJ (800) 633-1810
anti-DS6)
SB939 S*Bio late-stage solid tumors Phase I
Redwood City, CA (see also leukemia) (650) 730-2860
selumetinib Array BioPharma Phase II
(AZD6244/ Boulder, CO (800) 236-9933
ARRY-886) AstraZeneca
Wilmington, DE
selumetinib Array Bio Pharma Phase I
(AZD6244/ Boulder, CO (800) 236-9933
ARRY-886) AstraZeneca (800) 672-6372
MK-2206 Wilmington, DE
combination Merck
Whitehouse Station, NJ
SF1126 Semafore Pharmaceuticals (see also leukemia, Phase I
Indianapolis, IN multiple myeloma) (317) 876-3075
simotaxel Taxolog Phase I
Fairfield, NJ (877) 829-6564
SN2310 OncoGenex Phase I completed
Pharmaceuticals (425) 686-1500
Bothell, WA
sonepcizumab Lpath Phase II
San Diego, CA (858) 678-0800
Sym004 Symphogen Phase I
Lyngby, Denmark
TAK-441 Millennium Pharmaceuticals late-stage solid tumors Phase I
Cambridge, MA (800) 390-5663
TAK-701 Millennium Pharmaceuticals Phase I
Cambridge, MA (800) 390-5663
TAK-733 Millennium Pharmaceuticals Phase I
Cambridge, MA (800) 390-5663
TAK-901 Millennium Pharmaceuticals (see also other) Phase I
Cambridge, MA (800) 390-5663
TAK-960 Millennium Pharmaceuticals Phase I
Cambridge, MA (800) 390-5663
terameprocol Erimos Pharmaceuticals (see also brain, cervical, head/neck, Phase I
(intravenous) Houston, TX other) (713) 541-2000
70 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s o l i d t u M o r s
product name sponsor indication development status
TH-302 Threshold late-stage solid tumors Phase I/II
Pharmaceuticals (see also leukemia, sarcoma) (650) 474-8200
Redwood City, CA
TKM-PLK1 Tekmira Pharmaceuticals (see also lymphoma) Phase I
Vancouver, Canada (604) 419-3200
TLC388 Taiwan Liposome Phase I
Taipei, Taiwan
TRC093 TRACON Pharmaceuticals Phase I completed
San Diego, CA (858) 550-0780
TRC102 TRACON Pharmaceuticals Phase I
San Diego, CA (858) 550-0780
TRC105 TRACON Pharmaceuticals locally advanced or metastatic Phase I
San Diego, CA solid tumors (858) 550-0780
(see also prostate)
TRPM8 Dendreon Phase I
(D-3263) Seattle, WA (877) 256-4545
TST10088 Cangene Phase I
Winnipeg, Canada (204) 275-4200
U3-1565 Amgen Phase I
Thousand Oaks, CA (800) 772-6436
U3 Pharma (973) 359-2600
Martinsried, Germany
UNBS-5162 Drais Pharmaceuticals (see also lymphoma) Phase I
Bridgewater, NJ (908) 895-1200
V935 Merck Phase I
Whitehouse Station, NJ (800) 672-6372
vinorelbine Talon Therapeutics (see also lymphoma) Phase I
liposomal South San Francisco, CA (650) 588-6404
VX15 Vaccinex Phase I
Rochester, NY (585) 271-2700
WX-UK1 Wilex Phase I
Munich, Germany
X-82 Tyrogenex Phase I
West Palm Beach, FL (561) 835-9356
XMT-1001 Mersana Therapeutics refractory metastatic disease Phase I
Cambridge, MA (617) 498-0020
XMT-1107 Mersana Therapeutics Phase I
Cambridge, MA (617) 498-0020
s t o M a c H c a n c e r
product name sponsor indication development status
afinitor® Novartis Pharmaceuticals GIST Phase III
everolimus East Hanover, NJ (see also breast, kidney, liver, (888) 669-6682
lymphoma, other)
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 71
s t o M a c H c a n c e r
product name sponsor indication development status
AMG 386 Amgen gastric and gastroesophageal junction Phase II
Thousand Oaks, CA adenocarcinoma (800) 772-6436
(see also breast, colorectal, kidney,
liver, ovarian, other)
--------------------------------------------------------------------------------------
distal esophageal adenocarcinoma Phase II
(800) 772-6436
AT-101 Ascenta Therapeutics esophageal cancer Phase II
Malvern, PA (see also brain, leukemia, lung, (610) 408-0313
lymphoma, prostate)
AUY922 Novartis Pharmaceuticals gastric cancer Phase II
East Hanover, NJ (see also breast, colorectal, lung, (888) 669-6682
multiple myeloma)
AV-951 AVEO Pharmaceuticals gastrointestinal cancer Phase I/II
(tivozanib) Cambridge, MA (see also breast, kidney, lung) (617) 299-5000
BAY 73-4506 Bayer HealthCare late-stage GIST Phase III
(regorafenib) Pharmaceuticals (see also colorectal, kidney, lung) (888) 842-2937
(orphan drug) Wayne, NJ
brivanib Bristol-Myers Squibb gastrointestinal cancer Phase I
(VEGFR/FGFR Princeton, NJ (see also liver) (212) 546-4000
kinase inhibitor)
CNF-2024 Biogen Idec GIST Phase II
Weston MA (see also breast) (781) 464-2000
E7050 Eisai gastric cancer Phase I/II
Woodcliff Lake, NJ (see also liver, other) (888) 422-4743
ganetespib Synta Pharmaceuticals esophageal cancer, GIST Phase II
Lexington, MA (see also breast, colorectal, lung, (781) 274-8200
other)
ixempra® Bristol-Myers Squibb gastric cancer, esophageal cancer Phase II
ixabepilone Princeton, NJ (see also breast, lung, other) (212) 546-4000
masitinib AB Science USA GIST Phase III
Short Hills, NJ (see also leukemia, pancreatic) (973) 218-2437
oncoGel™ Protherics esophageal cancer Phase II
paclitaxel Brentwood, TN (615) 327-1027
controlled-release
(orphan drug)
perifosine Aeterna Zentaris late-stage GIST Phase II
(KRX-1401) Montreal, Canada (see also brain, colorectal, kidney, (212) 531-5965
Keryx Biopharmaceuticals leukemia, lymphoma, multiple
New York, NY myeloma, sarcoma, ovarian)
polyclonal antibody Cancer Advances gastric cancer Phase III
stimulator Durham, NC (see also colorectal, pancreatic) (919) 361-2162
(orphan drug)
ramucirumab Eli Lilly gastric cancer Phase III
(IMC-1121B) Indianapolis, IN (see also breast, colorectal, liver, lung) (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
72 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s t o M a c H c a n c e r
product name sponsor indication development status
rilotumumab Amgen gastric cancer Phase II
Thousand Oaks, CA (see also brain, colorectal, (800) 772-6436
lung, prostate)
S-1 Taiho Pharma USA gastric cancer Phase III
Princeton, NJ (609) 750-5300
tasigna® Novartis Pharmaceuticals GIST Phase III
nilotinib East Hanover, NJ (see also leukemia, skin) (888) 669-6682
(orphan drug)
telatinib ACT Biotech late-stage gastric cancer Phase II
(orphan drug) San Francisco, CA (see also colorectal) (415) 230-3900
tesetaxel Genta advanced gastric cancer (Fast Track) Phase II
(orphan drug) Berkeley Heights, NJ (see also bladder, breast, prostate, (908) 286-9800
skin)
tnferade™ GenVec esophageal cancer Phase II completed
golnerminogene Gaithersburg, MD (see also colorectal, head/neck, (240) 632-0740
pradenovec pancreatic, skin)
tremelimumab Pfizer gastointestinal cancer Phase II
(CP-675206) New York, NY (see also kidney, pancreatic, (860) 732-5156
skin, other)
tykerb® GlaxoSmithKline gastric cancer Phase III
lapatinib Rsch. Triangle Park, NC (see also breast, head/neck) (888) 825-5249
c a n c e r / c H e M o t H e r a p y - r e l a t e d c o n d i t i o n s
product name sponsor indication development status
acapodene® GTx complications from androgen application submitted
toremifene Memphis, TN deprivation therapy (901) 523-9700
(see also prostate)
ACE-011 Acceleron Pharma chemotherapy-induced anemia Phase II/III
(sotatercept) Cambridge, MA (see also other) (617) 649-9200
Celgene (908) 673-9000
Summit, NJ
AG013 ActoGeniX mucositis Phase I
Zwijnaarde, Belguim
ARX-02 AcelRx Pharmaceuticals cancer breakthrough pain Phase II
(sufentanil Redwood City, CA (650) 216-3500
sublingual)
campath® Genzyme chronic graft-versus-host disease Phase I
alemtuzumab Cambridge, MA (617) 252-7500
(intravenous)
CB1400 Canopus BioPharma mucositis (prevention) Phase II
Studio City, CA (818) 980-5008
emend® for Merck chemotherapy-induced nausea and Phase I
injection Whitehouse Station, NJ vomiting (CINV) in adolescents, (800) 672-6372
fosaprepitant Fate Therapeutics children and infants
San Diego, CA
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 73
c a n c e r / c H e M o t H e r a p y - r e l a t e d c o n d i t i o n s
product name sponsor indication development status
ereska™ Javelin Pharmaceuticals cancer pain Phase III
ketamine Cambridge, MA (617) 349-4500
intranasal
fentanyl sublingual INSYS Therapeutics cancer pain Phase III
spray Phoenix, AZ (602) 910-2617
FT1050 Fate Therapeutics hematopoietic stem cell support Phase I
(orphan drug) San Diego, CA in patients with hematological (858) 875-1800
malignancies
golotimod SciClone Pharmaceuticals chemotherapy-induced stomatitis Phase II
Foster City, CA (prevention) (650) 358-3456
morphine intranasal Marina Biotech cancer pain Phase II
Bothell, WA (425) 908-3600
MRX-1024 Molecular Therapeutics mucositis Phase I
Ann Arbor, MI (734) 259-4574
nabiximols Otsuka America advanced cancer pain Phase II
Pharmaceutical (800) 438-6124
Rockville, MD
nasalfent® Archimedes Pharma cancer pain application submitted
fentanyl intranasal Reading, United Kingdom
norepinephrine ProCertus BioPharm prevention of radiodermatitis in Phase I/II
topical Madison, WI patients undergoing radiation (608) 273-8862
therapy
--------------------------------------------------------------------------------------
prevention of oral mucositis in Phase I/II
patients undergoing radiation (608) 273-8862
therapy
--------------------------------------------------------------------------------------
prevention of chemo- and radio- Phase I/II
therapy-induced alopecia (608) 273-8862
NP-2 Diamyd Medical cancer pain Phase II
gene therapy Pittsburgh, PA (412) 770-1310
(intradermal)
nplate™ Amgen chemotherapy-induced Phase II
romiplostim Thousand Oaks, CA thrombocytopenia (800) 772-6436
(see also leukemia)
orBec® Soligenix graft-versus-host disease Phase III
beclometasone Princeton, NJ (Fast Track) (609) 538-8200
(orphan drug) Sigma-Tau Pharmaceuticals (800) 447-0169
Gaithersburg, MD --------------------------------------------------------------------------------------
graft-versus-host disease (prevention) Phase II
(609) 538-8200
(800) 447-0169
--------------------------------------------------------------------------------------
acute radiation enteritis Phase I/II
(Fast Track) (609) 538-8200
(800) 447-0169
PF-4383119 Pfizer cancer pain Phase II
(tanezumab) New York, NY (860) 732-5156
74 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
c a n c e r / c H e M o t H e r a p y - r e l a t e d c o n d i t i o n s
product name sponsor indication development status
PHY-906 PhytoCeutica chemoprotection Phase I/II
New Haven, CT (203) 777-3462
prochymal® Osiris Therapeutics graft-versus-host disease Phase III
remestemcel-L Columbia, MD (Fast Track) (443) 545-1800
(orphan drug)
promacta® GlaxoSmithKline chemotherapy-induced Phase II
eltrombopag Rsch. Triangle Park, NC thrombocytopenia (888) 825-5249
reviroc™ Kiadais Pharma bone marrow transplant rejection Phase II/III
(orphan drug) St. Laurent, Canada (514) 336-4886
--------------------------------------------------------------------------------------
graft-versus-host disease Phase I/II
(514) 336-4886
rolapitant TESARO chemotherapy-induced nausea Phase II completed
Waltham, MA and vomiting (339) 970-0900
SAR411298 sanofi-aventis cancer pain Phase I
(FAAH inhibitor) Bridgewater, NJ (800) 633-1810
tapentadol Grunenthal cancer pain Phase II
controlled-release Aachen, Germany (800) 817-5286
Johnson & Johnson
Pharmaceutical Research
& Development
Raritan, NJ
tavocept™ BioNumerik chemoprotection Phase III
dimesna Pharmaceuticals (Fast Track) (210) 614-1701
San Antonio, TX (see also lung)
TH-9402 Kiadis Pharma graft-versus-host disease Phase I/II
Amsterdam, The Netherlands
TXA127 Tarix Pharmaceuticals chemotherapy-induced Phase II
Brookline, MA thrombocytopenia (617) 827-6824
voraxaze® Protherics chemoprotection application submitted
glucarpidase Brentwood, TN (615) 327-1027
(orphan drug)
Xen2174 Xenome cancer pain Phase II
Queensland, Australia
o t H e r c a n c e r s
product name sponsor indication development status
8H9 mAb United Therapeutics peritoneal cancer Phase I
Silver Spring, MD (see also brain, sarcoma) (301) 608-9292
A° 6 Angstrom Pharmaceuticals advanced gynecological cancer Phase I
Solana Beach, CA (see also ovarian) (858) 314-2356
ABT-348 Abbott Laboratories hematological malignancies Phase I
Abbott Park, IL (see also solid tumors) (847) 937-6100
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 75
o t H e r c a n c e r s
product name sponsor indication development status
ABT-888 Abbott Laboratories fallopian tube cancer, Phase II
(veliparib) Abbott Park, IL peritoneal cancer (847) 937-6100
(see also brain, breast, colorectal,
ovarian, prostate, skin)
ACE-011 Acceleron Pharma cancer metastases Phase II
(sotatercept) Cambridge, MA (see also cancer/chemotherapy) (617) 649-9200
Celgene (908) 673-9000
Summit, NJ
AEG-41174 Aegera Therapeutics hematological malignancies Phase I
Montreal, Canada (514) 288-5532
AEW541 Novartis Pharmaceuticals hematological malignancies Phase I
East Hanover, NJ (see also solid tumors) (888) 669-6682
afinitor® Novartis Pharmaceuticals neuroendocrine tumors application submitted
everolimus East Hanover, NJ (see also breast, kidney, liver, (888) 669-6682
lymphoma, pancreatic, stomach)
--------------------------------------------------------------------------------------
urogenital cancer Phase I
(888) 669-6682
allostim™ Immunovative Therapies hematological malignancies Phase I/II
Shoham, Israel
AMG 319 Amgen hematological malignancies Phase I
Thousand Oaks, CA (800) 772-6436
AMG 386 Amgen fallopian tube cancer, Phase III
Thousand Oaks, CA peritoneal cancer (800) 772-6436
(see also breast, colorectal, kidney,
liver, ovarian, stomach)
AMG 479 Amgen neuroendocrine tumors Phase II
(ganitumab) Thousand Oaks, CA (see also breast, colorectal, lung, (800) 772-6436
pancreatic, sarcoma)
antineoplaston- Burzynski Research cancer metastases Phase II
AS2-1 oral Institute (713) 335-5697
Houston, TX
AR-67 Arno Therapeutics myelodysplastic syndromes Phase II
Parsippany, NJ (see also brain) (862) 703-7170
ARQ-197 ArQule germ cell and embryonal neoplasms Phase II
Woburn, MA (see also colorectal, kidney, liver, (781) 994-0300
Daiichi Sankyo lung, pancreatic, sarcoma, solid (973) 944-2600
Parsippany, NJ tumors)
AS703026 EMD Serono hematological malignancies Phase I/II
Rockland, MA (800) 283-8088
ATI-BC-1 Algeta bone metastases Phase III
Oslo, Norway (888) 842-2937
Bayer Healthcare
Pharmaceuticals
Wayne, NJ
avastin® Genentech high-risk carcinoid tumors Phase III
bevacizumab South San Francisco, CA (see also brain, breast, colorectal, (650) 225-1000
lung, ovarian)
76 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
o t H e r c a n c e r s
product name sponsor indication development status
axitinib Pfizer thyroid cancer Phase II
New York, NY (see also kidney, lung) (860) 732-5156
AZD1152 AstraZeneca hematological malignancies Phase II
(aurora kinase Wilmington, DE (800) 236-9933
inhibitor)
AZD1480 AstraZeneca myeloproliferative diseases Phase I
Wilmington, DE (see also solid tumors) (800) 236-9933
azedra™ Molecular Insight paraganglioma, pheochromocytoma Phase II
iodine-labeled Pharmaceuticals (Fast Track) (617) 492-5554
metaiodobenzyl- Cambridge, MA (see also brain)
guanidine
(orphan drug)
BAY 94-9392 Bayer HealthCare diagnosis of cancer Phase I
Pharmaceuticals (888) 842-2937
Wayne, NJ
belinostat Spectrum Pharmaceuticals cancer of unknown primary site Phase II
Irvine, CA (949) 788-6700
TopoTarget USA (973) 895-6900
Rockaway, NJ
Bonefos® Bayer HealthCare cancer metastases application submitted
clodronic acid Pharmaceuticals (888) 842-2937
Wayne, NJ
BP-100-1.01 Bio-Path hematological malignancies Phase I
Ogden, UT (801) 580-2326
cabozantinib Exelixis medullary thyroid cancer Phase III
(XL-184) South San Francisco, CA (see also lung) (650) 837-7000
(orphan drug)
CAT-8015 AstraZeneca hematological malignancies Phase I
(anti-CD22 Wilmington, DE (800) 236-9933
recombinant MedImmune (301) 398-0000
immunotoxin) Gaithersburg, MD
catumaxomab Fresenius Biotech malignant ascites Phase II
North America (see also ovarian)
Waltham, MA
CDB-4124 Repros Therapeutics uterine leiomyoma Phase I/II
The Woodlands, TX (281) 719-3400
cell therapy Cell Medica cancer-associated with Epstein-Barr Phase II
London, United Kingdom virus infections
Center for Cell and Gene (713) 798-1246
Therapy
Houston, TX
CLT-008 Cellerant Therapies hematological malignancies Phase I
San Carlos, CA (650) 232-2122
CNTO 328 Centocor Ortho Biotech giant lymph node hyperplasia Phase II
(siltuximab) Horsham, PA (see also multiple myeloma, prostate) (800) 457-6399
CPI-613 Cornerstone Pharmaceuticals hematological malignancies Phase I
Cranbury, NJ (see also pancreatic) (609) 409-7050
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 77
o t H e r c a n c e r s
product name sponsor indication development status
CS-7017 Daiichi Sankyo thyroid cancer Phase I/II
(efatutazone) Parsippany, NJ (see also colorectal, lung) (973) 944-2600
CX-4945 Cylene Pharmaceuticals giant lymph node hyperplasia Phase I
San Diego, CA (see also multiple myeloma, (858) 875-5100
solid tumors)
dalotuzumab Merck neuroendocrine tumors Phase II completed
Whitehouse Station, NJ (see also breast, lung, pancreatic) (800) 672-6372
dcvax®-l Northwest Biotherapeutics peritoneal cancer Phase I/II
ovarian cancer Bothell, WA (see also ovarian) (425) 608-3000
vaccine
DM-CHOC-PEN Dekk-Tec central nervous system cancer Phase I
New Orleans, LA (504) 583-6135
E7050 Eisai squamous cell carcinoma Phase I/II
Woodcliff Lake, NJ (see also liver, stomach) (888) 422-4743
EC-20 Endocyte diagnosis of folate receptor- Phase II
West Lafayette, IN positive cancers (765) 463-7175
EC-145 Endocyte endometrial cancer Phase II
West Lafayette, IN (see also lung, ovarian) (765) 463-7175
EGEN 001 EGEN recurrent fallopian tube cancer, Phase II
Huntsville, AL recurrent peritoneal cancer (356) 512-0077
(see also ovarian)
ELND002 Elan hematological malignancies Phase I
Dublin, Ireland
ENMD-2076 EntreMed refractory metastatic late-stage cancer Phase I
Rockville, MD (see also multiple myeloma, ovarian) (240) 864-2600
femara® Novartis Pharmaceuticals endometrial cancer Phase II
letrozole East Hanover, NJ (888) 669-6682
FP-1039 Five Prime Therapeutics endometrial cancer Phase II
San Francisco, CA (see also solid tumors) (415) 365-5600
ganetespib Synta Pharmaceuticals hematological malignancies Phase I/II
Lexington, MA (see also breast, colorectal, lung, (781) 274-8200
stomach)
GSK2110183 GlaxoSmithKline hematological malignancies Phase I
(AKT protein kinase Rsch. Triangle Park, NC (888) 825-5249
inhibitor)
HQK-1004 HemaQuest Epstein-Barr virus-related Phase II
Seattle, WA lymphoid malignancies (206) 682-1233
IPI-493 Infinity Pharmaceuticals hematological malignancies Phase I
Cambridge, MA (see also solid tumors) (617) 453-1000
ixempra® Bristol-Myers Squibb endometrial cancer Phase II
ixabepilone Princeton, NJ (see also breast, lung, stomach) (212) 546-4000
KB004 KaloBios Pharmaceuticals hematological malignancies Phase I
South San Francisco, CA (650) 243-3100
78 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
o t H e r c a n c e r s
product name sponsor indication development status
lenvatinib Eisai thyroid cancer Phase III
(E7080) Woodcliff Lake, NJ (see also brain, kidney, liver, skin) (888) 422-4743
--------------------------------------------------------------------------------------
endometrial cancer Phase II
(888) 422-4743
MEDI-551 AstraZeneca hematological malignancies Phase I
(anti-CD19 mAb) Wilmington, DE (800) 236-9933
MedImmune (301) 398-0000
Gaithersburg, MD
MER-101 Merrion Pharmaceuticals bone metastases Phase II
(oral zoledronic Wilmington, NC (910) 799-1847
acid)
mesenchymal stem Cephalon for bone marrow regeneration in Phase II
cell therapy Frazer, PA patients undergoing bone marrow (610) 344-0200
(implant) Mesoblast transplantation in hematological (212) 880-2060
New York, NY malignancies
Mirena® Bayer HealthCare endometrial cancer Phase II
levonorgestrel- Pharmaceuticals (888) 842-2937
releasing Wayne, NJ
intrauterine system
MK-2206 Merck neuroendocrine tumors Phase II
Whitehouse Station, NJ (see also breast, colorectal) (800) 672-6372
MLN4924 Millennium Pharmaceuticals hematological malignancies Phase I
Cambridge, MA (see also solid tumors) (800) 390-5663
MLN8237 Millennium Pharmaceuticals hematological malignancies Phase II
Cambridge, MA (see also solid tumors) (800) 390-5663
MLN9708 Millennium Pharmaceuticals hematological malignancies Phase I
Cambridge, MA (see also solid tumors) (800) 390-5663
NBI-56418 Abbott uterine leiomyoma Phase I
(elagolix) Abbott Park, IL (847) 937-6100
Neurocrine Biosciences (858) 617-7600
San Diego, CA
nexavar® Bayer HealthCare thyroid cancer Phase III
sorafenib Pharmaceuticals (see also breast, colorectal, kidney, (888) 842-2837
Wayne, NJ liver, lung, ovarian) (510) 597-6500
Onyx Pharmaceuticals
Emeryville, CA
NTX-10 Neotropix neuroendocrine tumors Phase I
Malvern, PA (see also lung) (617) 460-1200
octreotide implant Endo Pharmaceuticals malignant carcinoid syndrome Phase II
Chadds Ford, PA (610) 558-9800
opaxio™ Cell Therapeutics peritoneal cancer Phase III
paclitaxel Seattle, WA (see also lung, ovarian) (800) 215-2355
poliglumex Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
OSI-906 OSI Pharmaceuticals adrenocortical carcinoma Phase III
(linsitinib) Melville, NY (see also lung, ovarian) (631) 962-2000
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 79
o t H e r c a n c e r s
product name sponsor indication development status
panobinostat Novartis Pharmaceuticals hematological malignancies Phase II
(LBH589) East Hanover, NJ (see also lymphoma, multiple (888) 669-6682
myeloma)
pasireotide Novartis Pharmaceuticals neuroendocrine tumors Phase III
(SDM230) East Hanover, NJ (888) 669-6682
--------------------------------------------------------------------------------------
meningioma Phase II
(888) 669-6682
PF-04449913 Pfizer hematological malignancies Phase I
New York, NY (860) 732-5156
PHA-848125 Nerviano Medical Sciences inoperable/unresectable thymoma Phase II
Nerviano, Italy
phenoxodiol Marshall Edwards fallopian tube cancer Phase I/II
San Diego, CA (see also ovarian, prostate) (858) 792-6300
PM-00104 PharmaMar USA endometrial cancer Phase II
Cambridge, MA (see also cervical) (617) 868-3797
PTC299 PTC Therapeutics central nervous system cancer in Phase I
South Plainfield, NJ children (908) 222-7000
(see also breast, skin, solid tumors)
Quadramet® EUSA Pharma bone metastases Phase III
samarium sm-153 Langhorne, PA (see also multiple myeloma, (800) 833-3533
lexidronam prostate, sarcoma)
injection
quarfloxin Cylene Pharmaceuticals neuroendocrine tumors Phase II
San Diego, CA (858) 875-5100
R763 Rigel Pharmaceuticals hematological malignancies Phase I
South San Francisco, CA (650) 624-1100
RG7112 Roche hematological malignancies Phase I
Nutley, NJ (see also solid tumors) (973) 235-5000
SAR245408 Exelixis endometrial cancer Phase II
(XL-147) South San Francisco, CA (650) 837-7000
sanofi-aventis (800) 633-1810
Bridgewater, NJ
SAR650984 sanofi-aventis hematological malignancies Phase I
(anti-CD38 Bridgewater, NJ (800) 633-1810
naked mAb)
seliciclib Cyclacel Pharmaceuticals nasopharyngeal cancer Phase II
Short Hills, NJ (973) 847-5955
somatuline Tercica neuroendocrine tumors Phase III
autogel® Brisbane, CA (650) 624-4900
lanreotide
S-PRAnt Bayer HealthCare uterine leiomyoma Phase I
Pharmaceuticals (888) 842-2937
Wayne, NJ
80 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
o t H e r c a n c e r s
product name sponsor indication development status
stemex® Gamida Cell hematological malignancies Phase II/III
carlecortemcel-L Jerusalem, Israel (Fast Track) (215) 591-3000
(orphan drug) Teva Pharmaceuticals USA
North Wales, PA
TAK-901 Millennium Pharmaceuticals hematological malignancies Phase I
Cambridge, MA (see also solid tumors) (800) 390-5663
tarceva® Genentech gynecological cancer, squamous Phase II
erlotinib South San Francisco, CA cell cancer (650) 224-1000
OSI Pharmaceuticals (see also bladder, brain, breast, (800) 572-1932
Melville, NY colorectal, head/neck, leukemia,
liver, lung)
terameprocol Erimos Pharmaceuticals hematological malignancies Phase I
(intravenous) Houston, TX (see also brain, cervical, head/neck, (713) 541-2000
solid tumors)
testosterone vaginal Columbia Laboratories uterine leiomyoma Phase I
Livingston, NJ (866) 566-5636
TG-02 S*Bio hematological malignancies Phase I
Redwood City, CA (650) 730-2860
tremelimumab Pfizer genitourinary cancer Phase II
(CP-675206) New York, NY (see also kidney, pancreatic, (860) 732-5156
skin, stomach)
V503 Merck vulvovaginal cancer prevention Phase III
Whitehouse Station, NJ (see also cervical) (800) 672-6372
vandetanib AstraZeneca medullary thyroid cancer application submitted
Wilmington, DE (Fast Track) (800) 236-9933
VB-111 VBL Therapeutics thyroid cancer Phase II
Or Yehuda, Israel (see also brain)
volasertib Boehringer Ingelheim urogenital cancer Phase II
Pharmaceuticals (800) 243-0127
Ridgefield, CT
Xgeva™ Amgen prevention of bone metastases in Phase III
denosumab Thousand Oaks, CA breast cancer (800) 772-6436
--------------------------------------------------------------------------------------
prevention of bone metastases in Phase III
prostate cancer (800) 772-6436
Zolinza® Merck gynecological cancer, Phase I/II
vorinostat Whitehouse Station, NJ peritoneal cancer (800) 672-6372
(see also breast, multiple myeloma)
Zybrestat™ OXiGENE thyroid cancer (combination therapy) Phase II/III
fosbretabulin South San Francisco, CA (Fast Track) (650) 635-7000
(orphan drug) (see also lung, ovarian)
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 81
u n s p e c i f i e d c a n c e r s
( d r u G s t H a t H a v e p o t e n t i a l f o r o n e o r M o r e o f t H e p r e v i o u s c a n c e r s )
product name sponsor indication development status
AFX-9901 Afecta Pharmaceuticals in clinical trials
Irvine, CA (949) 253-4688
AGS-6MF Agensys Phase I
Santa Monica, CA (800) 695-4321
Astellas Pharma US
Deerfield, IL
AMG 337 Amgen Phase I
Thousand Oaks, CA (800) 772-6436
antineoplaston- Burzynski Research Phase II
A10 IV Institute (713) 335-5697
Houston, TX
antineoplaston- Burzynski Research Phase II
A10 oral Institute (713) 335-5697
Houston, TX
ANX-514 ADVENTRX Pharmaceuticals Phase I
(docetaxel San Diego, CA (858) 552-0866
emulsion)
ARRY-300 Array BioPharma Phase I
Boulder, CO (303) 381-6600
Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
AVL-292 Avila Therapeutics Phase I
Waltham, MA (781) 891-0086
B7-2/GM-CSF NuVax Therapeutics Phase I
cancer gene therapy Tustin, CA (714) 505-4461
BMS-663513 Bristol-Myers Squibb Phase I
(anti-CD137) Princeton, NJ (212) 235-5000
CA-18C3 Xbiotech Phase I
Austin, TX (512) 386-2900
cancer compound Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
cancer compound Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
cancer compound Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
cancer compound Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
cancer vaccine Immunitor USA Phase I/II
(oral) College Park, MD (301) 476-0930
carboxy- Tactical Therapeutics Phase I
amidotriazole New York, NY (212) 651-9653
orotate (CTO)
82 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
u n s p e c i f i e d c a n c e r s
( d r u G s t H a t H a v e p o t e n t i a l f o r o n e o r M o r e o f t H e p r e v i o u s c a n c e r s )
product name sponsor indication development status
chidamide HUYA Bioscience Phase I
International (858) 798-8800
San Diego, CA (919) 998-2003
Quintiles
Rsch. Triangle Park, NC
cixutumumab Eli Lilly Phase II
Indianapolis, IN (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
CNDO-101 Coronado Biosciences Phase I
New York, NY (212) 332-1665
crenolanib AROG Pharmaceuticals Phase I
(CP-868-596) Dallas, TX (214) 593-0500
docetaxel BIND Biosciences Phase I
nanopharmaceutical Cambridge, MA (617) 419-3400
E7016 Eisai Phase I
Woodcliff Lake, NJ (888) 422-4743
E6201 Eisai Phase I
Woodcliff Lake, NJ (888) 422-4743
EC-0225 Endocyte Phase I completed
West Lafayette, IN (765) 463-7175
EVO 011 Evolve Oncology in clinical trials
New York, NY (646) 723-8941
EVO 044 Evolve Oncology in clinical trials
New York, NY (646) 723-8941
fanG™ vaccine Gradalis Phase II
(autologous tumour Carrollton, TX (214) 442-8100
cell vaccine)
fenretinide CerRx Phase I
intravenous (4-HPR) Lubbock, TX
GI-6207 GlobeImmune Phase I
Louisville, CO (303) 625-2700
GSK2126458 GlaxoSmithKline Phase I
(PI3 kinase inhibitor) Rsch. Triangle Park, NC (888) 825-5249
GSK2586881 GlaxoSmithKline Phase I
Rsch. Triangle Park, NC (888) 825-5249
hTERT cancer Merck Phase I
vaccine Whitehouse Station, NJ (800) 672-6372
(human telomerase Vical (858) 646-1100
reverse transcriptase) San Diego, CA
HuCAL-derived Centocor Ortho Biotech Phase I
antibody Horsham, PA (800) 457-6399
MorphoSys
Munich, Germany
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 83
u n s p e c i f i e d c a n c e r s
( d r u G s t H a t H a v e p o t e n t i a l f o r o n e o r M o r e o f t H e p r e v i o u s c a n c e r s )
product name sponsor indication development status
IMC-3G3 Eli Lilly Phase II
(olaratumab) Indianapolis, IN (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
IMC-18F1 Eli Lilly Phase II
(icrucumab) Indianapolis, IN (800) 545-5979
ImClone Systems
New York, NY
ISIS-EIF4ERx Eli Lilly Phase II
(eIF-4E ASO) Indianapolis, IN (800) 545-5979
Isis Pharmaceuticals (760) 931-9200
Carlsbad, CA
ixabepilone Bristol-Myers Squibb Phase I/II
(oral formulation) Princeton, NJ (212) 546-4000
LY2090314 Eli Lilly Phase II
Indianapolis, IN (800) 545-5979
LY2157299 Eli Lilly Phase I
(TGF ß inhibitor) Indianapolis, IN (800) 545-5979
LY2181308 Eli Lilly Phase II
(survivin ASO) Indianapolis, IN (800) 545-5979
Isis Pharmaceuticals (760) 931-9200
Carlsbad, CA
LY2334737 Eli Lilly Phase I
(Gem prodrug) Indianapolis, IN (800) 545-5979
LY2523355 Eli Lilly Phase I
(Eg5 inhibitor) Indianapolis, IN (800) 545-5979
LY2584702 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2603618 Eli Lilly Phase II
(ChK-1 inhibitor) Indianapolis, IN (800) 545-5979
LY2606368 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2624587 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2780301 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2801653 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2874455 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2875358 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2940680 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
84 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
u n s p e c i f i e d c a n c e r s
( d r u G s t H a t H a v e p o t e n t i a l f o r o n e o r M o r e o f t H e p r e v i o u s c a n c e r s )
product name sponsor indication development status
MK-4101 Merck Phase I
Whitehouse Station, NJ (800) 672-6372
MK-8033 Merck Phase I
Whitehouse Station, NJ (800) 672-6372
MPC-3100 Myrexis Phase I
Salt Lake City, UT (801) 214-7800
notch signalling Eli Lilly Phase I
pathway inhibitor Indianapolis, IN (800) 545-5979
NRX-4204 NuRx Pharmaceuticals Phase I
Irvine, CA (949) 336-7111
OPB-31121 Otsuka America Phase I
Pharmaceutical (800) 562-3974
Rockville, MD
OPB-51602 Otsuka America Phase I
Pharmaceutical (800) 562-3974
Rockville, MD
OVI-237 OncoVista Phase II
San Antonio, TX (210) 677-6000
oxaliplatin Mebiopharm Phase I/II
liposomal Tokyo, Japan
PBI-05204 Phoenix Biotechnology Phase I
San Antonio, TX (877) 593-8945
PF-00562271 Pfizer Phase I
New York, NY (860) 732-5156
PF-03084014 Pfizer Phase I
New York, NY (860) 732-5156
PF-04554878 Pfizer Phase I
New York, NY (860) 732-5156
PF-05212384 Pfizer Phase I
(PKI-587) New York, NY (860) 732-5156
PRT062607 Portola Pharmaceuticals Phase I
South San Francisco, CA (650) 246-7000
QBI-139 Quintessence Biosciences Phase I
Madison, WI (608) 441-2950
SAR153192 Regeneron Pharmaceuticals Phase I
(anti-DLL4 mAb) Tarrytown, NY (914) 345-7400
sanofi-aventis (800) 833-1610
Bridgewater, NJ
SAR245409 Exelixis Phase II
(XL765) South San Francisco, CA (650) 837-7000
sanofi-aventis (800) 633-1810
Bridgewater, NJ
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 85
u n s p e c i f i e d c a n c e r s
( d r u G s t H a t H a v e p o t e n t i a l f o r o n e o r M o r e o f t H e p r e v i o u s c a n c e r s )
product name sponsor indication development status
SAR307746 Regeneron Pharmaceuticals Phase I
(REGN910) Tarrytown, NY (914) 345-7400
sanofi-aventis (800) 833-1610
Bridgewater, NJ
SB1578 S*Bio Phase I
Redwood City, CA (650) 730-2860
tasisulam Eli Lilly Phase II
Indianapolis, IN (800) 545-5979
TL32711 TetraLogic Pharmaceuticals Phase I/II
Malvern, PA (610) 889-9900
V930/V932 Merck Phase I completed
(hTERT cancer Whitehouse Station, NJ (800) 672-6372
vaccine) Vical (858) 646-1100
San Diego, CA
VTX-2337 VentiRx Pharmaceuticals Phase I completed
San Diego, CA (858) 436-1530
XL999 Symphony Evolution Phase I
Rockville, MD
evolution.com
ZYC 300 Eisai Phase I
Woodcliff Lake, NJ (888) 422-4743
The content of this report has been obtained through industry sources and the Adis “R&D Insight” database
based on the latest information. report current as of March 18, 2011. The information may not be comprehensive.
For more specific information about a particular product, contact the individual company directly or go to
The entire series of Medicines in Development is available on PhRMA’s web site.
A publication of PhRMA’s Communications & Public Affairs Department. (202) 835-3460
Provided as a Public Service by PhRMA. Founded in 1958 as the Pharmaceutical Manufacturers Association.
Copyright © 2011 by the Pharmaceutical Research and Manufacturers of America. Permission to reprint is awarded if
proper credit is given.
86 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
actinic keratoses—Roughness and
thickening of the skin caused by overexposure
to the sun’s ultraviolet rays.
It can degenerate into a skin cancer
called squamous cell carcinoma.
adenocarcinoma—Malignant tumor
derived from a gland or glandular
tissue.
adjunctive treatment—An auxiliary
treatment that is secondary to the
main treatment.
adjuvant—A substance or drug that
aids another substance in its action.
allogeneic—Refers to having cell
types that are distinct and cause
reactions in the immune system.
application submitted—An application
for marketing has been submitted
by the company to the Food and
Drug Admin istra tion (FDA).
ascites—Excess fluid in the space
between the tissues lining the
abdomen and abdominal organs (the
peritoneal cavity).
basal cell cancer—Cancer of the
lower layers of the skin.
B-cell—A class of white blood cells
important to the body’s immune
system.
biliary—Relating to bile.
carcinoma—A malignant tumor that
arises from epithelial tissues, such
as skin.
cervical—Relating to the neck of
the uterus.
chemoprotection—A therapeutic
technique in which bone marrow
cells are removed from an individual
with cancer and are genetically modified
to withstand higher doses of
chemotherapy before being returned
to the donor.
cholangiocarcinoma—A malignancy
of the biliary duct system that may
originate in the liver and extrahepatic
bile ducts. More than 90 percent are
adenocarcinomas, and the remainder
are squamous cell tumors. Cholangio -
carcinomas tend to grow slowly and
to infiltrate the walls of the ducts. Each
year, approximately 2,500 cases
occur, and the average incidence is
1 case per 100,000 people per year.
cutaneous—Pertaining to the skin.
dysplasia—Abnormal tissue development.
gastric—Of or relating to the stomach.
GISTs—Gastrointestinal stromal
tumors are uncommon tumors of the
GI tract. Not all GISTs are cancerous;
some are benign. Although these
cancers can arise anywhere in the
GI tract, they occur most often in
the stomach (60% to 70%) and less
commonly in the small intestine
(20% to 30%). The rest are found in
the esophagus, large intestine, rectum,
and anus. About 80% of people diagnosed
with GIST are older than 50.
It is slightly more common in men.
Blacks are more likely to develop
GISTs than whites.
glioblastoma—A fast growing and
highly malignant type of brain tumor
arising from glial (supporting) cells
within the brain. There are about
five to 10 new cases per million
population per year in the United
States, and the cause is unknown.
glioma—A type of brain tumor arising
from the supporting glial cells within
the brain. Gliomas make up about
60 percent of all primary brain tumors
and are frequently malignant.
graft-versus-host disease
(GVHD)—A complication in bone
marrow transplants where immune
system cells attack the transplant
recipient’s tissues.
head and neck cancer—The term
given to a variety of malignant tumors
that develop in the mouth, throat,
paranasal sinuses, nasal cavity, larynx,
and salivary glands. Many authorities
also include skin tumors of the
face and neck and tumors of the cervical
lymph nodes. There are more
than half a million survivors of oral,
head, and neck cancer living in the
United States today.
hematological malignancies—
Cancers of the blood or bloodforming
tissues, such as leukemia,
Hodgkin’s and non-Hodgkin’s lymphomas,
AIDS-related malignancies,
multiple myeloma, myelodysplasia
and myeloproliferative disorders.
hepatocellular cancer/carcinoma—
A cancer that begins in the liver cells.
hyperuricemia—An abnormally high
uric acid level in the blood.
imaging agent—A substance used to
enhance x-ray images of organs and
spaces in the body.
intraepithelial neoplasia, anal (AIN)
& cervical (CIN)— AIN is a consequence
of chronic human papillomavirus
infection in the anal canal
and appears to be driven by high
viral loads of human papillomavirus.
What is known of its natural history
resembles that of cervical intraepithelial
neoplasia. Dysplasia and cervical
intraepithelial neoplasia (CIN)
are different terms or names for the
same condition—it is a precursor to
cervical cancer. CIN may be mild,
moderate or severe.
Kaposi’s sarcoma—A rare, malignant
skin tumor that occurs in some AIDS
patients. It can be accompanied by
fever, enlarged lymph nodes and
gastro intestinal problems.
leiomyoma—A benign neoplasm
derived from smooth muscle.
leukemia—A form of cancer in which
abnormally growing white blood cells
are scattered throughout the body and
bone marrow. They can take over the
marrow and prevent it from making
enough normal blood cells (white,
red and platelets), leaving the patient
highly susceptible to serious infections,
anemia and bleeding episodes.
The cells can also spill into the blood,
infiltrating and interfering with the
function of other organs. The four
main types of leukemia are: acute
lympho blastic leukemia (ALL), acute
myeloid leukemia (AML), chronic
lymphocytic leukemia (CLL), and
chronic myeloid leukemia (CML).
The acute types have a rapid onset,
and overwhelming infection or blood
loss can cause death. The chronic
forms progress much more slowly.
lung cancer—The leading cause
of cancer deaths in both men and
G l o s s a r y
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 87
women. There are several types of
lung cancer, the most common being
squamous cell carcinoma, small (oat)
cell carcinoma, adenocarcinoma and
large cell carcinoma. Each has a different
growth pattern and response to
treatment. The squamous cell, small
cell and large cell types are all strongly
associated with tobacco abuse.
lymphoma—Cancers in which the
cells of lymphoid tissue, found mainly
in the lymph nodes and spleen, multiply
unchecked. Lymphomas fall into
two categories: Hodgkin disease,
characterized by a particular kind
of abnormal cell, and non-Hodgkin
lymphomas, which vary in their
malignancy according to the nature
and activity of the abnormal cells.
Mantle cell lymphoma is a type of
non-Hodgkin lymphoma.
macroglobulinemia—A disorder in
which plasma cells produce an
excessive quantity of macroglobulins
(large antibodies) that accumulate in
the blood. It results from a group of
abnormal, cancerous lymphocytes
and plasma cells. Men are affected
more often than women, and the
average age at onset is 65.
mastocytosis—A condition characterized
by infiltration of mast cells
into the tissues of the body. Mast
cells are connective tissue cells
which release chemicals including
histamine that are very irritating and
cause itching, swelling, and fluid
leakage from cells.
medullary—Relating to the medulla
(any soft marrow-like structure, especially
the innermost part) or marrow.
melanoma—A cancer made up of
pigmented (usually brown-colored)
skin cells anywhere in the body.
mesothelioma—A tumor of the lining of
the lung and chest cavity (the pleura).
metastases/metastatic—Areas of
secondary cancer that have spread
from the primary or original cancer
site.
mucositis—The swelling, irritation,
and ulceration of the mucosal cells
that line the digestive tract. Mucositis
can occur anywhere along the digestive
tract from the mouth to the anus.
It can be a very troublesome and
painful side effect of chemotherapy.
multiple myeloma—A malignant
condition of middle to old age,
characterized by the uncontrolled
proliferation and dis ordered function
of plasma cells in the bone marrow.
The condition, which makes the
patient particularly prone to infection,
is rare, with about three new cases
annually per 100,000 population.
myeloablation—A severe form of
myelosuppression, a condition in
which bone marrow activity is
decreased, resulting in fewer red
blood cells, white blood cells, and
platelets. It is a side effect of some
cancer treatments.
myelodysplastic syndromes (MDS)—
Blood disorders that ultimately are
fatal. Patients usually succumb to
infections or bleeding. The term
“preleukemia” has been used to
describe these disorders.
neoadjuvant therapy—Chemo -
therapy, radiation therapy, or hormone
therapy given before the
primary or main treatment. Neo -
adjuvant therapy, like chemotherapy
and radiation therapy, is often given
before surgery to reduce the size of
a tumor or to make surgery less
complicated.
neuroblastoma—A tumor of the
adrenal glands or sympathetic nervous
system (the part of the nervous
system responsible for certain automatic
body functions, such as the
control of heart rate). Neuro blastomas
are the most common extracranial
(outside the skull) solid tumors of
childhood.
osteosarcoma—Cancer of the bone
that occurs predominantly in adolescents
and young adults. It accounts
for 5 percent of cancer in children
peritoneal—Relating to the peritoneum,
the membrane that lines the
abdominal cavity and covers most of
the abdominal organs.
Phase 0—First-in-human trials conducted
in accordance with FDA’s
2006 guidance on exploratory
Investigational New Drug (IND) studies
designed to speed up development
of promising drugs by establishing
very early on whether the agent
behaves in human subjects as was
anticipated from preclinical studies.
Phase I—Safety testing and pharma -
cological profiling of new drugs in
small numbers of humans.
Phase II—Effectiveness testing and
identification of side effects of new
drugs in humans.
Phase III—Extensive clinical trials
in humans to verify effectiveness and
monitor adverse reactions of new drugs.
prolactinoma—A noncancerous
pituitary tumor that produces a hormone
called prolactin, which results
in too much prolactin in the blood.
refractory—Resistant to treatment or
cure.
sarcoma—A malignant tumor that
arises from deep body tissues, such
as muscle, bone or fibrous tissue.
T-cell—One of two main classes of
white blood cells called lymphocytes,
which are important to the body’s
disease-fighting immune system.
thrombocytopenia—A reduction in
the number of platelet cells in the
blood, which causes a tendency to
bleed, especially from the smaller
blood vessels.
thymoma—Although rare, thymomas
are the most common tumor of the
thymus, a small organ located in the
upper chest just below the neck that
produces certain types of white blood
cells (lymphocytes) before birth and
during childhood. Thymomas arise
from thymic epithelial cells, which
make up the covering of the thymus.
Up to 40 percent of thymomas are
invasive. They affect men and women
equally and are usually diagnosed
between the ages of 40 and 60.
Thymomas are uncommon in children.
unresectable—Unable to be
removed (resected) by surgery.
G l o s s a r y
88 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
S E L E C T E D F A C T S A B O U T C A N C E R I N T H E
U N I T E D S T A T E S
New Cancer Cases/Deaths 1
Cancer Type Estimated 2010 New Cases Estimated 2010 Deaths
All Sites 1,529,560 569,490
Male 789,620 299,200
Female 739,940 270,290
Acute Lymphocytic Leukemia 5,330 1,420
Male 3,150 790
Female 2,180 630
Acute Myeloid Leukemia 12,330 8,950
Male 6,590 5,280
Female 5,740 3,670
S E L E C T E D F A C T S A B O U T C A N C E R I N T H E
U N I T E D S T A T E S
Overview1
• In 2010, more than 1.5 million new cancer cases were expected to be diagnosed. The National Cancer Institute
estimates that approximately 11.4 million Americans with a history of cancer were alive in January 2006. The 5-year
relative survival rate for all cancers diagnosed between 1999 and 2005 is 68 percent, up from 50 percent in the
mid-70s.
• Men have a little less than a 1 in 2 lifetime risk of developing cancer, and for women, the risk is a little more than
1 in 3. About 78 percent of all cancers are diagnosed in people ages 55 and older.
• Scientific evidence suggests that about one-third of the cancer deaths expected this year will be related to overweight
or obesity, physical inactivity, and nutrition, and thus could be prevented.
• Cancer is the second leading cause of death by disease—1 of every 4 deaths—in the United States, exceeded only
by heart disease. This year, an estimated 569,490 are expected to die of cancer, more than 1,500 people a day.
Costs1
• The National Institutes of Health estimates overall costs for cancer in 2010 at $263.8 billion: $102.8 billion
for direct medical costs (total of all health expenditures); $20.9 billion for indirect morbidity costs (e.g., cost of
lost productivity due to illness); and $140.1 billion for indirect mortality costs (cost of lost productivity due
to premature death).
Pain
• pain, which can be caused by the disease itself or by treatments, is common in people with cancer, although not
all people with cancer will experience pain. Approximately 30 percent to 50 percent of people with cancer
experience pain while undergoing treatment, and 70 percent to 90 percent of people with advanced cancer
experience pain.2
• Breakthrough cancer pain is common among people with cancer-related pain. It occurs in 50 percent – 90 percent
of oncology inpatient settings, 89 percent of home care and inpatient hospice settings, 74 percent of U.S. pain
clinics, and 33 percent of community-based oncology practices.3
• Breakthrough cancer pain is associated with higher costs for people who suffer from it compared to those who
do not, for exmple, higher hospitalization rates (36.9 percent compared to 22.5 percent) and higher estimated
annual costs of care ($1.7 million compared to $192,000).3
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 89
S E L E C T E D F A C T S A B O U T C A N C E R I N T H E
U N I T E D S T A T E S
New Cancer Cases/Deaths 1 (continued)
Cancer Type Estimated 2010 New Cases Estimated 2010 Deaths
Bladder Cancer 70,530 14,680
Male 52,760 10,410
Female 17,770 4,270
Bone Cancer (and joints) 2,650 1,460
Male 1,530 830
Female 1,120 630
Brain Cancer (and other nervous system) 22,020 13,140
Male 11,980 7,420
Female 10,040 5,720
Breast Cancer 209,060 40,230
Male 1,970 390
Female 207,090 39,840
Cervical Cancer/Uterine Cancer 55,670 12,160
Male — —
Female 55,670 12,160
Chronic Lymphocytic Leukemia 14,990 4,390
Male 8,870 2,650
Female 6,120 1,740
Chronic Myeloid Leukemia 4,870 440
Male 2,800 190
Female 2,070 250
Colorectal Cancer 142,570 51,370
Male 72,090 26,580
Female 70,480 24,790
Esophageal Cancer 16,640 14,500
Male 13,130 11,650
Female 3,510 2,850
Kidney Cancer (and renal pelvis) 58,240 13,040
Male 35,370 8,210
Female 22,870 4,830
Leukemia (all types) 43,050 21,840
Male 24,690 12,660
Female 18,360 9,180
Liver Cancer 24,120 18,910
Male 17,430 12,720
Female 6,690 6,190
90 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
S E L E C T E D F A C T S A B O U T C A N C E R I N T H E
U N I T E D S T A T E S
New Cancer Cases/Deaths 1 (continued)
Cancer Type Estimated 2010 New Cases Estimated 2010 Deaths
Lung Cancer (and bronchus) 222,520 157,300
Male 116,750 86,220
Female 105,770 71,080
Lymphoma (all types) 74,030 21,530
Male 40,050 11,450
Female 33,980 10,080
Lymphoma (non-Hodgkin’s) 65,540 20,210
Male 35,380 10,710
Female 30,160 9,500
Melanoma-Skin Cancer 68,130 8,700
Male 38,870 5,670
Female 29,260 3,030
Multiple Myeloma 20,180 10,650
Male 11,170 5,760
Female 9,010 4,890
Ovarian Cancer 21,880 13,850
Male — —
Female 21,880 13,850
Pancreatic Cancer 43,140 36,800
Male 21,370 18,770
Female 21,770 18,030
Prostate Cancer 217,730 32,050
Male 217,730 32,050
Female — —
Stomach Cancer 21,000 10,570
Male 12,730 6,350
Female 8,270 4,220 CA (see also solid tumors) (650) 635-7000
PCI-32765 Pharmacyclics CLL Phase I
(BTK inhibitor) Sunnyvale, CA (see also lymphoma) (408) 774-0330
perifosine Aeterna Zentaris refractory metastatic CLL Phase II
(KRX-1401) Montreal, Canada (see also brain, colorectal, kidney, (212) 531-5965
Keryx Biopharmaceuticals lymphoma, multiple myeloma,
New York, NY ovarian, sarcoma, stomach)
polyphenon E Polyphenon Pharma CLL Phase I/II
(orphan drug) New York, NY (see also prostate) (212) 661-0578
ponatinib ARIAD Pharmaceuticals ALL, CML Phase II
(AP24534) Cambridge, MA (617) 494-0400
PR1 cancer Vaccine Company AML Phase III
vaccine South San Francisco, CA (650) 244-4100
--------------------------------------------------------------------------------------
CML, myelodysplastic syndromes Phase II
(650) 244-4100
PR104 Proacta Therapeutics AML Phase I/II
San Diego, CA (858) 642-0386
quizartinib Ambit Biosciences AML Phase II
San Diego, CA (see also solid tumors) (858) 334-2100
Astellas Pharma US (800) 727-7003
Deerfield, IL
sapacitabine Cyclacel Pharmaceuticals AML in elderly patients Phase III
Short Hills, NJ (see also lung) (973) 847-5955
SAR103168 sanofi-aventis AML Phase I
(multikinase Bridgewater, NJ (800) 633-1810
inhibitor)
SB939 S*Bio AML Phase II
Redwood City, CA (see also solid tumors) (650) 730-2860
24 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l e u K e M i a
product name sponsor indication development status
SB1518 S*Bio myeloid leukemia Phase I/II
Redwood City, CA (see also lymphoma) (650) 730-2860
SCH-900776 Merck (see also lymphoma) Phase I
Whitehouse Station, NJ (800) 672-6372
SF1126 Semafore Pharmaceuticals CLL Phase I
(orphan drug) Indianapolis, IN (see also multiple myeloma, (317) 876-3075
solid tumors)
SGI-110 SuperGen AML Phase I/II
Dublin, CA (925) 560-0100
SL-401 Stemline Therapeutics AML Phase I/II
New York, NY (212) 831-1111
SNDX-275 Syndax Pharmaceuticals (see also breast, leukemia, lung, Phase II
(entinostat) Waltham, MA lymphoma) (781) 419-1400
sprycel® Bristol-Myers Squibb myelodysplastic syndromes Phase II
dasatinib Princeton, NJ (see also brain, breast, colorectal, (212) 546-4000
lung, lymphoma, multiple myeloma,
prostate, skin)
tamibarotene CytRx acute promyelocytic leukemia (APL) Phase II
(orphan drug) Los Angeles, CA (Fast Track) (310) 826-5648
(see also lung)
tarceva® Genentech myelodysplastic syndromes Phase II
erlotinib South San Francisco, CA (see also bladder, brain, breast, (650) 224-1000
OSI Pharmaceuticals colorectal, head/neck, liver, lung, (800) 572-1932
Melville, NY other)
tasigna® Novartis Pharmaceuticals CML in adolescents and children Phase II
nilotinib East Hanover, NJ (see also skin, stomach) (888) 669-6682
(orphan drug)
telintra® Telik myelodysplastic syndromes Phase II
ezatiostat Palo Alto, CA (650) 845-7700
temodar® Merck AML Phase II
temozolomide Whitehouse Station, NJ (see also lung, skin) (800) 672-6372
TH-302 Threshold Pharmaceuticals advanced leukemia Phase I
Redwood City, CA (see also pancreatic, sarcoma, (650) 474-8200
solid tumors)
thiarabine Access Pharmaceuticals (see also lymphoma) Phase I/II
Dallas, TX (214) 905-5100
tosedostat Chroma Therapeutics AML Phase II
(orphan drug) Oxford, United Kingdom
therapeutics.com
treosulfan medac ALL, AML, myelodysplastic Phase II
Wedel, Germany syndromes
trisenox® Cephalon AML in elderly patients Phase III
arsenic trioxide Frazer, PA (see also brain, multiple myeloma) (610) 344-0200
TRU-016 Emergent Biosolutions CLL Phase I/II
(anti-CD37) Rockville, MD (see also lymphoma) (301) 795-1800
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 25
l e u K e M i a
product name sponsor indication development status
veltuzumab Immunomedics CLL Phase I/II completed
(IMMU-106) Morris Plains, NJ (see also lymphoma) (973) 605-8200
vidaza® Celgene AML Phase III
azacitidine Summit, NJ (908) 673-9000
(orphan drug)
vosaroxin Sunesis Pharmaceuticals AML (Fast Track) Phase III
(SNS-595) South San Francisco, CA (see also ovarian) (650) 266-3500
(orphan drug) --------------------------------------------------------------------------------------
AML in the elderly Phase II
(650) 266-3500
WT1 recombinant GlaxoSmithKline AML Phase II
vaccine Rsch. Triangle Park, NC (888) 825-5249
(antigen specific
cancer
immunotherapy)
XmAb®5574 Xencor CLL Phase I
(MOR-208) Monrovia, CA (626) 305-5900
MorphoSys
Munich, Germany
zosuquidar Kanisa Pharmaceuticals newly-diagnosed AML in elderly Phase I/II
(orphan drug) San Diego, CA patients (858) 436-1800
l i v e r c a n c e r
product name sponsor indication development status
ABT-869 Abbott Laboratories (see also breast, colorectal, Phase III
(linifarib) Abbott Park, IL kidney, lung) (847) 937-6100
ADI-PEG 20 Polaris Pharmaceuticals (see also lung, skin) Phase II
(orphan drug) San Diego, CA (858) 452-6688
afinitor® Novartis Pharmaceuticals advanced hepatocellular carcinoma Phase III
everolimus East Hanover, NJ (see also breast, liver, lymphoma, (888) 669-6682
stomach, other)
ALN-VSP Alnylam Pharmaceuticals Phase I
Cambridge, MA (617) 551-8200
AMG 386 Amgen (see also breast, colorectal, kidney, Phase II
Thousand Oaks, CA ovarian, stomach, other) (800) 772-6436
ARQ-197 ArQule hepatocellular carcinoma Phase II
Woburn, MA (see also colorectal, kidney, lung, (781) 994-0300
Daiichi Sankyo pancreatic, sarcoma, solid tumors, (973) 944-2600
Parsippany, NJ other)
bavituximab Peregrine Pharmaceuticals (see also breast, pancreatic) Phase I/II
Tustin, CA (714) 508-6000
BAY 86-9766 Bayer HealthCare Phase II
Pharmaceuticals (888) 842-2937
Wayne, NJ
26 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l i v e r c a n c e r
product name sponsor indication development status
BIIB 022 Biogen Idec (see also lung) Phase I
Cambridge, MA (617) 679-2000
brivanib Bristol-Myers Squibb hepatocellular carcinoma Phase III
(VEGFR/FGFR Princeton, NJ (see also stomach) (212) 546-4000
kinase inhibitor)
CRS-100 Aduro BioTech Phase I
Berkeley, CA (510) 848-4400
darinaparsin ZIOPHARM Oncology (see also lymphoma, Phase II completed
(ZIO-101) New York, NY multiple myeloma, solid tumors) (646) 214-0700
davanat™ Pro-Pharmaceuticals biliary cancer Phase II
galactomannan C Newton, MA (see also colorectal) (617) 559-0033
E7050 Eisai hepatocellular carcinoma Phase I/II
Woodcliff Lake, NJ (see also stomach, other) (888) 422-4743
GC-33/RG7686 Chugai Pharma USA Phase I
Berkeley Heights, NJ (908) 516-1350
Roche (973) 235-5000
Nutley, NJ
irinotecan Biocompatibles liver metastases from Phase II
eluting beads International colorectal cancer
Surrey, United Kingdom
JX-594 Jennerex Biotherapeutics (see also colorectal) Phase II
San Francisco, CA (415) 281-8886
lenvatinib Eisai hepatocellular carcinoma Phase I/II
(E7080) Woodcliff Lake, NJ (see also brain, kidney, ovarian, (888) 422-4743
skin, other)
mapatumumab Human Genome Sciences (see also lung, multiple myeloma) Phase I/II
Rockville, MD (301) 309-8504
MB-07133 Ligand Pharmaceuticals inoperable, unresectable Phase I/II completed
(orphan drug) La Jolla, CA liver cancer (858) 550-7500
melphalan drug Delcath Systems secondary liver cancer arising from application submitted
delivery system New York, NY metastatic ocular or cutaneous (212) 489-2100
melanoma
muparfostat Progen Pharmaceuticals (Fast Track) Phase III
(PI-88) Redwood City, CA (see also skin) (650) 610-7080
nexavar® Bayer HealthCare adjuvant therapy Phase III
sorafenib Pharmaceuticals (see also breast, colorectal, kidney, (888) 842-2837
Wayne, NJ lung, ovarian, other) (510) 597-6500
Onyx Pharmaceuticals
Emeryville, CA
NV1020 Catherex Phase I/II completed
Arlington, VA (703) 786-3790
patupilone Novartis Pharmaceuticals (see also brain) Phase II
(EPO906) East Hanover, NJ (888) 669-6682
prevonco™ Apricus Biosciences Phase II
lansoprazole San Diego, CA (858) 222-8041
(orphan drug)
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 27
l i v e r c a n c e r
product name sponsor indication development status
PV-10 Provectis Pharmaceuticals liver metastases Phase I
Knoxville, TN (see also skin) (866) 594-5999
ramucirumab Eli Lilly (see also breast, colorectal, Phase III
(IMC-1121B) Indianapolis, IN lung, stomach) (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
tarceva® Genentech inoperable, unresectable liver cancer Phase III
erlotinib South San Francisco, CA (see also bladder, brain, breast, (650) 224-1000
OSI Pharmaceuticals colorectal, head/neck, leukemia, (800) 572-1932
Melville, NY lung, other)
thermodox® Celsion inoperable, unresectable liver cancer Phase III
LTSDEL Columbia, MD (Fast Track) (410) 290-5390
(orphan drug) (see also breast)
tigatuzumab Daiichi Sankyo (see also colorectal, lymphoma, Phase II
Parsippany, NJ ovarian, pancreatic) (973) 359-2600
l u n G c a n c e r
product name sponsor indication development status
abraxane® Celgene advanced non-small-cell lung cancer Phase III
albumin-bound Summit, NJ (NSCLC) (908) 673-9000
paclitaxel (see also bladder, ovarian,
pancreatic, skin)
ABT-869 Abbott Laboratories NSCLC Phase II
(linifarib) Abbott Park, IL (see also breast, kidney, liver) (847) 937-6100
ADI-PEG 20 Polaris Pharmaceuticals small-cell lung cancer (SCLC) Phase II
(orphan drug) San Diego, CA (see also liver, skin) (858) 452-6688
--------------------------------------------------------------------------------------
mesothelioma Phase I
(858) 452-6688
aflibercept sanofi-aventis second-line NSCLC Phase III
(VEGF-trap) Bridgewater, NJ (see also colorectal, prostate) (800) 633-1610
Regeneron Pharmaceuticals (914) 345-7400
Tarrytown, NY
AMG 479 Amgen SCLC Phase I/II
(gunitumab) Thousand Oaks, CA (see also breast, colorectal, (800) 772-6436
pancreatic, sarcoma, other)
amrubicin Celgene second-line SCLC Phase III
(orphan drug) Summit, NJ (Fast Track) (908) 673-9000
--------------------------------------------------------------------------------------
first-line SCLC Phase II
(908) 673-9000
apricoxib Tragara Pharmaceuticals NSCLC Phase II
San Diego, CA (see also pancreatic) (858) 350-6900
28 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l u n G c a n c e r
product name sponsor indication development status
ARQ-197 ArQule NSCLC Phase III
Woburn, MA (see also colorectal, kidney, liver, (781) 994-0300
Daiichi Sankyo pancreatic, sarcoma, solid tumors, (973) 944-2600
Parsippany, NJ other)
AT-101 Ascenta Therapeutics NSCLC, SCLC Phase II
Malvern, PA (see also leukemia, lymphoma, (610) 408-0301
prostate, stomach)
AUY922 Novartis Pharmaceuticals NSCLC Phase II
East Hanover, NJ (see also breast, colorectal, multiple (888) 669-6682
myeloma, stomach)
AV-951 AVEO Pharmaceuticals NSCLC Phase I/II
(tivozanib) Cambridge, MA (see also breast, kidney, stomach) (617) 299-5000
avastin® Genentech NSCLC (adjuvant therapy) Phase III
bevacizumab South San Francisco, CA (see also brain, breast, colorectal, (650) 225-1000
ovarian, other)
axitinib Pfizer NSCLC Phase II
New York, NY (see also kidney, other) (860) 732-5156
bavituximab Peregrine Pharmaceuticals NSCLC Phase II
Tustin, CA (see also liver, pancreatic) (714) 508-6000
BAY 73-4506 Bayer HealthCare NSCLC Phase I
(regorafenib) Pharmaceuticals (see also colorectal, kidney, stomach) (888) 842-2937
Wayne, NJ
belinostat Spectrum Pharmaceuticals NSCLC Phase I/II
Irvine, CA (see also lymphoma, other) (949) 788-6700
TopoTarget USA (973) 895-6900
Rockaway, NJ
BI 2536 Boehringer Ingelheim SCLC Phase II completed
Pharmaceuticals (see also lymphoma) (800) 243-0127
Ridgefield, CT
BIBF 1120 Boehringer Ingelheim NSCLC Phase III
(intedanib) Pharmaceuticals (800) 243-0127
Ridgefield, CT
BIBW 2992 Boehringer Ingelheim NSCLC Phase III
(afatinib) Pharmaceuticals (Fast Track) (800) 243-0127
Ridgefield, CT (see also brain, breast, head/neck)
BIIB 022 Biogen Idec NSCLC Phase I
Cambridge, MA (see also liver) (617) 679-2000
BMS-690514 Bristol-Myers Squibb NSCLC Phase II
(HER/VEGFR2 Princeton, NJ (see also breast) (212) 546-4000
inhibitor)
BMS-844203 Bristol-Myers Squibb NSCLC Phase II
(VEGF R-2 Princeton, NJ (see also brain, colorectal) (212) 546-4000
adnectin)
cabozantinib Exelixis NSCLC Phase I/II
(XL-184) South San Francisco, CA (see also other) (650) 837-7000
CBP501 CanBas mesothelioma, NSCLC Phase II
Shizuoka, Japan
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 29
l u n G c a n c e r
product name sponsor indication development status
conatumumab Amgen NSCLC Phase I/II
Thousand Oaks, CA (see also colorectal, pancreatic, (800) 772-6436
sarcoma)
crizotinib Pfizer NSCLC (Fast Track) Phase III
New York, NY (860) 732-5156
CS-7017 Daiichi Sankyo NSCLC Phase II
(efatutazone) Parsippany, NJ (see also colorectal, other) (973) 944-2600
CST-101 ConKwest NSCLC, SCLC Phase I
Del Mar, CA (see also leukemia, lymphoma, skin) (858) 380-1999
dalotuzumab Merck NSCLC Phase I/II
Whitehouse Station, NJ (see also breast, colorectal, (800) 672-6372
pancreatic, other)
dinaciclib Merck NSCLC Phase II
Whitehouse Station, NJ (see also breast, leukemia, lymphoma) (800) 672-6372
EC-145 Endocyte late-stage NSCLC Phase II
West Lafayette, IN (see also ovarian, other) (765) 463-7175
erbitux® Bristol-Myers Squibb NSCLC Phase III
cetuximab Princeton, NJ (see also bladder, breast, head/neck) (212) 546-4000
Eli Lilly (800) 545-5979
Indianapolis, IN (212) 645-1405
ImClone Systems
New York, NY
eribulin Eisai NSCLC Phase I/II
(E7389) Woodcliff Lake, NJ (see also bladder, prostate, sarcoma) (888) 422-4743
exelbine™ ADVENTRX NSCLC application submitted
vinorelbine Pharmaceuticals (see also breast, lymphoma) (858) 552-0866
emulsion San Diego, CA
farletuzumab Eisai NSCLC Phase II
(MORAb-003) Woodcliff Lake, NJ (see also ovarian) (888) 422-4743
folotyn® Allos Therapeutics NSCLC Phase II
pralatrexate Westminster, CO (see also bladder, breast, lymphoma) (303) 426-6262
ganetespib Synta Pharmaceuticals NSCLC Phase II
Lexington, MA (see also breast, colorectal, (781) 274-8200
stomach, other)
GDC-0941 Genentech metastatic NSCLC Phase I
(PI3 kinase inhibitor) South San Francisco, CA (see also breast, lymphoma, solid (650) 224-1000
tumors)
GI-4000 GlobeImmune NSCLC Phase I
Louisville, CO (see also colorectal, pancreatic) (303) 625-2700
GRN-163L Geron NSCLC Phase II
(imetelstat) Menlo Park, CA (see also breast, leukemia, (650) 473-7700
multiple myeloma)
GSK2302032A GlaxoSmithKline resectable NSCLC Phase I
(PRAME Rsch. Triangle Park, NC (see also skin) (888) 825-5249
immunotherapeutic
recombinant
vaccine)
30 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l u n G c a n c e r
product name sponsor indication development status
HS-L1 Heat Biologics NSCLC Phase I
Miami Beach, FL (305) 432-4684
Hyperacute® lung NewLink Genetics NSCLC Phase I/II
lung cancer Ames, IA (515) 296-5555
vaccine
IMGN-901 ImmunoGen SCLC Phase I/II
(orphan drug) Cambridge, MA (see also multiple myeloma) (617) 995-2500
IMO-2055 EMD Serono NSCLC Phase I
(EMD-1201081) Rockland, MA (see also colorectal, kidney) (800) 283-8088
Idera Pharmaceuticals (617) 679-5500
Cambridge, MA
imprime pGG® Biothera NSCLC Phase II
Eagen, MN (see also colorectal, leukemia, skin) (651) 675-0300
iniparib BiPar Sciences squamous lung cancer Phase III
(BSI-201) South San Francisco, CA (see also breast, ovarian) (650) 615-7000
sanofi-aventis (800) 633-1810
Bridgewater, NJ
--------------------------------------------------------------------------------------
non-squamous NSCLC Phase II
(650) 615-7000
(800) 633-1810
ipilimumab Bristol-Myers Squibb NSCLC Phase II
Princeton, NJ (see also prostate, skin) (212) 546-4000
ixempra® Bristol-Myers Squibb NSCLC Phase II
ixabepilone Princeton, NJ (see also breast, stomach, other) (212) 546-4000
JNJ-26854165 Johnson & Johnson NSCLC Phase I
Pharmaceutical Research (see also prostate, solid tumors) (800) 817-5286
& Development
Raritan, NJ
lucanix® NovaRx NSCLC (Fast Track) Phase III
belagenpumatucel-L San Diego, CA (see also brain) (858) 552-8600
MAGE-A3 GlaxoSmithKline NSCLC Phase III
recombinant vaccine Rsch. Triangle Park, NC (see also skin) (888) 825-5249
(antigen-specific
cancer
immunotherapeutic)
mapatumumab Human Genome Sciences NSCLC Phase II
Rockville, MD (see also liver, multiple myeloma) (301) 309-8504
MetmAb Genentech NSCLC Phase II
(RG 3638) South San Francisco, CA (650) 225-1000
MGCD-265 MethylGene NSCLC Phase II
Montreal, Canada (see also solid tumors) (514) 337-3333
MORAb-009 Eisai mesothelioma Phase II
Woodcliff Lake, NJ (888) 422-4743
motesanib Amgen NSCLC Phase III
(AMG 706) Thousand Oaks, CA (see also breast) (800) 772-6436
Millennium Pharmaceuticals (800) 390-5663
Cambridge, MA
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 31
l u n G c a n c e r
product name sponsor indication development status
naptumomab Active Biotech NSCLC (Fast Track) Phase I completed
estafenatox Lund, Sweden (see also kidney, pancreatic)
navitoclax Abbott Laboratories SCLC Phase II
(ABT-263/RG7433) Abbott Park, IL (see also leukemia, lymphoma) (847) 937-6100
Genentech (650) 225-1000
South San Francisco, CA
necitumumab Bristol-Myers Squibb NSCLC Phase III
(IMC-11F8) Princeton, NJ (212) 546-4000
Eli Lilly (800) 545-5979
Indianapolis, IN (212) 645-1405
ImClone Systems
New York, NY
nexavar® Bayer HealthCare NSCLC Phase III
sorafenib Pharmaceuticals (see also breast, colorectal, kidney, (888) 842-2837
Wayne, NJ liver, ovarian, other) (510) 597-6500
Onyx Pharmaceuticals
Emeryville, CA
NK-012 Nippon Kayaku SCLC Phase II
Tokyo, Japan (see also breast)
NTX-10 Neotropix SCLC Phase II
Malvern, PA (see also other) (617) 460-1200
obatoclax Gemin X Biotechnologies SCLC Phase I/II
Montreal, Canada (see also leukemia, lymphoma, (514) 281-8989
multiple myeloma)
OBP-301 Oncolys Biopharma mesothelioma Phase I
Tokyo, Japan (see also breast, head/neck)
OGX-427 Oncogenex NSCLC Phase I
Pharmaceuticals (see also bladder, breast, ovarian, (425) 686-1500
Bothell, WA prostate)
onconase® Tamir Biotechnology NSCLC Phase II
ranpirnase Monmouth Junction, NJ (732) 823-1003
opaxio™ Cell Therapeutics NSCLC Phase III
paclitaxel Seattle, WA (see also ovarian, other) (800) 215-2355
poliglumex Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
OSI-906 OSI Pharmaceuticals NSCLC Phase II
(linsitinib) Melville, NY (see also ovarian, other) (631) 962-2000
P2045 Bryan Oncor NSCLC, SCLC Phase I
Somerville, MA (617) 273-2466
palifosfamide ZIOPHARM Oncology SCLC Phase I
(ZIO-201) New York, NY (see also sarcoma) (212) 214-0700
PF-00299804 Pfizer NSCLC Phase III
New York, NY (860) 732-5156
picoplatin Poniard Pharmaceuticals SCLC (Fast Track) Phase II
intravenous San Francisco, CA (see also colorectal, ovarian, prostate) (650) 583-3774
(orphan drug)
32 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l u n G c a n c e r
product name sponsor indication development status
plinabulin Nereus Pharmaceuticals NSCLC Phase II
(NPI-2358) San Diego, CA (858) 587-4090
PM-02734 Pharmamar USA NSCLC Phase II
(elisidepsin) New York, NY
ramucirumab Eli Lilly NSCLC Phase III
(IMC-1121B) Indianapolis, IN (see also breast, colorectal, (800) 545-5979
ImClone Systems liver, stomach) (212) 645-1405
New York, NY
rencentin™ AstraZeneca NSCLC Phase II
cediranib Wilmington, DE (800) 236-9933
reolysin® Oncolytics Biotech NSCLC Phase II
reovirus Calgary, Canada (see also brain, colorectal, head/neck, (403) 670-7377
pancreatic, sarcoma, skin)
retaspimycin Infinity Pharmaceuticals NSCLC Phase II
(IPI-504) Cambridge, MA (see also solid tumors) (617) 453-1000
ridaforolimus Merck NSCLC Phase II
Whitehouse Station, NJ (see also breast, sarcoma) (800) 672-6372
rilotumumab Amgen SCLC Phase II
Thousand Oaks, CA (see also brain, colorectal, prostate, (800) 772-6436
stomach)
salirasib Concordia Pharmaceuticals NSCLC Phase II
Ft. Lauderdale, FL (see also pancreatic)
sapacitabine Cyclacel Pharmaceuticals NSCLC Phase II
Short Hills, NJ (see also leukemia) (973) 847-5955
SNDX-275 Syndax Pharmaceuticals NSCLC Phase I/II
(entinostat) Waltham, MA (see also breast, colorectal, leukemia, (781) 419-1400
lymphoma)
sprycel® Bristol-Myers Squibb NSCLC Phase II
dasatinib Princeton, NJ (see also brain, breast, colorectal, (212) 546-4000
leukemia, lymphoma, multiple
myeloma, prostate, skin)
--------------------------------------------------------------------------------------
mesothelioma Phase I
(212) 546-4000
stimuvax® EMD Serono NSCLC (Fast Track) Phase III
emepepimut-S Rockland, MA (800) 283-8088
(BLP25 liposomal Oncothyreon (425) 450-0370
cancer vaccine) Bellevue, WA
talactoferrin Agennix NSCLC (Fast Track) Phase III
(orphan drug) Houston, TX (see also kidney) (713) 552-1091
tamibarotene CytRx NSCLC Phase II
Los Angeles, CA (see also leukemia) (310) 826-5648
tarceva® Roche NSCLC Phase III
erlotinib Nutley, NJ (see also bladder, brain, breast, (973) 235-5000
OSI Pharmaceuticals colorectal, head/neck, leukemia, (800) 572-1932
Melville, NY liver, other)
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 33
l u n G c a n c e r
product name sponsor indication development status
tavocept™ BioNumerik Pharmaceuticals (see also cancer/chemotherapy) Phase III
dimesna San Antonio, TX (210) 614-1701
telcyta® Telik NSCLC Phase III completed
canfosfimide Palo Alto, CA (see also lymphoma, ovarian) (650) 845-7700
temodar® Merck SCLC Phase II
temozolomide Whitehouse Station, NJ (see also leukemia, skin) (800) 672-6372
topotecan Talon Therapeutics SCLC Phase I
liposomal South San Francisco, CA (see also ovarian) (650) 588-6404
TV-1011/OGX-011 Teva Pharmaceutical NSCLC Phase I/II
(custiren) Tikva, Israel (see also prostate) (425) 686-1500
Oncogenex
Pharmaceuticals
Bothell, WA
veglin VasGene Therapeutics mesothelioma Phase I
(VEGF antisense) Los Angeles, CA (see also kidney, skin) (323) 221-7818
volociximab Biogen Idec NSCLC Phase II
Cambridge, MA (see also ovarian) (617) 679-2000
Facet Biotech (650) 454-1000
Redwood City, CA
XL647 Symphony Evolution NSCLC Phase II
Rockville, MD
evolution.com
Zybrestat™ OXiGENE first-line NSCLC Phase II
fosbretabulin South San Francisco, CA (see also ovarian, other) (650) 635-7000
l y M p H o M a
product name sponsor indication development status
AEG-35156 Aegera Therapeutics B-cell lymphoma Phase I/II
Montreal, Canada (see also leukemia) (514) 288-5532
AEZS-112 AEterna-Zentaris (see also solid tumors) Phase I
Warren, NJ (908) 626-5428
afinitor® Novartis Pharmaceuticals diffuse large B-cell lymphoma Phase III
everolimus East Hanover, NJ (see also breast, kidney, liver, (888) 669-6682
stomach, other)
--------------------------------------------------------------------------------------
mantle-cell lymphoma Phase II
(888) 669-6682
AFM13 Affimed Therapeutics Hodgkin’s lymphoma Phase I
Heidelberg, Germany
afutuzumab Biogen Idec indolent non-Hodgkin’s lymphoma Phase III
(GA101/RG7159) Cambridge, MA (see also leukemia) (617) 679-2000
Roche (973) 235-5000
Nutley, NJ --------------------------------------------------------------------------------------
aggressive non-Hodgkin’s lymphoma Phase II
(617) 679-2000
(973) 235-5000
34 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l y M p H o M a
product name sponsor indication development status
AME133 MENTRIK Biotech non-Hodgkin’s lymphoma Phase II completed
(anti-CD20mAb) Dallas, TX (214) 594-0002
amuvatinib SuperGen (see also solid tumors) Phase I
Dublin, CA (925) 560-0100
anti-CD22 ADC Genentech recurrent non-Hodgkin’s lymphoma Phase I
South San Francisco, CA (see also leukemia) (650) 225-1000
anti-CD22 mAb- Abiogen Pharma B-cell lymphoma Phase I
toxin conjugate Pisa, Italy
University of Texas
Southwestern Medical
Center
Dallas, TX
aplidin® PharmaMar USA (see also multiple myeloma, Phase I
plitidepsin Cambridge, MA solid tumors) (617) 868-3797
AR-12 Arno Therapeutics (see also solid tumors) Phase I
Parsippany, NJ (862) 703-7170
AR-42 Arno Therapeutics (see also leukemia, multiple Phase I/II
Parsippany, NJ myeloma) (862) 703-7170
arzerra® GlaxoSmithKline follicular lymphoma, Phase III
ofatumumab Rsch. Triangle Park, NC diffuse large B-cell lymphoma (888) 825-5249
(see also leukemia)
ASP-3026 Astellas Pharma US late-stage non-Hodgkin’s lymphoma Phase I
Deerfield, IL (800) 477-6472
AT-101 Ascenta Therapeutics non-Hodgkin’s lymphoma Phase II completed
Malvern, PA (see also brain, leukemia, lung, (610) 408-0301
prostate, stomach)
AT-406 Ascenta Therapeutics lymphoma Phase I
Malvern, PA (see also solid tumors) (610) 408-0313
AV-299 AVEO Pharmaceuticals (see also brain, multiple myeloma, Phase I
(ficlatuzumab) Cambridge, MA solid tumors) (617) 299-5000
belinostat Spectrum Pharmaceuticals peripheral T-cell lymphoma Phase II
Irvine, CA (see also lung, other) (949) 788-6700
TopoTarget USA (973) 895-6900
Rockaway, NJ
Bexxar® GlaxoSmithKline mantle-cell lymphoma Phase II
tositumomab Rsch. Triangle Park, NC (888) 825-5249
BI 2536 Boehringer Ingelheim non-Hodgkin’s lymphoma Phase I
Pharmaceuticals (see also lung) (800) 243-0127
Ridgefield, CT
Biovaxid® Biovest follicular lymphoma Phase III
B-cell lymphoma International (Fast Track) (813) 864-2554
vaccine Tampa, FL --------------------------------------------------------------------------------------
mantle-cell lymphoma Phase II
(813) 864-2554
blinatumomab Micromet non-Hodgkin’s lymphoma Phase I
Bethesda, MD (see also leukemia) (240) 752-1420
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 35
l y M p H o M a
product name sponsor indication development status
CAL-101 Calistoga Pharmaceuticals non-Hodgkin’s lymphoma Phase I
Seattle, WA (see also leukemia, (206) 728-4700
multiple myeloma)
cancer vaccine Bayer Innovation follicular lymphoma Phase I
Dusseldorf, Germany (prevention of relapse) (805) 488-2147
Stellar Biotechnologies
Port Hueneme, CA
CC-223 Celgene non-Hodgkin’s lymphoma Phase I/II
Summit, NJ (see also leukemia, solid tumors) (908) 673-9000
cilengitide EMD Serono late-stage lymphoma Phase I completed
Rockland, MA (see also brain, prostate) (800) 283-8088
CST-101 ConKwest (see also leukemia, lung, skin) Phase I
Del Mar, CA (858) 380-1999
CT-011 CureTech diffuse large B-cell lymphoma, Phase II
Yavne, Israel follicular lymphoma
(see also colorectal, leukemia)
dacetuzumab Seattle Genetics non-Hodgkin’s lymphoma Phase I
(anti-CD40) Bothell, WA (see also leukemia, (425) 527-4000
multiple myeloma)
darinaparsin ZIOPHARM Oncology (see also liver, multiple myeloma, Phase II
(ZIO-101) New York, NY solid tumors) (646) 214-0700
DI-Leu16-IL2 Provenance non-Hodgkin’s lymphoma Phase I
(antibody-cytokine Biopharmaceuticals (781) 497-9888
fusion protein) Waltham, MA
dinaciclib Merck mantle-cell lymphoma Phase II
Whitehouse Station, NJ (see also breast, leukemia, lung) (800) 672-6371
dulanermin Amgen non-Hodgkin’s lymphoma Phase I/II
(rhApo2L/TRAIL) Thousand Oaks, CA (see also colorectal) (800) 772-6436
Genentech (650) 225-1000
South San Francisco, CA
enzastaurin Eli Lilly diffuse large B-cell lymphoma Phase III
Indianapolis, IN (800) 545-5979
epratuzumab Immunomedics diffuse large B-cell lymphoma, Phase II
(orphan drug) Morris Plains, NJ follicular lymphoma (973) 605-8200
(see also leukemia)
epratuzumab Y-90 Immunomedics recurrent non-Hodgkin’s lymphoma Phase I/II
Morris Plains, NJ (973) 605-8200
exelbine™ ADVENTRX non-Hodgkin's lymphoma application submitted
vinorelbine Pharmaceuticals (see also breast, lung) (858) 552-0866
emulsion San Diego, CA
EZN-2968 Enzon Pharmaceuticals (see also solid tumors) Phase I
Bridgewater, NJ (908) 541-8600
EZN-3042 Enzon Pharmaceuticals (see also leukemia, solid tumors) Phase I
Bridgewater, NJ (908) 541-8600
fodosine™ BioCryst Pharmaceuticals cutaneous T-cell lymphoma Phase II
forodesine Birmingham, AL (see also leukemia) (205) 444-4600
36 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l y M p H o M a
product name sponsor indication development status
folotyn® Allos Therapeutics B-cell lymphoma Phase II
pralatrexate Westminster, CO (see also bladder, breast, lung) (303) 426-6262
(orphan drug) --------------------------------------------------------------------------------------
Hodgkin’s disease, non-Hodgkin’s Phase I/II
lymphoma (303) 426-6262
--------------------------------------------------------------------------------------
cutaneous T-cell lymphoma Phase I
(303) 426-6262
GDC-0917 Genentech (see also solid tumors) Phase I
(IAP antagonist) South San Francisco, CA (650) 224-1000
GDC-0941 Genentech non-Hodgkin’s lymphoma Phase I
(PI3 kinase inhibitor) South San Francisco, CA (see also breast, lung, solid tumors) (650) 224-1000
GDC-0980 Genentech non-Hodgkin’s lymphoma Phase I
(PI3 kinase/mTOR South San Francisco, CA (see also breast, solid tumors) (650) 224-1000
dual inhibitor)
Genasense® Genta non-Hodgkin’s lymphoma Phase II
oblimersen Berkeley Heights, NJ (see also leukemia, skin) (908) 286-9800
GSK2141795 GlaxoSmithKline (see also solid tumors) Phase I
(AKT protein kinase Rsch. Triangle Park, NC (888) 825-5249
inhibitor)
HGS-1029 Human Genome Sciences (see also solid tumors) Phase I
Rockville, MD (301) 309-8504
INK128 Intellikine Waldenström’s macroglobulinemia Phase I
(TORC1/2 inhibitor) La Jolla, CA (see also multiple myeloma, (858) 768-6500
solid tumors)
inotuzumab UCB aggressive non-Hodgkin’s lymphoma Phase III
ozogamicin Smyrna, GA (770) 970-7500
(CMC-544) Pfizer (860) 732-5156
New York, NY --------------------------------------------------------------------------------------
indolent non-Hodgkin’s lymphoma Phase II
(770) 970-7500
(860) 732-5156
ISF35 Memgen diffuse large-cell lymphoma, Phase II
Dallas, TX follicular lymphoma, (214) 731-3141
small lymphocytic lymphoma
istodax® Celgene peripheral T-cell lymphoma application submitted
romidepsin Summit, NJ (Fast Track) (908) 673-9000
(orphan drug)
LEE011 Novartis Pharmaceuticals (see also solid tumors) Phase I
East Hanover, NJ (888) 669-6682
LG740 Lentigen diffuse large B-cell lymphoma, Phase I
Gaithersburg, MD follicular lymphoma, (301) 527-4200
University of Pennsylvania mantle-cell lymphoma
Philadelphia, PA (see also leukemia)
lucatumumab Novartis Pharmaceuticals Phase I/II
(HCD122) East Hanover, NJ (888) 669-6682
XOMA (510) 204-7200
Berkeley, CA
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 37
l y M p H o M a
product name sponsor indication development status
Mabthera® sc/ Halozyme follicular lymphoma Phase III
rHuPH20/ San Diego, CA (858) 794-8889
rituximab Roche (973) 235-5000
Nutley, NJ
MDX-1203 Bristol-Myers Squibb non-Hodgkin’s lymphoma Phase I
(anti-CD70 ADC) Princeton, NJ (see also kidney) (212) 546-4000
mechlorethamine Yaupon Therapeutics cutaneous T-cell lymphoma Phase III
gel Radnor, PA (Fast Track) (610) 975-9290
(orphan drug)
MGCD-0103 MethylGene diffuse large B-cell lymphoma, Phase II
Montreal, Canada follicular lymphoma (514) 337-3333
(see also leukemia, solid tumors)
milatuzumab Immunomedics non-Hodgkin’s lymphoma Phase I/II
(IMMU-115) Morris Plains, NJ (see also leukemia, multiple (973) 605-8200
myeloma)
mogamulizumab Kyowa Hakko T-cell lymphoma Phase II
Kirin Pharma (609) 919-1100
Princeton, NJ
navitoclax Abbott Laboratories relapsed or refractory lymphoid Phase I/II
(ABT-263/RG7433) Abbott Park, IL malignancies (847) 937-6100
Genentech (see also leukemia, lung) (650) 225-1000
South San Francisco, CA
NPI-0052 Nereus Pharmaceuticals (see also multiple myeloma, Phase I
(marizomib) San Diego, CA solid tumors) (858) 587-4090
obatoclax Gemin X Biotechnologies follicular lymphoma Phase II
Montreal, Canada (see also leukemia, lung, (514) 281-8989
multiple myeloma)
--------------------------------------------------------------------------------------
mantle-cell lymphoma Phase I/II
(514) 281-8989
ON-01910 Onconova Therapeutics (see also leukemia, ovarian, Phase II
Princeton, NJ solid tumors) (609) 844-7735
ON-013105 Onconova Therapeutics (see also leukemia) Phase I
Princeton, NJ (609) 844-7735
OSI-027 OSI Pharmaceuticals (see also kidney) Phase I
Melville, NY (800) 572-1932
P276 Piramal Life Sciences mantle-cell lymphoma Phase II
Mumbai, India
panobinostat Novartis Pharmaceuticals Hodgkin’s lymphoma application submitted
(LBH589) East Hanover, NJ (see also multiple myeloma, (888) 669-6682
other)
PCI-24781 Pharmacyclics (see also sarcoma) Phase II
(HDAC inhibitor) Sunnyvale, CA (408) 774-0330
PCI-32765 Pharmacyclics mantle-cell lymphoma Phase II
(BTK inhibitor) Sunnyvale, CA (see also leukemia) (408) 774-0330
38 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
l y M p H o M a
product name sponsor indication development status
PD-0332991 Pfizer mantle-cell lymphoma Phase I
New York, NY (see also brain, breast, multiple (860) 732-5156
myeloma, sarcoma)
perifosine AEterna Zentaris recurrent lymphoma, Waldenström’s Phase II
(KRX-0401) Montreal, Canada macroglobulinemia (212) 531-5965
Keryx Biopharmaceuticals (see also brain, colorectal, kidney,
New York, NY leukemia, multiple myeloma, ovarian,
sarcoma, stomach)
pixuvri™ Cell Therapeutics non-Hodgkin’s lymphoma application submitted
pixantrone Seattle, WA (Fast Track) (800) 215-2355
(see also breast)
--------------------------------------------------------------------------------------
diffuse large B-cell lymphoma Phase II
(800) 215-2355
PLX3397 Plexxikon recurrent or refractory Phase II
Berkeley, CA Hodgkin’s disease (510) 647-4000
(see also solid tumors)
PX-478 Oncothyreon (see also solid tumors) Phase I completed
Seattle, WA (206) 801-2100
rituxan® Biogen Idec non-Hodgkin’s lymphoma Phase III
rituxumab Cambridge, MA (subcutaneous) (617) 679-2000
Roche (973) 235-5000
Nutley, NJ --------------------------------------------------------------------------------------
non-Hodgkin’s lymphoma Phase III
(fast fusion) (617) 679-2000
(973) 235-5000
SAR3419 sanofi-aventis non-Hodgkin’s lymphoma Phase I
Bridgewater, NJ (800) 633-1610
SB1518 S*Bio late-stage lymphoma Phase II
Redwood City, CA (see also leukemia) (650) 730-2860
SCH-900776 Merck (see also leukemia) Phase I
Whitehouse Station, NJ (800) 672-6372
SGN-35 Millennium Pharmaceuticals Hodgkin’s disease (combination application submitted
(brentuximab Cambridge, MA therapy), recurrent non-Hodgkin’s (800) 390-5663
vedotin) Seattle Genetics lymphoma (425) 527-4000
(orphan drug) Bothell, WA --------------------------------------------------------------------------------------
non-Hodgkin’s lymphoma Phase II
(monotherapy) (800) 390-5663
(Fast Track) (425) 527-4000
SGN-75 Seattle Genetics non-Hodgkin’s lymphoma Phase I
Bothell, WA (see also kidney) (425) 527-4000
SNDX-275 Syndax Pharmaceuticals Hodgkin’s disease Phase II
(entinostat) Waltham, MA (see also breast, colorectal, (781) 419-1400
leukemia, lung)
sprycel® Bristol-Myers Squibb non-Hodgkin’s lymphoma Phase I/II
dasatinib Princeton, NJ (see also brain, breast, colorectal, (212) 546-4000
leukemia, lung, multiple myeloma,
prostate, skin)
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 39
l y M p H o M a
product name sponsor indication development status
stem cell therapy Benitec AIDS-related lymphoma Phase I
Melbourne, Australia
City of Hope
Medical Center
Duarte, CA
telcyta® Telik diffuse large B-cell lymphoma, Phase II
canfosfamide Palo Alto, CA mantle-cell lymphoma (650) 845-7700
non-Hodgkin’s lymphoma
(see also lung, ovarian)
thiarabine Access Pharmaceuticals (see also leukemia) Phase I/II
Dallas, TX (214) 905-5100
tigatuzumab Daiichi Sankyo (see also colorectal, liver, ovarian, Phase I completed
Parsippany, NJ pancreatic) (973) 359-2600
TKM-PLK1 Tekmira Pharmaceuticals (see also solid tumors) Phase I
Vancouver, Canada (604) 419-3200
treanda® Cephalon first-line non-Hodgkin’s lymphoma Phase III
bendamustine Frazer, PA (610) 344-0200
--------------------------------------------------------------------------------------
mantle-cell lymphoma Phase II
(610) 344-0200
TRU-016 Emergent Biosolutions recurrent non-Hodgkin’s lymphoma Phase I
(anti-CD37) Rockville, MD (see also leukemia) (301) 795-1800
UNBS-5162 Drais Pharmaceuticals (see also solid tumors) Phase I
Bridgewater, NJ (908) 895-1200
velcade® Millennium Pharmaceuticals relapsed or refractory follicular Phase III
bortezomib Cambridge, MA lymphoma, first-line mantle-cell (800) 390-5663
lymphoma
(see also multiple myeloma)
--------------------------------------------------------------------------------------
diffuse large B-cell lymphoma Phase II
(800) 390-5663
veltuzumab Immunomedics non-Hodgkin’s lymphoma Phase I/II
(IMMU-106) Morris Plains, NJ (see also leukemia) (973) 605-8200
vinorelbine Talon Therapeutics non-Hodgkin’s lymphoma Phase I
liposomal South San Francisco, CA (see also solid tumors) (650) 588-6404
XmAb 2513 Xencor Hodgkin’s disease, Phase I
Monrovia, CA T-cell lymphoma (626) 305-5900
YM-155 Astellas Pharma US non-Hodgkin’s lymphoma Phase II
Deerfield, IL (see also breast) (800) 727-7003
zanolimumab TenX Biopharma cutaneous T-cell lymphoma Phase III
Philadelphia, PA (Fast Track) (215) 774-1176
--------------------------------------------------------------------------------------
peripheral T-cell lymphoma Phase II completed
(215) 774-1176
40 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
M u l t i p l e M y e l o M a
product name sponsor indication development status
ACE-041 Acceleron Pharma (see also solid tumors) Phase I
Cambridge, MA (617) 649-9200
actimid™ Celgene recurrent multiple myeloma Phase II
pomalidomide Summit, NJ (908) 673-9000
ALXN-6000 Alexion Pharmaceuticals (see also leukemia) Phase I/II
(samalizumab) Cheshire, CT (203) 272-2596
anti-FGFR3 mAb Genentech refractory, metastatic Phase I
(RG7444) South San Francisco, CA multiple myeloma (650) 224-1000
aplidin® PharmaMar USA (see also lymphoma, solid tumors) Phase III
plitidepsin Cambridge, MA (617) 868-3797
(orphan drug)
AR-42 Arno Therapeutics (see also leukemia, lymphoma) Phase I/II
Parsippany, NJ (862) 703-7170
ARRY-520 Array BioPharma (see also leukemia, solid tumors) Phase II
Boulder, CO (303) 381-6600
AT7519 Astex Therapeutics (see also solid tumors) Phase I/II
Cambridge, United Kingdom
com
ATN-224 Tactic Pharma (see also prostate, skin) Phase I/II
Evanston, IL (847) 733-0940
AUY922 Novartis Pharmaceuticals (see also breast, colorectal, Phase I/II
East Hanover, NJ lung, stomach) (888) 669-6682
AV-299 AVEO Pharmaceuticals (see also brain, lymphoma, Phase I
(ficlatuzumab) Cambridge, MA solid tumors) (617) 299-5000
BHQ880 Novartis Pharmaceuticals (see also solid tumors) Phase II
East Hanover, NJ (888) 669-6682
BI-505 BioInvent International late-stage multiple myeloma Phase I
Lund, Sweden
BIW-8962 BioWa Phase I/II
Princeton, NJ (609) 580-7500
BT-062 Biotest Phase I/II
(orphan drug) Dreieich, Germany
CAL-101 Calistoga Pharmaceuticals (see also leukemia, lymphoma) Phase I
Seattle, WA (206) 728-4700
carfilzomib Onyx Pharmaceuticals (Fast Track) application submitted
(orphan drug) Emeryville, CA (see also solid tumors) (510) 597-6500
CB3304 Cougar Biotechnology Phase I/II
Los Angeles, CA (310) 943-8040
CC-223 Celgene (see also lymphoma, solid tumors) Phase I/II
Summit, NJ (908) 673-9000
CEP-18770 Cephalon Phase II
(proteasome Frazer, PA (610) 344-0200
inhibitor)
CNTO 328 Centocor Ortho Biotech (see also prostate, other) Phase II
(siltuximab) Horsham, PA (800) 457-6399
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 41
M u l t i p l e M y e l o M a
product name sponsor indication development status
CX-4945 Cylene Pharmaceuticals (see also solid tumors, other) Phase I
San Diego, CA (858) 875-5100
dacetuzumab Seattle Genetics (see also leukemia, lymphoma) Phase I
(anti-CD40) Bothell, WA (425) 527-4000
(orphan drug)
darinaparsin Ziopharm Oncology (see also liver, lymphoma, Phase II completed
(ZIO-101) New York, NY solid tumors) (646) 214-0700
elotuzumab Bristol-Myers Squibb Phase I/II
(BMS-901608) Princeton, NJ (212) 546-4000
Facet Biotech (650) 454-1000
Redwood City, CA
ENMD-2076 EntreMed relapsed or refractory multiple Phase I
Rockville, MD myeloma (240) 864-2600
(see also ovarian, other)
GRN-163L Geron (see also breast, leukemia, lung) Phase II
(imetelstat) Menlo Park, CA (650) 473-7700
GvaX® Multiple BioSante Pharmaceuticals (see also breast, colorectal, Phase II
Myeloma Lincolnshire, IL leukemia, pancreatic) (847) 478-0500
IMGN-901 ImmunoGen (see also lung) Phase I
Cambridge, MA (617) 995-2500
INK128 Intellikine (see also lymphoma, solid tumors) Phase I
(TORC1/2 inhibitor) La Jolla, CA (858) 768-6500
IPH-2101 Innate Pharma Phase II
Marseille, France
KW-2478 Kyowa Hakko Kirin Pharma Phase I/II
Princeton, NJ (609) 919-1100
LY2127399 Applied Molecular Evolution Phase I
(BAFF antibody) San Diego, CA (800) 545-5979
Eli Lilly
Indianapolis, IN
mapatumumab Human Genome Sciences (see also liver, lung) Phase II
Rockville, MD (301) 309-8504
melphalan CyDex Pharmaceuticals Phase II
intravenous Lenexa, KS (888) 436-6910
(orphan drug)
milatuzumab Immunomedics (see also leukemia, lymphoma) Phase I/II
(IMMU-115) Morris Plains, NJ (973) 605-8200
(orphan drug)
NPI-0052 Nereus Pharmaceuticals (see also lymphoma, solid tumors) Phase I
(marizomib) San Diego, CA (858) 587-4090
obatoclax Gemin X Biotechnologies (see also leukemia, lung, lymphoma) Phase I
Montreal, Canada (514) 281-8989
panobinostat Novartis Pharmaceuticals (see also lymphoma, other) Phase III
(LBH589) East Hanover, NJ (888) 669-6682
PD-0332991 Pfizer (see also brain, breast, lymphoma, Phase I/II
New York, NY sarcoma) (860) 732-5156
42 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
M u l t i p l e M y e l o M a
product name sponsor indication development status
perifosine AEterna Zentaris recurrent multiple myeloma Phase III
(KRX-0401) Montreal, Canada (Fast Track) (212) 531-5965
(orphan drug) Keryx Biopharmaceuticals (see also brain, colorectal, kidney,
New York, NY leukemia, lymphoma, ovarian,
sarcoma, stomach)
Quadramet® EUSA Pharma (see also prostate, sarcoma, Phase I/II completed
samarium sm-153 Langhorne, PA other) (800) 833-3533
lexidronam
injection
SF1126 Semafore Pharmaceuticals (see also multiple myeloma, Phase I
Indianapolis, IN solid tumors) (317) 876-3075
sprycel® Bristol-Myers Squibb (see also brain, breast, colorectal, Phase I
dasatinib Princeton, NJ leukemia, lung, lymphoma, (212) 546-4000
prostate, skin)
treanda® Cephalon (see also lymphoma) Phase II
bendamustine Frazer, PA (610) 344-0200
trisenox® Cephalon combination therapy Phase II
arsenic trioxide Frazer, PA (see also brain, leukemia) (610) 344-0200
VEL-0230 Velcura Therapeutics Phase I completed
Ann Arbor, MI (734) 973-1000
velcade® Millennium Pharmaceuticals (see also lymphoma) Phase III
bortezomib Cambridge, MA (800) 390-5663
(subcutaneous)
Zolinza® Merck (see also breast, other) Phase III
vorinostat Whitehouse Station, NJ (800) 672-6372
(orphan drug)
o v a r i a n c a n c e r
product name sponsor indication development status
A° 6 Angstrom Pharmaceuticals (see also other) Phase II
Solana Beach, CA (858) 314-2356
abagovomab Menarini Phase II/III
(anti-idiotype Florence, Italy
ovarian cancer
vaccine)
(orphan drug)
abraxane® Celgene (see also bladder, lung, pancreatic, Phase II
albumin-bound Summit, NJ skin) (908) 673-9000
paclitaxel
ABT-888 Abbott Laboratories (see also brain, breast, Phase II
(veliparib) Abbott Park, IL colorectal, prostate, skin, other) (847) 937-6100
AE-37 Antigen Express (see also breast) Phase I
Worcester, MA (508) 852-8783
AMG 386 Amgen (see also breast, colorectal, kidney, Phase III
Thousand Oaks, CA liver, stomach, other) (800) 772-6436
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 43
o v a r i a n c a n c e r
product name sponsor indication development status
avastin® Genentech first-line metastatic ovarian cancer, Phase III
bevacizumab South San Francisco, CA recurrent platinum-sensitive ovarian (650) 225-1000
cancer
(see also brain, breast, colorectal,
lung, other)
BC-819 BioCancell Therapeutics (see also bladder, pancreatic) Phase I/II
Jerusalem, Israel
catumaxomab Fresenius Biotech (see also other) Phase II
North America
Waltham, MA
cvax™ Prima BioMed Phase II
MUC-2 Armadale, Australia
cancer vaccine biomed.com.au
dcvax®-l Northwest Biotherapeutics (see also other) Phase I/II
ovarian cancer Bothell, WA (425) 608-3000
vaccine
DPX-0907 Immunovaccine (see also breast, prostate) Phase I
Halifax, Canada (902) 492-1819
EC-145 Endocyte (see also lung, other) Phase II
West Lafayette, IN (765) 463-7175
EGEN 001 EGEN recurrent ovarian cancer Phase II
(orphan drug) Huntsville, AL (see also other) (256) 512-0077
--------------------------------------------------------------------------------------
refractory metastatic ovarian cancer Phase I
(256) 512-0077
ENMD-2076 EntreMed platinum-resistant ovarian cancer Phase II
Rockville, MD (see also multiple myeloma, other) (240) 864-2600
farletuzumab Eisai (see also lung) Phase III
(MORAb-003) Woodcliff Lake, NJ (888) 422-4743
iboctadekin GlaxoSmithKline Phase I
Rsch. Triangle Park, NC (888) 825-5249
IMT-1012 Immunotope (see also breast) Phase I
(immunotherapeutic Doylestown, PA (215) 253-4180
vaccine)
iniparib BiPar Sciences (see also breast, lung) Phase II
(BSI-201) South San Francisco, CA (800) 633-1810
sanofi-aventis
Bridgewater, NJ
Karenitecin® BioNumerik advanced epithelial ovarian cancer Phase III
cositecan Pharmaceuticals (210) 614-1701
San Antonio, TX
KHK-2866 Kyowa Hakko Kirin Pharma (see also solid tumors) Phase I
Princeton, NJ (609) 919-1100
lenvatinib Eisai (see also brain, kidney, liver, Phase I/II
(E7080) Woodcliff Lake, NJ skin, other) (888) 422-4743
44 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
o v a r i a n c a n c e r
product name sponsor indication development status
nexavar® Bayer HealthCare (see also breast, colorectal, kidney, Phase II
sorafenib Pharmaceuticals liver, lung, other) (888) 842-2837
Wayne, NJ (510) 597-6500
Onyx Pharmaceuticals
Emeryville, CA
NKTR-102 Nektar Therapeutics metastatic ovarian cancer Phase II
San Francisco, CA (see also breast, colorectal) (415) 482-5300
NOV-002 Novelos Therapeutics (see also breast) Phase II completed
Newton, MA (617) 244-1616
OGX-427 Oncogenex (see also bladder, breast, lung, Phase I
Pharmaceuticals prostate) (425) 686-1500
Bothell, WA
olaparib AstraZeneca serous ovarian cancer Phase II
Wilmington, DE (800) 236-9933
ON-01910 Onconova Therapeutics (see also leukemia, lymphoma, Phase II
Princeton, NJ solid tumors) (609) 844-7735
opaxio™ Cell Therapeutics (see also lung, other) Phase III
paclitaxel Seattle, WA (800) 215-2355
poliglumex Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
oregovomab Quest Pharmatech Phase I/II
Edmonton, Canada (780) 448-1400
OSI-906 OSI Pharmaceuticals (see also lung, other) Phase II
(linsitinib) Melville, NY (631) 962-2000
ovax® AVAX Technologies Phase I/II
ovarian cancer Philadelphia, PA (215) 241-9760
vaccine
(orphan drug)
perifosine AEterna Zentaris (see also brain, colorectal, kidney, Phase I
(KRX-0401) Montreal, Canada leukemia, lymphoma, multiple (212) 531-5965
Keryx Biopharmaceuticals myeloma, sarcoma, stomach)
New York, NY
PF-01367338 Pfizer (see also breast, skin) Phase II
New York, NY (860) 732-5156
phenoxodiol Marshall Edwards late-stage ovarian cancer Phase III
San Diego, CA (Fast Track) (858) 792-6300
(see also prostate, other)
picoplatin Poniard Pharmaceuticals (see also colorectal, lung, prostate) Phase II
intravenous San Francisco, CA (650) 583-3774
Quinamed® ChemGenex (see also breast, prostate) Phase II
amonafide Pharmaceuticals (650) 474-9800
Menlo Park, CA
sagopilone Bayer HealthCare (see also brain, breast, prostate) Phase II
Pharmaceuticals (888) 842-2937
Wayne, NJ
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 45
o v a r i a n c a n c e r
product name sponsor indication development status
SAR256212 Merrimack Pharmaceuticals (see also breast, solid tumors) Phase I
(MM-121) Cambridge, MA (617) 441-1000
sanofi-aventis (800) 633-1810
Bridgewater, NJ
SG2000 Spirogen Phase II
London, United Kingdom
squalamine OHR Pharmaceuticals resistant ovarian cancer Phase II
New York, NY (212) 682-8452
telcyta® Telik (see also lung, lymphoma) Phase III completed
canfosfimide Palo Alto, CA (650) 845-7700
tigatuzumab Daiichi Sankyo (see also colorectal, liver, lymphoma, Phase II
Parsippany, NJ pancreatic) (973) 359-2600
topotecan Talon Therapeutics (see also lung) Phase I
liposomal South San Francisco, CA (650) 588-6404
trabectedin Johnson & Johnson (see also breast, prostate, sarcoma) application submitted
(orphan drug) Pharmaceutical Research (800) 817-5286
& Development
Raritan, NJ
volociximab Biogen Idec (see also lung) Phase II
Cambridge, MA (617) 679-2000
Facet Biotech (650) 454-1000
Redwood City, CA
vosaroxin Sunesis Pharmaceuticals platinum-resistant ovarian cancer Phase II
(SNS-595) South San Francisco, CA (see also leukemia) (650) 266-3500
votrient® GlaxoSmithKline (see also breast, kidney, sarcoma) Phase III
pazopanib Rsch. Triangle Park, NC (888) 825-5249
Zybrestat™ OXiGENE (see also lung, other) Phase II
fosbretabulin South San Francisco, CA (650) 635-7000
(orphan drug)
p a n c r e a t i c c a n c e r
product name sponsor indication development status
abraxane® Celgene (see also bladder, lung, Phase III
albumin-bound Summit, NJ ovarian, skin) (908) 673-9000
paclitaxel
(orphan drug)
AGS-1C4D4 Agensys Phase II
Santa Monica, CA (310) 820-8029
Astellas Pharma US (800) 477-6472
Deerfield, IL
AMG 479 Amgen (see also breast, colorectal, lung, Phase III
(ganitumab) Thousand Oaks, CA sarcoma, other) (800) 772-6436
anti-MUC1 mAb Quest PharmaTech Phase I/II
Edmonton, Canada (780) 448-1400
46 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
p a n c r e a t i c c a n c e r
product name sponsor indication development status
apricoxib Tragara Pharmaceuticals (see also lung) Phase II
San Diego, CA (858) 350-6900
ARC-100 Archer Biosciences (see also brain, prostate, skin) Phase II
New York, NY (646) 747-9090
ARQ-197 ArQule (see also colorectal, kidney, liver, Phase I
Woburn, MA lung, sarcoma, solid tumors, other) (781) 994-0300
Daiichi Sankyo (973) 944-2600
Parsippany, NJ
ASG-5ME Agensys metastatic pancreatic cancer Phase I
Santa Monica, CA (see also prostate) (301) 820-8029
Astellas Pharma US (800) 477-6472
Deerfield, IL
bavituximab Peregrine Pharmaceuticals (see also breast, liver) Phase II
Tustin, CA (714) 508-6000
BC-819 BioCancell Therapeutics inoperable/unresectable Phase I/II
Jerusalem, Israel pancreatic cancer
(see also bladder, ovarian)
CO-101/CP-4126 Clovis Oncology Phase II
(orphan drug) Boulder, CO (303) 625-5000
conatumumab Amgen (see also colorectal, lung, sarcoma) Phase I/II
Thousand Oaks, CA (800) 772-6436
CPI-613 Cornerstone (see also other) Phase I/II
(orphan drug) Pharmaceuticals (609) 409-7050
Cranbury, NJ
dalotuzumab Merck (see also breast, colorectal, Phase I/II
Whitehouse Station, NJ lung, other) (888) 669-6682
encapsulated cell Rogosin Institute refactory metastatic pancreatic Phase II
therapy New York, NY cancer (212) 746-1225
(macrobeads) (see also colorectal, prostate)
ensituximab Neogenix Oncology inoperable/unresectable, late-stage, Phase I
Great Neck, NY metastatic pancreatic cancer (516) 482-1200
(see also colorectal)
FG-3019 Fibrogen Phase II
San Francisco, CA (415) 978-1200
GI-4000 GlobeImmune (see also colorectal, lung) Phase II
Louisville, CO (303) 625-2700
glufosfamide Eleison Pharmaceuticals (Fast Track) Phase III completed
(orphan drug) Princeton, NJ (215) 416-7620
GSK1120212 GlaxoSmithKline (see also skin, solid tumors) Phase II
(MEK inhibitor) Rsch. Triangle Park, NC (888) 825-5249
GvaX® pancreatic BioSante Pharmaceuticals (see also breast, colorectal, Phase II
(orphan drug) Lincolnshire, IL leukemia, multiple myeloma) (847) 478-0500
Hyperacute® NewLink Genetics (Fast Track) Phase III
pancreas Ames, IA (515) 296-5555
algenpantucel-L
(orphan drug)
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 47
p a n c r e a t i c c a n c e r
product name sponsor indication development status
IPI-926 Infinity Pharmaceuticals (see also sarcoma, solid tumors) Phase I/II
Cambridge, MA (617) 453-1000
JX-929 Jenerex Biotherapeutics Phase I
San Francisco, CA (415) 281-8886
LE-DT NeoPharm late-stage, metastatic pancreatic Phase II
Lake Bluff, IL cancer (847) 887-0800
(see also prostate)
masitinib AB Science USA (see also leukemia, stomach) Phase III
Short Hills, NJ (973) 218-2437
MM-398 Merrimack Pharmaceuticals metastatic pancreatic cancer Phase II
Cambridge, MA (617) 441-1000
naptumomab Active Biotech (see also kidney, lung) Phase I completed
estafenatox Lund, Sweden
pancatak™ Advantagene Phase I
gene therapy Auburndale, MA (617) 916-5445
PCI-27483 Pharmacyclics Phase II
(factor VIIa Sunnyvale, CA (408) 774-0330
inhibitor)
polyclonal antibody Cancer Advances (see also colorectal, stomach) Phase III
stimulator Durham, NC (919) 361-2162
(orphan drug)
reolysin® Oncolytics Biotech (see also brain, colorectal, head/neck, Phase II
reovirus Calgary, Canada lung, sarcoma, skin) (403) 670-7377
rexin-G™ Epeius Biotechnologies recurrent, refractory metastatic Phase I/II
tumor-targeted San Marino, CA pancreatic cancer (Fast Track) (626) 441-6695
gene therapy (see also breast, sarcoma)
(orphan drug)
RX-0201 Rexahn Pharmaceuticals Phase II
(orphan drug) Rockville, MD (240) 268-5300
salirasib Concordia Pharmaceuticals (see also lung) Phase I/II
(orphan drug) Ft. Lauderdale, FL
sutent® Pfizer pancreatic islet cell tumors application submitted
sunitinib New York, NY (see also kidney) (860) 732-5156
TH-302 Threshold Pharmaceuticals (see also leukemia, sarcoma, Phase II
Redwood City, CA solid tumors) (650) 474-8200
tigatuzumab Daiichi Sankyo (see also colorectal, liver, Phase II completed
Parsippany, NJ lymphoma, ovarian) (973) 359-2600
tremelimumab Pfizer (see also kidney, skin, stomach, other) Phase II
(CP-675206) New York, NY (860) 732-5156
virulizin Zor Pharmaceuticals Phase III
Wilmington, NC (919) 946-4457
Y-90 hPAM4 Immunomedics Phase I/II
(IMMU-107) Morris Plains, NJ (973) 605-8200
(orphan drug)
48 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
p r o s t a t e c a n c e r
product name sponsor indication development status
ABI-008 Celgene hormone-refractory prostate cancer Phase II
(nab®-docetaxel) Summit, NJ (908) 673-9000
abiraterone acetate Cougar Biotechnology metastatic advanced prostate cancer application submitted
(CB7630) Raritan, NJ (see also breast) (800) 817-5286
ABR-215050 Active Biotech Phase III
(tasquinimod) Lund, Sweden
ABT-888 Abbott Laboratories (see also brain, breast, Phase I
(veliparib) Abbott Park, IL colorectal ovarian, skin, other) (847) 937-6100
acapodene® GTx prostatic intraepithelial neoplasia Phase III
toremifene Memphis, TN (prevention) (901) 523-9700
(see also cancer/chemotherapy)
AEZS-108 AEterna-Zentaris (see also bladder) Phase I/II
Warren, NJ (908) 626-5428
aflibercept sanofi-aventis first-line metastatic prostate Phase III
(VEGF-trap) Bridgewater, NJ cancer (800) 633-1610
Regeneron Pharmaceuticals (see also colorectal, lung) (714) 345-7400
Tarrytown, NY
androgen receptor Endo Pharmaceuticals Phase I
antagonist Chadds Ford, PA (800) 462-3636
Orion
Espoo, Finland
ARC-100 Archer Biosciences (see also brain, pancreatic, skin) Phase II
New York, NY (646) 747-9090
ARN-509 Aragon Pharmaceuticals Phase I/II
San Diego, CA (858) 369-7600
ASG-5ME Agensys castration-resistant prostate cancer Phase I
Santa Monica, CA (see also pancreatic) (301) 820-8029
Astellas Pharma US (800) 477-6472
Deerfield, IL
AT-101 Ascenta Therapeutics (see also brain, leukemia, lung, Phase II
Malvern, PA lymphoma, stomach) (618) 408-0301
ATN-224 Tactic Pharma (see also multiple myeloma, skin) Phase II
Evanston, IL (847) 733-0940
avodart® GlaxoSmithKline prostate cancer prevention, application submitted
dutasteride Rsch. Triangle Park, NC prostatic intraepithelial neoplasia (888) 825-5249
AZD3514 AstraZeneca Phase I
(androgen receptor Wilmington, DE (800) 236-9933
down regulator)
bafetinib CytRx hormone-refractory prostate cancer Phase II
Los Angeles, CA (see also leukemia) (310) 826-5648
BPX-101 Bellicum Pharmaceuticals Phase I/II
(BP-GMAX-CD1) Houston, TX (713) 341-6472
carlumab Centocor Ortho Biotech metastatic prostate cancer Phase II
Horsham, PA (see also solid tumors) (800) 457-6399
cilengitide EMD Serono (see also brain, lymphoma) Phase II
Rockland, MA (800) 283-8088
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 49
p r o s t a t e c a n c e r
product name sponsor indication development status
CNTO 95 Centocor Ortho Biotech (see also skin, solid tumors) Phase II completed
Horsham, PA (800) 457-6399
CNTO 328 Centocor Ortho Biotech hormone-refractory prostate cancer Phase I
(siltuximab) Horsham, PA (see also multiple myeloma, other) (800) 457-6399
CV9103 Curevac Phase I/II
Tübingen, Germany
dcvax®-prostate Northwest Biotherapeutics Phase III
prostate cancer Bothell, WA (425) 608-3000
vaccine
DPX-0907 Immunovaccine (see also breast, ovarian) Phase I
Halifax, Canada (902) 492-1819
encapsulated cell Rogosin Institute refractory metastatic pancreatic Phase II
therapy New York, NY cancer (212) 746-1225
(macrobeads) (see also colorectal, pancreatic)
eribulin Eisai (see also bladder, lung, sarcoma) Phase II
(E7389) Woodcliff Lake, NJ (888) 422-4743
Gleevec® Novartis Pharmaceuticals Phase II/III
imatinib East Hanover, NJ (888) 669-6682
GRNVAC1 Geron (see also leukemia) Phase I/II
Menlo Park, CA (650) 473-7700
GTx-758 GTx Phase II completed
Memphis, TN (901) 523-9700
HE-3235 Harbor Biosciences hormone-resistant prostate cancer Phase II completed
San Diego, CA (858) 587-9333
Hyperacute® NewLink Genetics hormone-refractory prostate cancer Phase I/II completed
prostate Ames, IA (515) 296-5555
prostate cancer
vaccine
INSM-18 Triact Therapeutics Phase I/II
Palo Alto, CA
ipilimumab Bristol-Myers Squibb (see also lung, skin) Phase III
Princeton, NJ (212) 546-4000
irofulven Eisai Phase II
(E7850) Woodcliff Lake, NJ (888) 422-4743
irosustat Ipsen Phase I
Paris, France
JNJ-26854165 Johnson & Johnson (see also lung, solid tumors) Phase I
Pharmaceutical Research (800) 817-5286
& Development
Raritan, NJ
KX2-391 Kinex Pharmaceuticals Phase II
Buffalo, NY (716) 881-8984
LE-DT NeoPharm castration-resistant metastatic Phase II
Lake Bluff, IL prostate cancer (847) 887-0800
(see also pancreatic)
50 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
p r o s t a t e c a n c e r
product name sponsor indication development status
leupron depot® Abbott Pharmaceuticals application submitted
leuprorelin depot Abbott Park, IL (847) 937-6100
(6-month
formulation)
MDV-3100 Astellas Pharma US hormone-refractory prostate Phase III
Deerfield, IL cancer (800) 727-7003
Medivation (415) 543-3470
San Francisco, CA
mepacrine Incuron hormone-refractory prostate Phase II completed
(CBLC102) Buffalo, NY cancer (716) 849-6810
MER-104 Merrion Pharmaceuticals Phase I
Wilmington, NC (910) 799-1847
MIP1095 Molecular Insight diagnosis of prostate cancer Phase I
Pharmaceuticals (617) 492-5554
Cambridge, MA
MVA-5T4 Oxford BioMedica Phase II
Oxford, United Kingdom
co.uk
Mva-Bn®-pro BN ImmunoTherapeutics Phase I/II
Mountain View, CA (650) 681-4660
neuvax™ Apthera (see also breast) Phase I/II
E75 cancer Scottsdale, AZ
vaccine
nimotuzumab YM Biosciences USA (see also brain, breast) Phase II
Lehigh Valley, PA (610) 560-0600
OGX-427 Oncogenex hormone-refractory prostate cancer Phase II
Pharmaceuticals (see also bladder, breast, lung, (425) 686-1500
Bothell, WA ovarian)
onyvax-p VaxOnco Phase II
anti-idiotype Seoul, South Korea
cancer vaccine
105AD7
ozarelix Spectrum Pharmaceuticals Phase II
Irvine, CA (949) 788-6700
phenoxodiol Marshall Edwards (Fast Track) Phase II completed
San Diego, CA (see also ovarian, other) (858) 792-6300
picoplatin Poniard Pharmaceuticals (see also colorectal, lung, ovarian) Phase II
intravenous San Francisco, CA (650) 583-3774
polyphenon E Polyphenon Pharma prostatic intraepithelial neoplasia Phase II
New York, NY (see also leukemia) (212) 661-0578
proscar® Merck prevention of prostate cancer Phase III completed
finasteride Whitehouse Station, NJ (800) 673-6372
prostatak™ Advantagene Phase II completed
gene therapy Auburndale, MA (617) 916-5445
prostvac®-vf BN ImmunoTherapeutics metastatic prostate cancer Phase II
prostate Mountain View, CA (Fast Track) (650) 681-4660
cancer vaccine
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 51
p r o s t a t e c a n c e r
product name sponsor indication development status
provenge® Dendreon androgen-dependent recurrent Phase III
sipuleucel-T Seattle, WA prostate cancer (877) 256-4545
--------------------------------------------------------------------------------------
early-stage prostate cancer Phase II
(neoadjuvant therapy) (877) 256-4545
PRX302 Protox Therapeutics Phase II
Vancouver, Canada (604) 688-0199
PSMA ADC Progenics Pharmaceuticals Phase I
Tarrytown, NY (914) 789-2800
PSMA subunit Progenics Phase I
vaccine Tarrytown, NY (914) 789-2800
PSMA VRP Progenics Pharmaceuticals Phase I
Tarrytown, NY (914) 789-2800
Quadramet® EUSA Pharma (see also multiple myeloma, Phase II
samarium SM-153 Langhorne, PA sarcoma, other) (800) 833-3533
lexidronam
injection
Quinamed® ChemGenex (see also breast, ovarian) Phase II
amonafide Pharmaceuticals (650) 474-9800
Menlo Park, CA
REIC gene therapy Momotaro-Gene Phase I
Okayama, Japan
revlimid® Celgene Phase III
lenalidomide Summit, NJ (908) 673-9000
rilotumumab Amgen (see also brain, colorectal, lung, Phase II
Thousand Oaks, CA stomach) (800) 772-6436
sagopilone Bayer HealthCare (see also brain, breast, ovarian) Phase II
Pharmaceuticals (888) 842-2937
Wayne, NJ
seocalcitol Cougar Biotechnology Phase I
(CB1089) Los Angeles, CA (310) 943-8040
SL052 Quest PharmaTech Phase I/II
Edmonton, Canada (780) 448-1400
sprycel® Bristol-Myers Squibb (see also brain, breast, colorectal, Phase II/III
dasatinib Princeton, NJ leukemia, lung, lymphoma, (212) 546-4000
multiple myeloma, skin)
TAK-448 Millennium Pharmaceuticals Phase I/II
Cambridge, MA (800) 390-5663
TAK-700 Millennium Pharmaceuticals metastatic hormone-refractory Phase III
(orteronel) Cambridge, MA prostate cancer (800) 390-5663
tesetaxel Genta advanced prostate cancer Phase II
Berkeley Heights, NJ (see also bladder, breast, skin, (908) 286-9800
stomach)
tigapotide Kotinos Pharmaceuticals Phase II
New York, NY
52 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
p r o s t a t e c a n c e r
product name sponsor indication development status
TOK-01 Tokai Pharmaceuticals Phase I/II
Cambridge, MA (617) 225-4305
trabectedin Johnson & Johnson (see also breast, ovarian, Phase II
Pharmaceutical Research sarcoma) (800) 817-5286
& Development
Raritan, NJ
TRC105 TRACON Pharmaceuticals metastatic prostate cancer Phase I/II
San Diego, CA (see also solid tumors) (858) 550-0780
trofex™ Molecular Insight diagnosis of prostate cancer Phase I
radiolabelled Pharmaceuticals (617) 492-5554
diagnostic Cambridge, MA
TV-1001/OCX-011 OncoGenex metastatic prostate cancer Phase III
(custiren) Pharmaceuticals (Fast Track) (425) 686-1500
Bothell, WA (see also lung)
Teva Pharmaceutical
Tikva, Israel
zibotentan AstraZeneca castration-resistant prostate cancer Phase III
Wilmington, DE (Fast Track) (800) 236-9933
s a r c o M a
product name sponsor indication development status
8H9 mAb United Therapeutics soft tissue sarcoma Phase I
Silver Spring, MD (see also brain, other) (301) 608-9292
AMG 479 Amgen (see also breast, colorectal, lung, Phase II
(ganitumab) Thousand Oaks, CA pancreatic, other) (800) 772-6436
ARQ-197 ArQule soft tissue sarcoma Phase II
Woburn, MA (see also colorectal, liver, lung, (781) 994-0300
Daiichi Sankyo pancreatic, sarcoma, other) (973) 944-2600
Parsippany, NJ
cancer vaccine MabVax Therapeutics Phase II
San Diego, CA (858) 259-9405
conatumumab Amgen (see also colorectal, lung, Phase I/II
Thousand Oaks, CA pancreatic) (800) 772-6436
eribulin Eisai (see also bladder, lung, prostate) Phase II
(E7389) Woodcliff Lake, NJ (888) 422-4743
IPI-926 Infinity Pharmaceuticals inoperable/unresectable Phase I
Cambridge, MA chondrosarcoma (617) 453-1000
mifamurtide Millennium Pharmaceuticals osteosarcoma Phase III
Cambridge, MA (800) 390-5663
ombrabulin sanofi-aventis Phase III
(AVE8062) Bridgewater, NJ (800) 633-1610
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 53
s a r c o M a
product name sponsor indication development status
palifosfamide ZIOPHARM Oncology soft-tissue sarcoma (first-line therapy) Phase III
(ZIO-201) New York, NY (see also lung) (212) 214-0700
(orphan drug) --------------------------------------------------------------------------------------
soft-tissue sarcoma Phase I/II
(second-line therapy) (212) 214-0700
PCI-24781 Pharmacyclics (see also lymphoma) Phase I
(HDAC inhibitor) Sunnyvale, CA (408) 774-0330
PD-0332991 Pfizer late-stage liposarcoma Phase II
New York, NY (see also brain, breast, lymphoma) (860) 732-5156
perifosine AEterna Zentaris (see also brain, colorectal, kidney, Phase II
(KRX-0401) Montreal, Canada leukemia, lymphoma, multiple (212) 531-5965
Keryx Biopharmaceuticals myeloma, ovarian, stomach)
New York, NY
Quadramet® EUSA Pharma osteosarcoma Phase I/II
samarium sm-153 Langhorne, PA (see also multiple myeloma, (800) 833-3533
lexidronam prostate, other)
injection
reolysin® Oncolytics Biotech (see also brain, colorectal, Phase II
reovirus Calgary, Canada head/neck, lung, pancreatic, skin) (403) 670-7377
rexin-G™ Epeius Biotechnologies osteosarcoma Phase II
tumor-targeted San Marino, CA (see also breast, pancreatic) (626) 441-6695
gene therapy --------------------------------------------------------------------------------------
(orphan drug) soft tissue sarcoma Phase I/II
(626) 441-6695
ridaforolimus Merck oral formulation (Fast Track) Phase III
(orphan drug) Whitehouse Station, NJ (see also breast, lung) (800) 672-6372
--------------------------------------------------------------------------------------
intravenous formulation Phase II
(800) 672-6372
robatumumab Merck osteosarcoma, sarcoma Phase II
Whitehouse Station, NJ (see also solid tumors) (800) 672-6372
TH-302 Threshold soft tissue sarcoma Phase I/II
Pharmaceuticals (see also leukemia, pancreatic, (650) 474-8200
Redwood City, CA solid tumors)
trabectedin Johnson & Johnson soft tissue sarcoma Phase III
(orphan drug) Pharmaceutical Research (see also breast, ovarian, prostate, (800) 817-5286
& Development other)
Raritan, NJ --------------------------------------------------------------------------------------
soft tissue sarcoma in adolescents Phase II
and children (800) 817-5286
votrient® GlaxoSmithKline (see also breast, kidney, ovarian) Phase III
pazopanib Rsch. Triangle Park, NC (888) 669-6682
54 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s K i n c a n c e r
product name sponsor indication development status
abraxane® Celgene malignant melanoma Phase III
albumin-bound Summit, NJ (see also bladder, lung, ovarian, (908) 673-9000
paclitaxel pancreatic)
(orphan drug)
ABT-888 Abbott Laboratories malignant melanoma Phase II
(veliparib) Abbott Park, IL (see also brain, breast, colorectal, (847) 937-6100
ovarian, prostate, other)
AD-1001 Intrexon late-stage malignant melanoma Phase I
Germantown, MD (646) 214-0700
ZIOPHARM Oncology
New York, NY
ADI-PEG 20 Polaris Pharmaceuticals malignant melanoma Phase II
(orphan drug) San Diego, CA (see also liver, lung) (858) 452-6688
allovectin-7® Vical malignant melanoma Phase III
velimogene San Diego, CA (Fast Track) (858) 646-1100
aliplasmid
(immunotherapeutic
vaccine)
(orphan drug)
ALS-357 Advanced Life Sciences malignant melanoma Phase I
(betulinic topical) Woodridge, IL (630) 739-6744
ALT-801 Altor BioScience malignant melanoma Phase I/II
Miramar, FL (954) 443-8600
APN301 Apeiron Biologics malignant melanoma Phase II
(hu14.18-IL2) Vienna, Austria (see also brain)
com
ARC-100 Archer Biosciences malignant melanoma Phase II
New York, NY (see also brain, pancreatic, prostate) (646) 747-9090
ATN-224 Tactic Pharma malignant melanoma Phase II
Evanston, IL (see also multiple myeloma, prostate) (847) 733-0940
azixa™ Myrexis malignant melanoma Phase II
(verubulin) Salt Lake City, UT (see also brain) (801) 214-7800
BMS-908662 Bristol-Myers Squibb malignant melanoma Phase I
(RAF kinase Princeton, NJ (see also colorectal) (212) 546-4000
inhibitor) Exelixis
South San Francisco, CA
BMS-936558 Bristol-Myers Squibb inoperable/unresectable malignant Phase I
(anti-PD1) Princeton, NJ melanoma (212) 546-4000
(see also solid tumors)
CDX-011 Celldex Therapeutics malignant melanoma Phase II
Needham, MA (see also breast) (781) 433-0771
CNTO 95 Centocor Ortho Biotech malignant melonoma Phase I/II
Horsham, PA (see also prostate, solid tumors) (800) 457-6399
CST-101 ConKwest stage IV malignant melanoma Phase I
Del Mar, CA (see also leukemia, lung, lymphoma) (858) 380-1999
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 55
s K i n c a n c e r
product name sponsor indication development status
CYT-107 Cytheris malignant melanoma Phase I
Rockville, MD (see also kidney, leukemia, (301) 231-0450
solid tumors)
denenicokin Bristol-Myers Squibb malignant melanoma Phase II
(IL-21) Princeton, NJ (212) 546-5000
(orphan drug)
E7272 Eisai melanoma Phase II
Woodcliff Lake, NJ (888) 422-4743
ecromeximab Life Sciences malignant melanoma Phase II
Pharmaceuticals (203) 656-2500
Darien, CT
GC-1008 Genzyme malignant melanoma Phase I
(fresolimumab) Cambridge, MA (see also kidney) (617) 252-7000
Genasense® Genta malignant melanoma Phase III
oblimersen Berkeley Heights, NJ (Fast Track) (908) 286-9800
(orphan drug) (see also leukemia, lymphoma)
GMX-1777 Gemin X Biotechnologies malignant melanoma Phase I completed
(teglarinad) Montreal, Canada (514) 281-8989
GSK1120212 GlaxoSmithKline malignant melanoma Phase III
(MEK inhibitor) Rsch. Triangle Park, NC (see also pancreatic, solid tumors) (888) 825-5249
--------------------------------------------------------------------------------------
combination therapy Phase II
(888) 825-5249
GSK2118436 GlaxoSmithKline metastatic malignant melanoma Phase III
(BRaf protein kinase Rsch. Triangle Park, NC (see also lung) (888) 825-5249
inhibitor)
GSK2302032A GlaxoSmithKline metastatic melanoma Phase I
(PRAME Rsch. Triangle Park, NC (888) 825-5249
immunotherapeutic
recombinant
vaccine)
GSK2401502 GlaxoSmithKline malignant melanoma Phase I
Rsch. Triangle Park, NC (888) 825-5249
Lipotek
Acton, Australia
Hyperacute® NewLink Genetics malignant melanoma Phase II
Melanoma Ames, IA (515) 296-5555
melanoma vaccine
IMC-20D7S Eli Lilly malignant melanoma Phase I
Indianapolis, IN (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
IMC-gp100 Immunocore malignant melanoma Phase 0
Oxon, United Kingdom
imprime pGG® Biothera malignant melanoma Phase I/II
Eagen, MN (see also colorectal, leukemia, lung) (651) 675-0300
56 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s K i n c a n c e r
product name sponsor indication development status
ioflubenzamide Molecular Insight malignant melanoma Phase I
I-131 Pharmaceuticals (617) 492-5554
Cambridge, MA
ipilimumab Bristol-Myers Squibb metastatic melanoma, combination Phase III
(orphan drug) Princeton, NJ therapy, first-line therapy (212) 546-4000
(Fast Track)
(see also lung, prostate)
lenvatinib Eisai melanoma Phase I/II
(E7080) Woodcliff Lake, NJ (see also brain, kidney, liver, other) (888) 422-4743
levulan® Kerastick® DUSA Pharmaceuticals prevention of skin cancer in solid Phase II
aminolevulinic acid Wilmington, MA organ transplant patients (978) 657-7500
lymphoseek™ Neoprobe diagnosis of malignant melanoma Phase III
Dublin, OH (see also breast, head/neck) (800) 793-0079
MAGE-A3 GlaxoSmithKline malignant melanoma Phase III
recombinant Rsch. Triangle Park, NC (see also lung) (888) 825-5249
vaccine (antigenspecific
cancer
immunotherapeutic)
Marqibo® Talon Therapeutics malignant melanoma Phase II
vincristine South San Francisco, CA (see also leukemia) (650) 588-6404
liposomal
(orphan drug)
melanoma Ichor Medical Systems malignant melanoma Phase I
vaccine San Diego, CA (858) 550-2022
Memorial Sloan-Kettering
Cancer Center
New York, NY
Metvixia® PhotoCure basal cell cancer Phase III
methyl Oslo, Norway
aminolevulinate
MKC1106-MT MannKind malignant melanoma Phase II
Valencia, CA (661) 775-5300
MORAb-028 Eisai malignant melanoma Phase I
Woodcliff Lake, NJ (888) 422-4743
muparfostat Progen Pharmaceuticals malignant melanoma Phase II
(PI-88) Redwood City, CA (see also liver) (650) 610-7080
(orphan drug)
OncoVEXGM-csf BioVex malignant melanoma Phase III
Woburn, MA (see also head/neck) (781) 376-4900
ontak® Eisai melanoma Phase II
denileukin diftitox Woodcliff Lake, NJ (888) 422-4743
PEP005 LEO Pharma non-melanoma skin cancer Phase II
Parsippany, NJ (877) 494-4536
PF-1367338 Pfizer malignant melanoma Phase II
New York, NY (see also breast, ovarian) (860) 732-5156
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 57
s K i n c a n c e r
product name sponsor indication development status
prophage Agenus malignant melanoma Phase III
(vitespen) Lexington, MA (Fast Track) (781) 674-4400
(orphan drug) (see also brain, kidney)
PTC299 PTC Therapeutics Kaposi’s sarcoma Phase I/II
South Plainfield, NJ (see also breast, solid tumors, other) (908) 222-7000
PTI-188 Pain Therapeutics malignant melanoma Phase I completed
San Mateo, CA (650) 624-8200
PV-10 Provectus Pharmaceuticals malignant melanoma Phase II
Knoxville, TN (see also liver) (866) 594-5999
RAF265 Novartis Pharmaceuticals malignant melanoma Phase I
East Hanover, NJ (888) 669-6682
reolysin® Oncolytics Biotech malignant melanoma Phase II
reovirus Calgary, Canada (see also brain, colorectal, head/neck, (403) 670-7377
lung, pancreatic, sarcoma)
RG3616 Curis basal cell carcinoma Phase II
(systemic hedgehog Lexington, MA (973) 235-5000
antagonist) Roche
Nutley, NJ
RG7204 Plexxikon first-line malignant melanoma Phase III
(BRAF kinase Berkeley, CA (510) 647-4000
inhibitor) Roche (973) 235-5000
Nutley, NJ --------------------------------------------------------------------------------------
second- and third-line malignant Phase II
melanoma (510) 647-4000
(973) 235-5000
RG7256 Roche BRAF-mutated malignant melanoma Phase I
Nutley, NJ (973) 235-5000
sprycel® Bristol-Myers Squibb malignant melanoma Phase I/II
dasatinib Princeton, NJ (see also brain, breast, colorectal, (212) 546-4000
leukemia, lung, lymphoma,
multiple myeloma, prostate)
tasigna® Novartis Pharmaceuticals malignant melanoma Phase III
nilotinib East Hanover, NJ (see also leukemia, stomach) (888) 669-6682
temodar® Merck malignant melanoma Phase I
temozolomide Whitehouse Station, NJ (see also leukemia, lung) (800) 672-6372
tesetaxel Genta advanced melanoma Phase II
(orphan drug) Berkeley Heights, NJ (see also bladder, breast, prostate, (908) 286-9800
stomach)
tnferade™ GenVec malignant melanoma Phase II completed
golnerminogene Gaithersburg, MD (see also colorectal, head/neck, (240) 632-0740
pradenovec stomach)
tremelimumab Pfizer malignant melanoma Phase II
(CP-675206) New York, NY (see also kidney, pancreatic, stomach, (860) 732-5156
other)
TRX518 Tolerx malignant melanoma Phase I
Cambridge, MA (617) 354-8100
58 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s K i n c a n c e r
product name sponsor indication development status
veglin VasGene Therapeutics Kaposi’s sarcoma Phase I
(VEGF antisense) Los Angeles, CA (see also kidney, lung) (323) 221-7818
Zadaxin® SciClone Pharmaceuticals malignant melanoma Phase II completed
thymalfasin Foster City, CA (650) 358-3456
(orphan drug)
s o l i d t u M o r s
product name sponsor indication development status
1MT NewLink Genetics metastatic disease Phase I
Ames, IA (515) 296-5555
ABI-009 Celgene Phase I
(nab®-rapamycin) Summit, NJ (908) 673-9000
ABI-101 Celgene Phase I
(nab®-17AAG) Summit, NJ (908) 673-9000
ABT-348 Abbott Laboratories late-stage disease Phase I
Abbott Park, IL (see also other) (847) 937-6100
ABT-806 Abbott Laboratories Phase I
Abbott Park, IL (847) 937-6100
AC480 Ambit Biosciences (see also brain) Phase II completed
San Diego, CA (858) 334-2100
--------------------------------------------------------------------------------------
solid tumors (combination therapy) Phase I
(858) 334-2100
ACE-041 Acceleron Pharma (see also multiple myeloma) Phase I
Cambridge, MA (617) 649-9200
AEW541 Novartis Pharmaceuticals (see also other) Phase I
East Hanover, NJ (888) 669-6682
AEZS-112 AEterna-Zentaris (see also lymphoma) Phase I
Warren, NJ (908) 626-5428
AFP-464 Tigris Pharmaceuticals Phase I
Bonita Springs, FL (239) 444-5400
AI-850 Acusphere Phase I
Watertown, MA (617) 648-8800
Cephalon (610) 344-0200
Frazer, PA
ALB 109564(a) AMRI Phase I
Albany, NY (518) 512-2000
AMG 208 Amgen Phase I
Thousand Oaks, CA (800) 772-6436
AMG 780 Amgen Phase I
Thousand Oaks, CA (800) 772-6436
AMG 820 Amgen Phase I
Thousand Oaks, CA (800) 772-6436
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 59
s o l i d t u M o r s
product name sponsor indication development status
AMG 888 Amgen Phase I
(U3-1287) Thousand Oaks, CA (800) 772-6436
AMG 900 Amgen Phase I
Thousand Oaks, CA (800) 772-6436
amplimexon® AmpliMed Phase I/II completed
imexon Tucson, AZ (520) 529-1000
amuvatinib SuperGen (see also lymphoma) Phase I
Dublin, CA (925) 560-0100
anti-EGFL7 mAb Genentech Phase I
(RG7414) South San Francisco, CA (650) 224-1000
anti-HER3/EGFR Genentech Phase I
DAF (RG7597) South San Francisco, CA (650) 224-1000
aplidin® PharmaMar USA (see also lymphoma, Phase I
plitidepsin Cambridge, MA multiple myeloma) (617) 868-3797
AR-12 Arno Therapeutics (see also lymphoma) Phase I
Parsippany, NJ (862) 703-7170
ARQ-621 ArQule late-stage solid tumors Phase I
Woburn, MA (781) 994-0300
ARQ-736 ArQule late-stage solid tumors Phase I
Woburn, MA (781) 994-0300
ARRY-520 Array BioPharma (see also leukemia, multiple Phase I
Boulder, CO myeloma) (303) 381-6600
ARRY-543 Array BioPharma Phase II
(varlitinib) Boulder, CO (303) 381-6600
AT-406 Ascenta Therapeutics (see also lymphoma) Phase I
Malvern, PA (610) 408-0313
AT7519 Astex Therapeutics (see also multiple myeloma) Phase I
Cambridge, United Kingdom
com
AT9283 Astex Therapeutics (see also leukemia) Phase I
Cambridge, United Kingdom
com
ATI-1123 Azaya Therapeutics Phase I
San Antonio, TX (210) 341-6600
AT13387 Astex Therapeutics Phase I
Cambridge, United Kingdom
com
ATN-161 Tactic Pharma Phase II
Evanston, IL (847) 733-0940
AV-299 AVEO Pharmaceuticals (see also glioblastoma, lymphoma, Phase I
(ficlatuzumab) Cambridge, MA multiple myeloma) (617) 299-5000
AZD1480 AstraZeneca (see also other) Phase I
(JAK2 inhibitor) Wilmington, DE (800) 236-9933
AZD2014 AstraZeneca Phase I
(TOR kinase Wilmington, DE (800) 236-9933
inhibitor)
60 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s o l i d t u M o r s
product name sponsor indication development status
AZD2461 AstraZeneca Phase I
(PARP inhibitor) Wilmington, DE (800) 236-9933
AZD4547 AstraZeneca Phase I/II
(FGFR tyrosine Wilmington, DE (800) 236-9933
kinase inhibitor)
AZD5363 AstraZeneca Phase I
(AKT inhibitor) Wilmington, DE (800) 236-9933
AZD7762 AstraZeneca Phase I
(CHK1 kinase Wilmington, DE (800) 236-9933
inhibitor)
AZD8055 AstraZeneca Phase I
(TOR kinase Wilmington, DE (800) 236-9933
inhibitor)
AZD8330 Array Bio Pharma Phase I
(ARRY-704) Boulder, CO (800) 236-9933
AstraZeneca
Wilmington, DE
AZD8931 AstraZeneca (see also breast) Phase II
(erbB kinase Wilmington, DE (800) 236-9933
inhibitor)
BAY 79-4620 Bayer HealthCare Phase I
Pharmaceuticals (888) 842-2937
Wayne, NJ
BAY 80-6946 Bayer HealthCare Phase I
Pharmaceuticals (888) 842-2937
Wayne, NJ
BAY 10-00394 Bayer HealthCare Phase I
Pharmaceuticals (888) 842-2937
Wayne, NJ
BBI608 Boston Biomedical Phase I
Norwood, MA (781) 278-0900
BEZ235 Novartis Pharmaceuticals late-stage solid tumors Phase I/II
East Hanover, NJ (888) 669-6682
BGJ398 Novartis Pharmaceuticals Phase I
East Hanover, NJ (888) 669-6682
BGT226 Novartis Pharmaceuticals Phase I/II
East Hanover, NJ (888) 669-6682
BHQ880 Novartis Pharmaceuticals (see also multiple myeloma) Phase I
East Hanover, NJ (888) 669-6682
BI 811283 Boehringer Ingelheim (see also leukemia) Phase I
Pharmaceuticals (800) 243-0127
Ridgefield, CT
BI 831266 Boehringer Ingelheim Phase I
Pharmaceuticals (800) 243-0127
Ridgefield, CT
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 61
s o l i d t u M o r s
product name sponsor indication development status
BIIB 015 Biogen Idec Phase I
Cambridge, MA (617) 679-2000
BKM120 Novartis Pharmaceuticals (see also breast) Phase I
East Hanover, NJ (888) 669-6682
BMN-673 BioMarin Pharmaceuticals Phase I/II
Novato, CA (415) 506-6700
BMS-247615 Bristol-Myers Squibb Phase I
(DNA topoisomerase Princeton, NJ (212) 546-4000
I and II inhibitor)
BMS-754807 Bristol-Myers Squibb (see also breast) Phase I/II
(IGF-1R antagonist) Princeton, NJ (212) 546-4000
BMS-777607 Bristol-Myers Squibb advanced solid tumors Phase I/II completed
(receptor protein- Princeton, NJ (212) 546-4000
tyrosine kinase
antagonists)
BMS-833923 Bristol-Myers Squibb Phase I
(SMO inhibitor) Princeton, NJ (212) 546-4000
BMS-936558 Bristol-Myers Squibb (see also skin) Phase I
(anti-PD1) Princeton, NJ (212) 546-4000
BMS-936559 Bristol-Myers Squibb Phase I
(anti-PDL-L1) Princeton, NJ (212) 546-4000
BQS481 Novartis Pharmaceuticals Phase I
East Hanover, NJ (888) 669-6682
BYL719 Novartis Pharmaceuticals late-stage solid tumors Phase I
East Hanover, NJ (888) 669-6682
c31510 Cytotech Labs Phase I
for injection Natick, MA
CALAA 01 Calando Pharmaceuticals Phase I
Pasadena, CA (626) 683-7200
carfilzomib Onyx Pharmaceuticals (see also multiple myeloma) Phase II
Emeryville, CA (510) 597-6500
carlumab Centocor Ortho Biotech (see also prostate) Phase I
Horsham, PA (800) 457-6399
CC-223 Celgene late-stage solid tmors Phase I/II
Summit, NJ (see also leukemia, lymphoma) (908) 673-9000
CDX-1401 Celldex Therapeutics Phase I/II
Needham, MA (781) 433-0771
CEP-9722 Cephalon Phase I
(PARP inhibitor) Frazer, PA (610) 344-0200
CEP-11981 Cephalon Phase I
(VEGF-R/TIE2 Frazer, PA (610) 344-0200
kinase inhibitor)
CG201 CG Therapeutics Phase II
Seattle, WA (206) 336-5604
62 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s o l i d t u M o r s
product name sponsor indication development status
CLR1404 Cellectar Phase I
Madison, WI (608) 441-8120
CNTO 95 Centocor Ortho Biotech (see also prostate, skin) Phase I completed
Horsham, PA (800) 457-6399
CRLX101 Cerulean Pharma late-stage solid tumors Phase I/II
Cambridge, MA (617) 551-9600
crolibulin EpiCept Phase I/II
Tarrytown, NY (914) 606-3500
CRS-207 Aduro BioTech Phase I
Berkeley, CA (510) 848-4400
CUDC-101 Curis Phase I
Cambridge, MA (617) 503-6500
CX-4945 Cylene Pharmaceuticals (see also multiple myeloma, other) Phase I
San Diego, CA (858) 875-5100
CYC-116 Cyclacel Pharmaceuticals Phase I
Berkeley Heights, NJ (908) 517-7330
CYT-107 Cytheris vaccine enhancer Phase I
Rockville, MD (see also kidney, leukemia, skin) (301) 231-0450
CYT 6091 CytImmune Sciences Phase I
Rockville, MD (301) 825-3041
darinaparsin oral ZIOPHARM Oncology (see also liver, lymphoma, Phase I
(ZIO-101) New York, NY multiple myeloma) (646) 214-0700
denibulin MediciNova Phase I
(MN-029) San Diego, CA (858) 373-1500
dovitinib Novartis Pharmaceuticals Phase II
(TKI258) East Hanover, NJ (888) 669-6682
EC-0489 Endocyte Phase I
West Lafayette, IN (765) 463-7175
elsamitrucin Spectrum advanced solid tumors Phase I
Pharmaceuticals (949) 788-6700
Irvine, CA
EMD-1204831 EMD Serono late-stage solid tumors Phase I
(c-Met kinase Rockland, MA (800) 283-8088
inhibitor)
EMD-1214063 EMD Serono Phase I
(c-Met kinase Rockland, MA (800) 283-8088
inhibitor)
EP-100 Esperance Pharmaceuticals Phase I
Baton Rouge, LA (225) 615-8944
ETBX-011 Etubics late-stage solid tumors Phase I
Seattle, WA (206) 838-5110
EZN-2208 Enzon Pharmaceuticals refractory metastatic solid tumors Phase I
Bridgewater, NJ (see also breast, colorectal) (908) 541-8600
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 63
s o l i d t u M o r s
product name sponsor indication development status
EZN-2968 Enzon Pharmaceuticals (see also lymphoma) Phase I
Bridgewater, NJ (908) 541-8600
EZN-3042 Enzon Pharmaceuticals (see also leukemia, lymphoma) Phase I
Bridgewater, NJ (908) 541-8600
fluciclatide F-18 GE Healthcare diagnosis of solid tumors Phase II
Waukesha, WI
FP-1039 Five Prime Therapeutics (see also other) Phase I
San Francisco, CA (415) 365-5600
G-202 GenSpera Phase I
San Antonio, TX (210) 479-8112
GDC-0068 Genentech Phase I
(Akt inhibitor) South San Francisco, CA (650) 224-1000
GDC-0623 Genentech Phase I
(MEK inhibitor) South San Francisco, CA (650) 224-1000
GDC-0917 Genentech (see also lymphoma) Phase I
(IAP antagonist) South San Francisco, CA (650) 224-1000
GDC-0941 Genentech (see also breast, lung, lymphoma) Phase I
(PI3 kinase South San Francisco, CA (650) 224-1000
inhibitor)
GDC-0973 Exelixis Phase I
(MEK inhibitor) South San Francisco, CA (650) 837-7000
Genentech
South San Francisco, CA
GDC-0980 Genentech (see also breast, lymphoma) Phase I
(PI3 kinase/mTOR South San Francisco, CA (650) 224-1000
dual inhibitor)
Genasense® Genta brief, high-dose IV-infusion Phase I/II
oblimersen Berkeley Heights, NJ (see also breast, leukemia, lung, (908) 286-9800
lymphoma, skin)
--------------------------------------------------------------------------------------
intermittent therapy Phase I
(908) 286-9800
Genz-644282 Genzyme Phase I
Cambridge, MA (617) 252-7500
GGTI-2418 Tigris Pharmaceuticals Phase I
Bonita Springs, FL (239) 444-5400
GL-ONC1 Genelux Phase I
San Diego, CA (858) 483-0024
GO-203-2c Genus Oncology advanced solid tumors Phase I
Vernon Hills, IL (847) 549-6500
GS 6624 Gilead Sciences Phase I
Foster City, CA (800) 445-3235
GSK1070916A GlaxoSmithKline Phase I
Rsch. Triangle Park, NC (888) 825-5249
GSK1120212 GlaxoSmithKline (see also pancreatic, skin) Phase I
(MEK inhibitor) Rsch. Triangle Park, NC (888) 825-5249
64 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s o l i d t u M o r s
product name sponsor indication development status
GSK2141795 GlaxoSmithKline (see also lymphoma) Phase I
(AKT protein kinase Rsch. Triangle Park, NC (888) 825-5249
inhibitor)
GSK2256098 GlaxoSmithKline Phase I
(FAK inhibitor) Rsch. Triangle Park, NC (888) 825-5249
HER2/neu receptor Dendreon Phase I
(active cellular Seattle, WA (877) 256-4545
immunotherapy)
HGS-1029 Human Genome Sciences (see also lymphoma) Phase I
Rockville, MD (301) 309-8504
HSP990 Novartis Pharmaceuticals Phase I
East Hanover, NJ (888) 669-6682
IMC-RON8 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
IMGN-388 ImmunoGen Phase I
Waltham, MA (781) 895-0600
INCB-18424 Incyte Phase I
(ruxolitinib) Wilmington, DE (302) 498-6700
INCB-24360 Incyte Phase I/II
(IDO inhibitor) Wilmington, DE (302) 498-6700
INCB-28060 Incyte Phase I/II
(c-MET inhibitor) Wilmington, DE (302) 498-6700
Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
INK128 Intellikine (see also lymphoma, multiple Phase I
(TORC1/2 inhibitor) La Jolla, CA myeloma) (858) 768-6500
INNO-206 CytRx Phase I completed
Los Angeles, CA (310) 826-5648
IPI-493 Infinity Pharmaceuticals advanced solid tumors Phase I
Cambridge, MA (see also other) (617) 453-1000
IPI-926 Infinity Pharmaceuticals (see also pancreatic, sarcoma) Phase I
Cambridge, MA (617) 453-1000
JI-101 Jubilant Innovation Phase I/II
Bedminster, NJ (215) 369-0965
JNJ-26854165 Johnson & Johnson late-stage solid tumors Phase I
Pharmaceutical Research (see also lung, prostate) (800) 817-5286
& Development
Raritan, NJ
JNJ-38877605 Johnson & Johnson Phase I/II
Pharmaceutical Research (800) 817-5286
& Development
Raritan, NJ
KHK-2866 Kyowa Hakko Kirin Pharma (see also ovarian) Phase I
Princeton, NJ (609) 919-1100
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 65
s o l i d t u M o r s
product name sponsor indication development status
LCL161 Novartis Pharmaceuticals Phase I
East Hanover, NJ (888) 669-6682
LDE225 Novartis Pharmaceuticals Phase II
East Hanover, NJ (888) 669-6682
LDK378 Novartis Pharmaceuticals Phase II
East Hanover, NJ (888) 669-6682
LEE011 Novartis Pharmaceuticals (see also lymphoma) Phase I
East Hanover, NJ (888) 669-6682
LEQ506 Novartis Pharmaceuticals Phase I
East Hanover, NJ (888) 669-6682
L-MDAM BioNumerik Phase I
Pharmaceuticals (210) 614-1701
San Antonio, TX
LOR-253 Lorus Therapeutics Phase I
Toronto, Canada (416) 798-1200
LP-261 Ansaris Phase I
Blue Bell, PA (215) 358-2000
MEDI-565 AstraZeneca Phase I
(anti-CEA BiTE) Wilmington, DE (800) 236-9933
MedImmune (301) 398-0000
Gaithersburg, MD
MEDI-573 AstraZeneca Phase I
(anti-IGF mAb) Wilmington, DE (800) 236-9933
MedImmune (301) 398-0000
Gaithersburg, MD
MEDI-575 AstraZeneca Phase II
Wilmington, DE (800) 236-9933
MedImmune (301) 398-0000
Gaithersburg, MD
MEDI-3617 AstraZeneca Phase I
(anti-ANG-2 mAb) Wilmington, DE (800) 236-9933
MedImmune (301) 398-0000
Gaithersburg, MD
MEK162/ Array BioPharma Phase I
ARRY-162 Boulder, CO (303) 381-6600
Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
MGAH22 Macrogenics Phase I
(anti-HER2) Rockville, MD (301) 251-5172
MGCD-265 MethylGene late-stage solid tumors Phase I
Montreal, Canada (see also lung) (514) 337-3333
MGCD-0103 MethylGene (see also leukemia, lymphoma) Phase I/II
Montreal, Canada (514) 337-3333
MINT-1526A Genentech advanced solid tumors Phase I
(anti-angiogenic) South San Francisco, CA (650) 224-1000
66 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s o l i d t u M o r s
product name sponsor indication development status
MK-0752 Merck (see also breast) Phase I
Whitehouse Station, NJ (800) 672-6372
MK-1496 Merck Phase I completed
Whitehouse Station, NJ (800) 672-6372
MK-1775 Merck Phase I
Whitehouse Station, NJ (800) 672-6372
MK-4827 Merck late-stage solid tumors Phase I
Whitehouse Station, NJ (800) 672-6372
MK-5108 Merck late-stage or refractory solid tumors Phase I
(VX-689) Whitehouse Station, NJ (800) 672-6372
Vertex Pharmaceuticals
Cambridge, MA
MKC1106-PP MannKind Phase I completed
Valencia, CA (661) 775-5300
MLN4924 Millennium Pharmaceuticals (see also other) Phase I
Cambridge, MA (800) 390-5663
MLN8237 Millennium Pharmaceuticals (see also other) Phase I/II
Cambridge, MA (800) 390-5663
MLN9708 Millennium Pharmaceuticals (see also other) Phase I/II
Cambridge, MA (800) 390-5663
MM-111 Merrimack Pharmaceuticals (see also breast) Phase I/II
Cambridge, MA (617) 441-1000
MN-201 Marillion advanced solid tumors Phase I
Pharmaceuticals (484) 875-3018
Exton, PA
MORAb-004 Eisai Phase I
Woodcliff Lake, NJ (888) 422-4743
MT-110 Micromet Phase I
Bethesda, MD (240) 752-1420
NB-1011 Kiadis Pharma Phase I/II
Amsterdam,
The Netherlands
NKTR-105 Nektar Therapeutics Phase I
(pegylated San Francisco, CA (415) 482-5300
docetaxel)
NMS-1116354 Nerviano Medical Sciences metastatic solid tumors Phase I
Milan, Italy
NMS-1286937 Nerviano Medical Sciences Phase I
Milan, Italy
NPI-0052 Nereus Pharmaceuticals (see also lymphoma, Phase I
(marizomib) San Diego, CA multiple myeloma) (858) 587-4090
OMP-21M18 GlaxoSmithKline Phase I
Rsch. Triangle Park, NC (888) 825-5249
OncoMed Pharmaceuticals (650) 995-8200
Redwood City, CA
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 67
s o l i d t u M o r s
product name sponsor indication development status
OMP-59R5 GlaxoSmithKline late-stage solid tumors Phase I
Rsch. Triangle Park, NC (888) 825-5249
OncoMed Pharmaceuticals (650) 995-8200
Redwood City, CA
omtriptolide Pharmagenesis Phase I
Redwood City, CA (650) 842-7060
Pierre Fabre (973) 898-1042
Pharmaceuticals
Parsippany, NJ
ON-01910 Onconova Therapeutics (see also leukemia, lymphoma, Phase I
Princeton, NJ ovarian) (609) 844-7735
ONX-0801 Onyx Pharmaceuticals Phase I
Emeryville, CA (510) 597-6500
ONX-0912 Onyx Pharmaceuticals late-stage solid tumors Phase I
Emeryville, CA (510) 597-6500
ortatexal Spectrum Pharmaceuticals taxane-refractory solid tumors Phase II
Irvine, CA (949) 788-6700
OSI-930 OSI Pharmaceuticals late-stage solid tumors Phase I
Melville, NY (631) 962-2000
OXi4503 OXiGENE (see also leukemia) Phase I/II
South San Francisco, CA (650) 635-7000
PA799 Chugai Pharma USA Phase I
Berkeley Heights, NJ (908) 516-1350
PDL-192 Facet Biotech Phase I
(enavatuzumab) Redwood City, CA (650) 454-1000
PEGPH20 Halozyme Phase I
(pegylated San Diego, CA (858) 794-8889
recombinant human
hyaluronidase)
PF-03446962 Pfizer late-stage solid tumors Phase I
New York, NY (860) 732-5156
PF-03758309 Pfizer Phase I
New York, NY (860) 732-5156
PF-04605412 Pfizer Phase I
New York, NY (860) 732-5156
PF-04691502 Pfizer Phase I
New York, NY (860) 732-5156
PF-04856884 Pfizer Phase I
(CVX060) New York, NY (860) 732-5156
PF-05057459 Pfizer Phase I
(CVX 241) New York, NY (860) 732-5156
PG11047 Progen Pharmaceuticals Phase I
Redwood City, CA (650) 610-7800
picoplatin Poniard Pharmaceuticals Phase I
oral San Francisco, CA (650) 583-3774
68 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s o l i d t u M o r s
product name sponsor indication development status
PLX3397 Plexxikon (see also lymphoma) Phase I
Berkeley, CA (510) 647-4000
PM-01183 PharmaMar USA Phase I completed
Cambridge, MA (617) 868-3797
PM-060184 PharmaMar USA Phase I
Cambridge, MA (617) 868-3797
PNT2258 ProNAi Therapeutics Phase I
Kalamazoo, MI (269) 815-8098
PRLX-93936 Prolexys Pharmaceuticals Phase I
Salt Lake City, UT (801) 303-1700
PTC299 PTC Therapeutics (see also breast, skin, other) Phase I
South Plainfield, NJ (908) 222-7000
purine nucleoside PNP Therapeutics Phase I
phosphorylase Birmingham, AL
gene therapy
PX-478 Oncothyreon (see also lymphoma) Phase I completed
Seattle, WA (206) 801-2100
PX-866 Oncothyreon Phase I/II
Seattle, WA (206) 801-2100
quizartinib Ambit Biosciences late-stage solid tumors Phase I
San Diego, CA (see also leukemia) (858) 334-2100
Astellas Pharma US (800) 727-7003
Deerfield, IL
retaspimycin Infinity Pharmaceuticals (see also lung) Phase I
(IPI 504) Cambridge, MA (617) 453-1000
RG7112 Roche (see also other) Phase I
Nutley, NJ (973) 235-5000
RG7160 Roche Phase I
(HumAb EGFR) Nutley, NJ (973) 235-5000
RG7167 Roche Phase I
Nutley, NJ (973) 235-5000
RG7304 Roche Phase I
(Raf/MEK dual Nutley, NJ (973) 235-5000
inhibitor)
RG7334 Roche Phase I
(anti-PLGF mAb) Nutley, NJ (973) 235-5000
RG7347 Genentech Phase I
South San Francisco, CA (650) 224-1000
RG7422 Genentech Phase I
(PI3 kinase inhibitor) South San Francisco, CA (650) 224-1000
RG7593 Genentech Phase I
South San Francisco, CA (650) 224-1000
RG7594 Genentech Phase I
South San Francisco, CA (650) 224-1000
rindopepimut Celldex Therapeutics (see also brain) Phase I
Needham, MA (860) 732-5156
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 69
s o l i d t u M o r s
product name sponsor indication development status
robatumumab Merck solid tumors Phase II
Whitehouse Station, NJ (see also sarcoma) (800) 672-6372
--------------------------------------------------------------------------------------
solid tumors in children Phase I
(800) 672-6372
SAR256212 Merrimack Pharmaceuticals (see also ovarian) Phase I
(MM-121) Cambridge, MA (617) 441-1000
sanofi-aventis (800) 633-1810
Bridgewater, NJ
SAR566658 sanofi-aventis Phase I
(maytansin-loaded Bridgewater, NJ (800) 633-1810
anti-DS6)
SB939 S*Bio late-stage solid tumors Phase I
Redwood City, CA (see also leukemia) (650) 730-2860
selumetinib Array BioPharma Phase II
(AZD6244/ Boulder, CO (800) 236-9933
ARRY-886) AstraZeneca
Wilmington, DE
selumetinib Array Bio Pharma Phase I
(AZD6244/ Boulder, CO (800) 236-9933
ARRY-886) AstraZeneca (800) 672-6372
MK-2206 Wilmington, DE
combination Merck
Whitehouse Station, NJ
SF1126 Semafore Pharmaceuticals (see also leukemia, Phase I
Indianapolis, IN multiple myeloma) (317) 876-3075
simotaxel Taxolog Phase I
Fairfield, NJ (877) 829-6564
SN2310 OncoGenex Phase I completed
Pharmaceuticals (425) 686-1500
Bothell, WA
sonepcizumab Lpath Phase II
San Diego, CA (858) 678-0800
Sym004 Symphogen Phase I
Lyngby, Denmark
TAK-441 Millennium Pharmaceuticals late-stage solid tumors Phase I
Cambridge, MA (800) 390-5663
TAK-701 Millennium Pharmaceuticals Phase I
Cambridge, MA (800) 390-5663
TAK-733 Millennium Pharmaceuticals Phase I
Cambridge, MA (800) 390-5663
TAK-901 Millennium Pharmaceuticals (see also other) Phase I
Cambridge, MA (800) 390-5663
TAK-960 Millennium Pharmaceuticals Phase I
Cambridge, MA (800) 390-5663
terameprocol Erimos Pharmaceuticals (see also brain, cervical, head/neck, Phase I
(intravenous) Houston, TX other) (713) 541-2000
70 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s o l i d t u M o r s
product name sponsor indication development status
TH-302 Threshold late-stage solid tumors Phase I/II
Pharmaceuticals (see also leukemia, sarcoma) (650) 474-8200
Redwood City, CA
TKM-PLK1 Tekmira Pharmaceuticals (see also lymphoma) Phase I
Vancouver, Canada (604) 419-3200
TLC388 Taiwan Liposome Phase I
Taipei, Taiwan
TRC093 TRACON Pharmaceuticals Phase I completed
San Diego, CA (858) 550-0780
TRC102 TRACON Pharmaceuticals Phase I
San Diego, CA (858) 550-0780
TRC105 TRACON Pharmaceuticals locally advanced or metastatic Phase I
San Diego, CA solid tumors (858) 550-0780
(see also prostate)
TRPM8 Dendreon Phase I
(D-3263) Seattle, WA (877) 256-4545
TST10088 Cangene Phase I
Winnipeg, Canada (204) 275-4200
U3-1565 Amgen Phase I
Thousand Oaks, CA (800) 772-6436
U3 Pharma (973) 359-2600
Martinsried, Germany
UNBS-5162 Drais Pharmaceuticals (see also lymphoma) Phase I
Bridgewater, NJ (908) 895-1200
V935 Merck Phase I
Whitehouse Station, NJ (800) 672-6372
vinorelbine Talon Therapeutics (see also lymphoma) Phase I
liposomal South San Francisco, CA (650) 588-6404
VX15 Vaccinex Phase I
Rochester, NY (585) 271-2700
WX-UK1 Wilex Phase I
Munich, Germany
X-82 Tyrogenex Phase I
West Palm Beach, FL (561) 835-9356
XMT-1001 Mersana Therapeutics refractory metastatic disease Phase I
Cambridge, MA (617) 498-0020
XMT-1107 Mersana Therapeutics Phase I
Cambridge, MA (617) 498-0020
s t o M a c H c a n c e r
product name sponsor indication development status
afinitor® Novartis Pharmaceuticals GIST Phase III
everolimus East Hanover, NJ (see also breast, kidney, liver, (888) 669-6682
lymphoma, other)
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 71
s t o M a c H c a n c e r
product name sponsor indication development status
AMG 386 Amgen gastric and gastroesophageal junction Phase II
Thousand Oaks, CA adenocarcinoma (800) 772-6436
(see also breast, colorectal, kidney,
liver, ovarian, other)
--------------------------------------------------------------------------------------
distal esophageal adenocarcinoma Phase II
(800) 772-6436
AT-101 Ascenta Therapeutics esophageal cancer Phase II
Malvern, PA (see also brain, leukemia, lung, (610) 408-0313
lymphoma, prostate)
AUY922 Novartis Pharmaceuticals gastric cancer Phase II
East Hanover, NJ (see also breast, colorectal, lung, (888) 669-6682
multiple myeloma)
AV-951 AVEO Pharmaceuticals gastrointestinal cancer Phase I/II
(tivozanib) Cambridge, MA (see also breast, kidney, lung) (617) 299-5000
BAY 73-4506 Bayer HealthCare late-stage GIST Phase III
(regorafenib) Pharmaceuticals (see also colorectal, kidney, lung) (888) 842-2937
(orphan drug) Wayne, NJ
brivanib Bristol-Myers Squibb gastrointestinal cancer Phase I
(VEGFR/FGFR Princeton, NJ (see also liver) (212) 546-4000
kinase inhibitor)
CNF-2024 Biogen Idec GIST Phase II
Weston MA (see also breast) (781) 464-2000
E7050 Eisai gastric cancer Phase I/II
Woodcliff Lake, NJ (see also liver, other) (888) 422-4743
ganetespib Synta Pharmaceuticals esophageal cancer, GIST Phase II
Lexington, MA (see also breast, colorectal, lung, (781) 274-8200
other)
ixempra® Bristol-Myers Squibb gastric cancer, esophageal cancer Phase II
ixabepilone Princeton, NJ (see also breast, lung, other) (212) 546-4000
masitinib AB Science USA GIST Phase III
Short Hills, NJ (see also leukemia, pancreatic) (973) 218-2437
oncoGel™ Protherics esophageal cancer Phase II
paclitaxel Brentwood, TN (615) 327-1027
controlled-release
(orphan drug)
perifosine Aeterna Zentaris late-stage GIST Phase II
(KRX-1401) Montreal, Canada (see also brain, colorectal, kidney, (212) 531-5965
Keryx Biopharmaceuticals leukemia, lymphoma, multiple
New York, NY myeloma, sarcoma, ovarian)
polyclonal antibody Cancer Advances gastric cancer Phase III
stimulator Durham, NC (see also colorectal, pancreatic) (919) 361-2162
(orphan drug)
ramucirumab Eli Lilly gastric cancer Phase III
(IMC-1121B) Indianapolis, IN (see also breast, colorectal, liver, lung) (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
72 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
s t o M a c H c a n c e r
product name sponsor indication development status
rilotumumab Amgen gastric cancer Phase II
Thousand Oaks, CA (see also brain, colorectal, (800) 772-6436
lung, prostate)
S-1 Taiho Pharma USA gastric cancer Phase III
Princeton, NJ (609) 750-5300
tasigna® Novartis Pharmaceuticals GIST Phase III
nilotinib East Hanover, NJ (see also leukemia, skin) (888) 669-6682
(orphan drug)
telatinib ACT Biotech late-stage gastric cancer Phase II
(orphan drug) San Francisco, CA (see also colorectal) (415) 230-3900
tesetaxel Genta advanced gastric cancer (Fast Track) Phase II
(orphan drug) Berkeley Heights, NJ (see also bladder, breast, prostate, (908) 286-9800
skin)
tnferade™ GenVec esophageal cancer Phase II completed
golnerminogene Gaithersburg, MD (see also colorectal, head/neck, (240) 632-0740
pradenovec pancreatic, skin)
tremelimumab Pfizer gastointestinal cancer Phase II
(CP-675206) New York, NY (see also kidney, pancreatic, (860) 732-5156
skin, other)
tykerb® GlaxoSmithKline gastric cancer Phase III
lapatinib Rsch. Triangle Park, NC (see also breast, head/neck) (888) 825-5249
c a n c e r / c H e M o t H e r a p y - r e l a t e d c o n d i t i o n s
product name sponsor indication development status
acapodene® GTx complications from androgen application submitted
toremifene Memphis, TN deprivation therapy (901) 523-9700
(see also prostate)
ACE-011 Acceleron Pharma chemotherapy-induced anemia Phase II/III
(sotatercept) Cambridge, MA (see also other) (617) 649-9200
Celgene (908) 673-9000
Summit, NJ
AG013 ActoGeniX mucositis Phase I
Zwijnaarde, Belguim
ARX-02 AcelRx Pharmaceuticals cancer breakthrough pain Phase II
(sufentanil Redwood City, CA (650) 216-3500
sublingual)
campath® Genzyme chronic graft-versus-host disease Phase I
alemtuzumab Cambridge, MA (617) 252-7500
(intravenous)
CB1400 Canopus BioPharma mucositis (prevention) Phase II
Studio City, CA (818) 980-5008
emend® for Merck chemotherapy-induced nausea and Phase I
injection Whitehouse Station, NJ vomiting (CINV) in adolescents, (800) 672-6372
fosaprepitant Fate Therapeutics children and infants
San Diego, CA
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 73
c a n c e r / c H e M o t H e r a p y - r e l a t e d c o n d i t i o n s
product name sponsor indication development status
ereska™ Javelin Pharmaceuticals cancer pain Phase III
ketamine Cambridge, MA (617) 349-4500
intranasal
fentanyl sublingual INSYS Therapeutics cancer pain Phase III
spray Phoenix, AZ (602) 910-2617
FT1050 Fate Therapeutics hematopoietic stem cell support Phase I
(orphan drug) San Diego, CA in patients with hematological (858) 875-1800
malignancies
golotimod SciClone Pharmaceuticals chemotherapy-induced stomatitis Phase II
Foster City, CA (prevention) (650) 358-3456
morphine intranasal Marina Biotech cancer pain Phase II
Bothell, WA (425) 908-3600
MRX-1024 Molecular Therapeutics mucositis Phase I
Ann Arbor, MI (734) 259-4574
nabiximols Otsuka America advanced cancer pain Phase II
Pharmaceutical (800) 438-6124
Rockville, MD
nasalfent® Archimedes Pharma cancer pain application submitted
fentanyl intranasal Reading, United Kingdom
norepinephrine ProCertus BioPharm prevention of radiodermatitis in Phase I/II
topical Madison, WI patients undergoing radiation (608) 273-8862
therapy
--------------------------------------------------------------------------------------
prevention of oral mucositis in Phase I/II
patients undergoing radiation (608) 273-8862
therapy
--------------------------------------------------------------------------------------
prevention of chemo- and radio- Phase I/II
therapy-induced alopecia (608) 273-8862
NP-2 Diamyd Medical cancer pain Phase II
gene therapy Pittsburgh, PA (412) 770-1310
(intradermal)
nplate™ Amgen chemotherapy-induced Phase II
romiplostim Thousand Oaks, CA thrombocytopenia (800) 772-6436
(see also leukemia)
orBec® Soligenix graft-versus-host disease Phase III
beclometasone Princeton, NJ (Fast Track) (609) 538-8200
(orphan drug) Sigma-Tau Pharmaceuticals (800) 447-0169
Gaithersburg, MD --------------------------------------------------------------------------------------
graft-versus-host disease (prevention) Phase II
(609) 538-8200
(800) 447-0169
--------------------------------------------------------------------------------------
acute radiation enteritis Phase I/II
(Fast Track) (609) 538-8200
(800) 447-0169
PF-4383119 Pfizer cancer pain Phase II
(tanezumab) New York, NY (860) 732-5156
74 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
c a n c e r / c H e M o t H e r a p y - r e l a t e d c o n d i t i o n s
product name sponsor indication development status
PHY-906 PhytoCeutica chemoprotection Phase I/II
New Haven, CT (203) 777-3462
prochymal® Osiris Therapeutics graft-versus-host disease Phase III
remestemcel-L Columbia, MD (Fast Track) (443) 545-1800
(orphan drug)
promacta® GlaxoSmithKline chemotherapy-induced Phase II
eltrombopag Rsch. Triangle Park, NC thrombocytopenia (888) 825-5249
reviroc™ Kiadais Pharma bone marrow transplant rejection Phase II/III
(orphan drug) St. Laurent, Canada (514) 336-4886
--------------------------------------------------------------------------------------
graft-versus-host disease Phase I/II
(514) 336-4886
rolapitant TESARO chemotherapy-induced nausea Phase II completed
Waltham, MA and vomiting (339) 970-0900
SAR411298 sanofi-aventis cancer pain Phase I
(FAAH inhibitor) Bridgewater, NJ (800) 633-1810
tapentadol Grunenthal cancer pain Phase II
controlled-release Aachen, Germany (800) 817-5286
Johnson & Johnson
Pharmaceutical Research
& Development
Raritan, NJ
tavocept™ BioNumerik chemoprotection Phase III
dimesna Pharmaceuticals (Fast Track) (210) 614-1701
San Antonio, TX (see also lung)
TH-9402 Kiadis Pharma graft-versus-host disease Phase I/II
Amsterdam, The Netherlands
TXA127 Tarix Pharmaceuticals chemotherapy-induced Phase II
Brookline, MA thrombocytopenia (617) 827-6824
voraxaze® Protherics chemoprotection application submitted
glucarpidase Brentwood, TN (615) 327-1027
(orphan drug)
Xen2174 Xenome cancer pain Phase II
Queensland, Australia
o t H e r c a n c e r s
product name sponsor indication development status
8H9 mAb United Therapeutics peritoneal cancer Phase I
Silver Spring, MD (see also brain, sarcoma) (301) 608-9292
A° 6 Angstrom Pharmaceuticals advanced gynecological cancer Phase I
Solana Beach, CA (see also ovarian) (858) 314-2356
ABT-348 Abbott Laboratories hematological malignancies Phase I
Abbott Park, IL (see also solid tumors) (847) 937-6100
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 75
o t H e r c a n c e r s
product name sponsor indication development status
ABT-888 Abbott Laboratories fallopian tube cancer, Phase II
(veliparib) Abbott Park, IL peritoneal cancer (847) 937-6100
(see also brain, breast, colorectal,
ovarian, prostate, skin)
ACE-011 Acceleron Pharma cancer metastases Phase II
(sotatercept) Cambridge, MA (see also cancer/chemotherapy) (617) 649-9200
Celgene (908) 673-9000
Summit, NJ
AEG-41174 Aegera Therapeutics hematological malignancies Phase I
Montreal, Canada (514) 288-5532
AEW541 Novartis Pharmaceuticals hematological malignancies Phase I
East Hanover, NJ (see also solid tumors) (888) 669-6682
afinitor® Novartis Pharmaceuticals neuroendocrine tumors application submitted
everolimus East Hanover, NJ (see also breast, kidney, liver, (888) 669-6682
lymphoma, pancreatic, stomach)
--------------------------------------------------------------------------------------
urogenital cancer Phase I
(888) 669-6682
allostim™ Immunovative Therapies hematological malignancies Phase I/II
Shoham, Israel
AMG 319 Amgen hematological malignancies Phase I
Thousand Oaks, CA (800) 772-6436
AMG 386 Amgen fallopian tube cancer, Phase III
Thousand Oaks, CA peritoneal cancer (800) 772-6436
(see also breast, colorectal, kidney,
liver, ovarian, stomach)
AMG 479 Amgen neuroendocrine tumors Phase II
(ganitumab) Thousand Oaks, CA (see also breast, colorectal, lung, (800) 772-6436
pancreatic, sarcoma)
antineoplaston- Burzynski Research cancer metastases Phase II
AS2-1 oral Institute (713) 335-5697
Houston, TX
AR-67 Arno Therapeutics myelodysplastic syndromes Phase II
Parsippany, NJ (see also brain) (862) 703-7170
ARQ-197 ArQule germ cell and embryonal neoplasms Phase II
Woburn, MA (see also colorectal, kidney, liver, (781) 994-0300
Daiichi Sankyo lung, pancreatic, sarcoma, solid (973) 944-2600
Parsippany, NJ tumors)
AS703026 EMD Serono hematological malignancies Phase I/II
Rockland, MA (800) 283-8088
ATI-BC-1 Algeta bone metastases Phase III
Oslo, Norway (888) 842-2937
Bayer Healthcare
Pharmaceuticals
Wayne, NJ
avastin® Genentech high-risk carcinoid tumors Phase III
bevacizumab South San Francisco, CA (see also brain, breast, colorectal, (650) 225-1000
lung, ovarian)
76 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
o t H e r c a n c e r s
product name sponsor indication development status
axitinib Pfizer thyroid cancer Phase II
New York, NY (see also kidney, lung) (860) 732-5156
AZD1152 AstraZeneca hematological malignancies Phase II
(aurora kinase Wilmington, DE (800) 236-9933
inhibitor)
AZD1480 AstraZeneca myeloproliferative diseases Phase I
Wilmington, DE (see also solid tumors) (800) 236-9933
azedra™ Molecular Insight paraganglioma, pheochromocytoma Phase II
iodine-labeled Pharmaceuticals (Fast Track) (617) 492-5554
metaiodobenzyl- Cambridge, MA (see also brain)
guanidine
(orphan drug)
BAY 94-9392 Bayer HealthCare diagnosis of cancer Phase I
Pharmaceuticals (888) 842-2937
Wayne, NJ
belinostat Spectrum Pharmaceuticals cancer of unknown primary site Phase II
Irvine, CA (949) 788-6700
TopoTarget USA (973) 895-6900
Rockaway, NJ
Bonefos® Bayer HealthCare cancer metastases application submitted
clodronic acid Pharmaceuticals (888) 842-2937
Wayne, NJ
BP-100-1.01 Bio-Path hematological malignancies Phase I
Ogden, UT (801) 580-2326
cabozantinib Exelixis medullary thyroid cancer Phase III
(XL-184) South San Francisco, CA (see also lung) (650) 837-7000
(orphan drug)
CAT-8015 AstraZeneca hematological malignancies Phase I
(anti-CD22 Wilmington, DE (800) 236-9933
recombinant MedImmune (301) 398-0000
immunotoxin) Gaithersburg, MD
catumaxomab Fresenius Biotech malignant ascites Phase II
North America (see also ovarian)
Waltham, MA
CDB-4124 Repros Therapeutics uterine leiomyoma Phase I/II
The Woodlands, TX (281) 719-3400
cell therapy Cell Medica cancer-associated with Epstein-Barr Phase II
London, United Kingdom virus infections
Center for Cell and Gene (713) 798-1246
Therapy
Houston, TX
CLT-008 Cellerant Therapies hematological malignancies Phase I
San Carlos, CA (650) 232-2122
CNTO 328 Centocor Ortho Biotech giant lymph node hyperplasia Phase II
(siltuximab) Horsham, PA (see also multiple myeloma, prostate) (800) 457-6399
CPI-613 Cornerstone Pharmaceuticals hematological malignancies Phase I
Cranbury, NJ (see also pancreatic) (609) 409-7050
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 77
o t H e r c a n c e r s
product name sponsor indication development status
CS-7017 Daiichi Sankyo thyroid cancer Phase I/II
(efatutazone) Parsippany, NJ (see also colorectal, lung) (973) 944-2600
CX-4945 Cylene Pharmaceuticals giant lymph node hyperplasia Phase I
San Diego, CA (see also multiple myeloma, (858) 875-5100
solid tumors)
dalotuzumab Merck neuroendocrine tumors Phase II completed
Whitehouse Station, NJ (see also breast, lung, pancreatic) (800) 672-6372
dcvax®-l Northwest Biotherapeutics peritoneal cancer Phase I/II
ovarian cancer Bothell, WA (see also ovarian) (425) 608-3000
vaccine
DM-CHOC-PEN Dekk-Tec central nervous system cancer Phase I
New Orleans, LA (504) 583-6135
E7050 Eisai squamous cell carcinoma Phase I/II
Woodcliff Lake, NJ (see also liver, stomach) (888) 422-4743
EC-20 Endocyte diagnosis of folate receptor- Phase II
West Lafayette, IN positive cancers (765) 463-7175
EC-145 Endocyte endometrial cancer Phase II
West Lafayette, IN (see also lung, ovarian) (765) 463-7175
EGEN 001 EGEN recurrent fallopian tube cancer, Phase II
Huntsville, AL recurrent peritoneal cancer (356) 512-0077
(see also ovarian)
ELND002 Elan hematological malignancies Phase I
Dublin, Ireland
ENMD-2076 EntreMed refractory metastatic late-stage cancer Phase I
Rockville, MD (see also multiple myeloma, ovarian) (240) 864-2600
femara® Novartis Pharmaceuticals endometrial cancer Phase II
letrozole East Hanover, NJ (888) 669-6682
FP-1039 Five Prime Therapeutics endometrial cancer Phase II
San Francisco, CA (see also solid tumors) (415) 365-5600
ganetespib Synta Pharmaceuticals hematological malignancies Phase I/II
Lexington, MA (see also breast, colorectal, lung, (781) 274-8200
stomach)
GSK2110183 GlaxoSmithKline hematological malignancies Phase I
(AKT protein kinase Rsch. Triangle Park, NC (888) 825-5249
inhibitor)
HQK-1004 HemaQuest Epstein-Barr virus-related Phase II
Seattle, WA lymphoid malignancies (206) 682-1233
IPI-493 Infinity Pharmaceuticals hematological malignancies Phase I
Cambridge, MA (see also solid tumors) (617) 453-1000
ixempra® Bristol-Myers Squibb endometrial cancer Phase II
ixabepilone Princeton, NJ (see also breast, lung, stomach) (212) 546-4000
KB004 KaloBios Pharmaceuticals hematological malignancies Phase I
South San Francisco, CA (650) 243-3100
78 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
o t H e r c a n c e r s
product name sponsor indication development status
lenvatinib Eisai thyroid cancer Phase III
(E7080) Woodcliff Lake, NJ (see also brain, kidney, liver, skin) (888) 422-4743
--------------------------------------------------------------------------------------
endometrial cancer Phase II
(888) 422-4743
MEDI-551 AstraZeneca hematological malignancies Phase I
(anti-CD19 mAb) Wilmington, DE (800) 236-9933
MedImmune (301) 398-0000
Gaithersburg, MD
MER-101 Merrion Pharmaceuticals bone metastases Phase II
(oral zoledronic Wilmington, NC (910) 799-1847
acid)
mesenchymal stem Cephalon for bone marrow regeneration in Phase II
cell therapy Frazer, PA patients undergoing bone marrow (610) 344-0200
(implant) Mesoblast transplantation in hematological (212) 880-2060
New York, NY malignancies
Mirena® Bayer HealthCare endometrial cancer Phase II
levonorgestrel- Pharmaceuticals (888) 842-2937
releasing Wayne, NJ
intrauterine system
MK-2206 Merck neuroendocrine tumors Phase II
Whitehouse Station, NJ (see also breast, colorectal) (800) 672-6372
MLN4924 Millennium Pharmaceuticals hematological malignancies Phase I
Cambridge, MA (see also solid tumors) (800) 390-5663
MLN8237 Millennium Pharmaceuticals hematological malignancies Phase II
Cambridge, MA (see also solid tumors) (800) 390-5663
MLN9708 Millennium Pharmaceuticals hematological malignancies Phase I
Cambridge, MA (see also solid tumors) (800) 390-5663
NBI-56418 Abbott uterine leiomyoma Phase I
(elagolix) Abbott Park, IL (847) 937-6100
Neurocrine Biosciences (858) 617-7600
San Diego, CA
nexavar® Bayer HealthCare thyroid cancer Phase III
sorafenib Pharmaceuticals (see also breast, colorectal, kidney, (888) 842-2837
Wayne, NJ liver, lung, ovarian) (510) 597-6500
Onyx Pharmaceuticals
Emeryville, CA
NTX-10 Neotropix neuroendocrine tumors Phase I
Malvern, PA (see also lung) (617) 460-1200
octreotide implant Endo Pharmaceuticals malignant carcinoid syndrome Phase II
Chadds Ford, PA (610) 558-9800
opaxio™ Cell Therapeutics peritoneal cancer Phase III
paclitaxel Seattle, WA (see also lung, ovarian) (800) 215-2355
poliglumex Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
OSI-906 OSI Pharmaceuticals adrenocortical carcinoma Phase III
(linsitinib) Melville, NY (see also lung, ovarian) (631) 962-2000
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 79
o t H e r c a n c e r s
product name sponsor indication development status
panobinostat Novartis Pharmaceuticals hematological malignancies Phase II
(LBH589) East Hanover, NJ (see also lymphoma, multiple (888) 669-6682
myeloma)
pasireotide Novartis Pharmaceuticals neuroendocrine tumors Phase III
(SDM230) East Hanover, NJ (888) 669-6682
--------------------------------------------------------------------------------------
meningioma Phase II
(888) 669-6682
PF-04449913 Pfizer hematological malignancies Phase I
New York, NY (860) 732-5156
PHA-848125 Nerviano Medical Sciences inoperable/unresectable thymoma Phase II
Nerviano, Italy
phenoxodiol Marshall Edwards fallopian tube cancer Phase I/II
San Diego, CA (see also ovarian, prostate) (858) 792-6300
PM-00104 PharmaMar USA endometrial cancer Phase II
Cambridge, MA (see also cervical) (617) 868-3797
PTC299 PTC Therapeutics central nervous system cancer in Phase I
South Plainfield, NJ children (908) 222-7000
(see also breast, skin, solid tumors)
Quadramet® EUSA Pharma bone metastases Phase III
samarium sm-153 Langhorne, PA (see also multiple myeloma, (800) 833-3533
lexidronam prostate, sarcoma)
injection
quarfloxin Cylene Pharmaceuticals neuroendocrine tumors Phase II
San Diego, CA (858) 875-5100
R763 Rigel Pharmaceuticals hematological malignancies Phase I
South San Francisco, CA (650) 624-1100
RG7112 Roche hematological malignancies Phase I
Nutley, NJ (see also solid tumors) (973) 235-5000
SAR245408 Exelixis endometrial cancer Phase II
(XL-147) South San Francisco, CA (650) 837-7000
sanofi-aventis (800) 633-1810
Bridgewater, NJ
SAR650984 sanofi-aventis hematological malignancies Phase I
(anti-CD38 Bridgewater, NJ (800) 633-1810
naked mAb)
seliciclib Cyclacel Pharmaceuticals nasopharyngeal cancer Phase II
Short Hills, NJ (973) 847-5955
somatuline Tercica neuroendocrine tumors Phase III
autogel® Brisbane, CA (650) 624-4900
lanreotide
S-PRAnt Bayer HealthCare uterine leiomyoma Phase I
Pharmaceuticals (888) 842-2937
Wayne, NJ
80 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
o t H e r c a n c e r s
product name sponsor indication development status
stemex® Gamida Cell hematological malignancies Phase II/III
carlecortemcel-L Jerusalem, Israel (Fast Track) (215) 591-3000
(orphan drug) Teva Pharmaceuticals USA
North Wales, PA
TAK-901 Millennium Pharmaceuticals hematological malignancies Phase I
Cambridge, MA (see also solid tumors) (800) 390-5663
tarceva® Genentech gynecological cancer, squamous Phase II
erlotinib South San Francisco, CA cell cancer (650) 224-1000
OSI Pharmaceuticals (see also bladder, brain, breast, (800) 572-1932
Melville, NY colorectal, head/neck, leukemia,
liver, lung)
terameprocol Erimos Pharmaceuticals hematological malignancies Phase I
(intravenous) Houston, TX (see also brain, cervical, head/neck, (713) 541-2000
solid tumors)
testosterone vaginal Columbia Laboratories uterine leiomyoma Phase I
Livingston, NJ (866) 566-5636
TG-02 S*Bio hematological malignancies Phase I
Redwood City, CA (650) 730-2860
tremelimumab Pfizer genitourinary cancer Phase II
(CP-675206) New York, NY (see also kidney, pancreatic, (860) 732-5156
skin, stomach)
V503 Merck vulvovaginal cancer prevention Phase III
Whitehouse Station, NJ (see also cervical) (800) 672-6372
vandetanib AstraZeneca medullary thyroid cancer application submitted
Wilmington, DE (Fast Track) (800) 236-9933
VB-111 VBL Therapeutics thyroid cancer Phase II
Or Yehuda, Israel (see also brain)
volasertib Boehringer Ingelheim urogenital cancer Phase II
Pharmaceuticals (800) 243-0127
Ridgefield, CT
Xgeva™ Amgen prevention of bone metastases in Phase III
denosumab Thousand Oaks, CA breast cancer (800) 772-6436
--------------------------------------------------------------------------------------
prevention of bone metastases in Phase III
prostate cancer (800) 772-6436
Zolinza® Merck gynecological cancer, Phase I/II
vorinostat Whitehouse Station, NJ peritoneal cancer (800) 672-6372
(see also breast, multiple myeloma)
Zybrestat™ OXiGENE thyroid cancer (combination therapy) Phase II/III
fosbretabulin South San Francisco, CA (Fast Track) (650) 635-7000
(orphan drug) (see also lung, ovarian)
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 81
u n s p e c i f i e d c a n c e r s
( d r u G s t H a t H a v e p o t e n t i a l f o r o n e o r M o r e o f t H e p r e v i o u s c a n c e r s )
product name sponsor indication development status
AFX-9901 Afecta Pharmaceuticals in clinical trials
Irvine, CA (949) 253-4688
AGS-6MF Agensys Phase I
Santa Monica, CA (800) 695-4321
Astellas Pharma US
Deerfield, IL
AMG 337 Amgen Phase I
Thousand Oaks, CA (800) 772-6436
antineoplaston- Burzynski Research Phase II
A10 IV Institute (713) 335-5697
Houston, TX
antineoplaston- Burzynski Research Phase II
A10 oral Institute (713) 335-5697
Houston, TX
ANX-514 ADVENTRX Pharmaceuticals Phase I
(docetaxel San Diego, CA (858) 552-0866
emulsion)
ARRY-300 Array BioPharma Phase I
Boulder, CO (303) 381-6600
Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
AVL-292 Avila Therapeutics Phase I
Waltham, MA (781) 891-0086
B7-2/GM-CSF NuVax Therapeutics Phase I
cancer gene therapy Tustin, CA (714) 505-4461
BMS-663513 Bristol-Myers Squibb Phase I
(anti-CD137) Princeton, NJ (212) 235-5000
CA-18C3 Xbiotech Phase I
Austin, TX (512) 386-2900
cancer compound Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
cancer compound Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
cancer compound Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
cancer compound Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
cancer vaccine Immunitor USA Phase I/II
(oral) College Park, MD (301) 476-0930
carboxy- Tactical Therapeutics Phase I
amidotriazole New York, NY (212) 651-9653
orotate (CTO)
82 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
u n s p e c i f i e d c a n c e r s
( d r u G s t H a t H a v e p o t e n t i a l f o r o n e o r M o r e o f t H e p r e v i o u s c a n c e r s )
product name sponsor indication development status
chidamide HUYA Bioscience Phase I
International (858) 798-8800
San Diego, CA (919) 998-2003
Quintiles
Rsch. Triangle Park, NC
cixutumumab Eli Lilly Phase II
Indianapolis, IN (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
CNDO-101 Coronado Biosciences Phase I
New York, NY (212) 332-1665
crenolanib AROG Pharmaceuticals Phase I
(CP-868-596) Dallas, TX (214) 593-0500
docetaxel BIND Biosciences Phase I
nanopharmaceutical Cambridge, MA (617) 419-3400
E7016 Eisai Phase I
Woodcliff Lake, NJ (888) 422-4743
E6201 Eisai Phase I
Woodcliff Lake, NJ (888) 422-4743
EC-0225 Endocyte Phase I completed
West Lafayette, IN (765) 463-7175
EVO 011 Evolve Oncology in clinical trials
New York, NY (646) 723-8941
EVO 044 Evolve Oncology in clinical trials
New York, NY (646) 723-8941
fanG™ vaccine Gradalis Phase II
(autologous tumour Carrollton, TX (214) 442-8100
cell vaccine)
fenretinide CerRx Phase I
intravenous (4-HPR) Lubbock, TX
GI-6207 GlobeImmune Phase I
Louisville, CO (303) 625-2700
GSK2126458 GlaxoSmithKline Phase I
(PI3 kinase inhibitor) Rsch. Triangle Park, NC (888) 825-5249
GSK2586881 GlaxoSmithKline Phase I
Rsch. Triangle Park, NC (888) 825-5249
hTERT cancer Merck Phase I
vaccine Whitehouse Station, NJ (800) 672-6372
(human telomerase Vical (858) 646-1100
reverse transcriptase) San Diego, CA
HuCAL-derived Centocor Ortho Biotech Phase I
antibody Horsham, PA (800) 457-6399
MorphoSys
Munich, Germany
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 83
u n s p e c i f i e d c a n c e r s
( d r u G s t H a t H a v e p o t e n t i a l f o r o n e o r M o r e o f t H e p r e v i o u s c a n c e r s )
product name sponsor indication development status
IMC-3G3 Eli Lilly Phase II
(olaratumab) Indianapolis, IN (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
IMC-18F1 Eli Lilly Phase II
(icrucumab) Indianapolis, IN (800) 545-5979
ImClone Systems
New York, NY
ISIS-EIF4ERx Eli Lilly Phase II
(eIF-4E ASO) Indianapolis, IN (800) 545-5979
Isis Pharmaceuticals (760) 931-9200
Carlsbad, CA
ixabepilone Bristol-Myers Squibb Phase I/II
(oral formulation) Princeton, NJ (212) 546-4000
LY2090314 Eli Lilly Phase II
Indianapolis, IN (800) 545-5979
LY2157299 Eli Lilly Phase I
(TGF ß inhibitor) Indianapolis, IN (800) 545-5979
LY2181308 Eli Lilly Phase II
(survivin ASO) Indianapolis, IN (800) 545-5979
Isis Pharmaceuticals (760) 931-9200
Carlsbad, CA
LY2334737 Eli Lilly Phase I
(Gem prodrug) Indianapolis, IN (800) 545-5979
LY2523355 Eli Lilly Phase I
(Eg5 inhibitor) Indianapolis, IN (800) 545-5979
LY2584702 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2603618 Eli Lilly Phase II
(ChK-1 inhibitor) Indianapolis, IN (800) 545-5979
LY2606368 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2624587 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2780301 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2801653 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2874455 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2875358 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2940680 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
84 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
u n s p e c i f i e d c a n c e r s
( d r u G s t H a t H a v e p o t e n t i a l f o r o n e o r M o r e o f t H e p r e v i o u s c a n c e r s )
product name sponsor indication development status
MK-4101 Merck Phase I
Whitehouse Station, NJ (800) 672-6372
MK-8033 Merck Phase I
Whitehouse Station, NJ (800) 672-6372
MPC-3100 Myrexis Phase I
Salt Lake City, UT (801) 214-7800
notch signalling Eli Lilly Phase I
pathway inhibitor Indianapolis, IN (800) 545-5979
NRX-4204 NuRx Pharmaceuticals Phase I
Irvine, CA (949) 336-7111
OPB-31121 Otsuka America Phase I
Pharmaceutical (800) 562-3974
Rockville, MD
OPB-51602 Otsuka America Phase I
Pharmaceutical (800) 562-3974
Rockville, MD
OVI-237 OncoVista Phase II
San Antonio, TX (210) 677-6000
oxaliplatin Mebiopharm Phase I/II
liposomal Tokyo, Japan
PBI-05204 Phoenix Biotechnology Phase I
San Antonio, TX (877) 593-8945
PF-00562271 Pfizer Phase I
New York, NY (860) 732-5156
PF-03084014 Pfizer Phase I
New York, NY (860) 732-5156
PF-04554878 Pfizer Phase I
New York, NY (860) 732-5156
PF-05212384 Pfizer Phase I
(PKI-587) New York, NY (860) 732-5156
PRT062607 Portola Pharmaceuticals Phase I
South San Francisco, CA (650) 246-7000
QBI-139 Quintessence Biosciences Phase I
Madison, WI (608) 441-2950
SAR153192 Regeneron Pharmaceuticals Phase I
(anti-DLL4 mAb) Tarrytown, NY (914) 345-7400
sanofi-aventis (800) 833-1610
Bridgewater, NJ
SAR245409 Exelixis Phase II
(XL765) South San Francisco, CA (650) 837-7000
sanofi-aventis (800) 633-1810
Bridgewater, NJ
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 85
u n s p e c i f i e d c a n c e r s
( d r u G s t H a t H a v e p o t e n t i a l f o r o n e o r M o r e o f t H e p r e v i o u s c a n c e r s )
product name sponsor indication development status
SAR307746 Regeneron Pharmaceuticals Phase I
(REGN910) Tarrytown, NY (914) 345-7400
sanofi-aventis (800) 833-1610
Bridgewater, NJ
SB1578 S*Bio Phase I
Redwood City, CA (650) 730-2860
tasisulam Eli Lilly Phase II
Indianapolis, IN (800) 545-5979
TL32711 TetraLogic Pharmaceuticals Phase I/II
Malvern, PA (610) 889-9900
V930/V932 Merck Phase I completed
(hTERT cancer Whitehouse Station, NJ (800) 672-6372
vaccine) Vical (858) 646-1100
San Diego, CA
VTX-2337 VentiRx Pharmaceuticals Phase I completed
San Diego, CA (858) 436-1530
XL999 Symphony Evolution Phase I
Rockville, MD
evolution.com
ZYC 300 Eisai Phase I
Woodcliff Lake, NJ (888) 422-4743
The content of this report has been obtained through industry sources and the Adis “R&D Insight” database
based on the latest information. report current as of March 18, 2011. The information may not be comprehensive.
For more specific information about a particular product, contact the individual company directly or go to
The entire series of Medicines in Development is available on PhRMA’s web site.
A publication of PhRMA’s Communications & Public Affairs Department. (202) 835-3460
Provided as a Public Service by PhRMA. Founded in 1958 as the Pharmaceutical Manufacturers Association.
Copyright © 2011 by the Pharmaceutical Research and Manufacturers of America. Permission to reprint is awarded if
proper credit is given.
86 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
actinic keratoses—Roughness and
thickening of the skin caused by overexposure
to the sun’s ultraviolet rays.
It can degenerate into a skin cancer
called squamous cell carcinoma.
adenocarcinoma—Malignant tumor
derived from a gland or glandular
tissue.
adjunctive treatment—An auxiliary
treatment that is secondary to the
main treatment.
adjuvant—A substance or drug that
aids another substance in its action.
allogeneic—Refers to having cell
types that are distinct and cause
reactions in the immune system.
application submitted—An application
for marketing has been submitted
by the company to the Food and
Drug Admin istra tion (FDA).
ascites—Excess fluid in the space
between the tissues lining the
abdomen and abdominal organs (the
peritoneal cavity).
basal cell cancer—Cancer of the
lower layers of the skin.
B-cell—A class of white blood cells
important to the body’s immune
system.
biliary—Relating to bile.
carcinoma—A malignant tumor that
arises from epithelial tissues, such
as skin.
cervical—Relating to the neck of
the uterus.
chemoprotection—A therapeutic
technique in which bone marrow
cells are removed from an individual
with cancer and are genetically modified
to withstand higher doses of
chemotherapy before being returned
to the donor.
cholangiocarcinoma—A malignancy
of the biliary duct system that may
originate in the liver and extrahepatic
bile ducts. More than 90 percent are
adenocarcinomas, and the remainder
are squamous cell tumors. Cholangio -
carcinomas tend to grow slowly and
to infiltrate the walls of the ducts. Each
year, approximately 2,500 cases
occur, and the average incidence is
1 case per 100,000 people per year.
cutaneous—Pertaining to the skin.
dysplasia—Abnormal tissue development.
gastric—Of or relating to the stomach.
GISTs—Gastrointestinal stromal
tumors are uncommon tumors of the
GI tract. Not all GISTs are cancerous;
some are benign. Although these
cancers can arise anywhere in the
GI tract, they occur most often in
the stomach (60% to 70%) and less
commonly in the small intestine
(20% to 30%). The rest are found in
the esophagus, large intestine, rectum,
and anus. About 80% of people diagnosed
with GIST are older than 50.
It is slightly more common in men.
Blacks are more likely to develop
GISTs than whites.
glioblastoma—A fast growing and
highly malignant type of brain tumor
arising from glial (supporting) cells
within the brain. There are about
five to 10 new cases per million
population per year in the United
States, and the cause is unknown.
glioma—A type of brain tumor arising
from the supporting glial cells within
the brain. Gliomas make up about
60 percent of all primary brain tumors
and are frequently malignant.
graft-versus-host disease
(GVHD)—A complication in bone
marrow transplants where immune
system cells attack the transplant
recipient’s tissues.
head and neck cancer—The term
given to a variety of malignant tumors
that develop in the mouth, throat,
paranasal sinuses, nasal cavity, larynx,
and salivary glands. Many authorities
also include skin tumors of the
face and neck and tumors of the cervical
lymph nodes. There are more
than half a million survivors of oral,
head, and neck cancer living in the
United States today.
hematological malignancies—
Cancers of the blood or bloodforming
tissues, such as leukemia,
Hodgkin’s and non-Hodgkin’s lymphomas,
AIDS-related malignancies,
multiple myeloma, myelodysplasia
and myeloproliferative disorders.
hepatocellular cancer/carcinoma—
A cancer that begins in the liver cells.
hyperuricemia—An abnormally high
uric acid level in the blood.
imaging agent—A substance used to
enhance x-ray images of organs and
spaces in the body.
intraepithelial neoplasia, anal (AIN)
& cervical (CIN)— AIN is a consequence
of chronic human papillomavirus
infection in the anal canal
and appears to be driven by high
viral loads of human papillomavirus.
What is known of its natural history
resembles that of cervical intraepithelial
neoplasia. Dysplasia and cervical
intraepithelial neoplasia (CIN)
are different terms or names for the
same condition—it is a precursor to
cervical cancer. CIN may be mild,
moderate or severe.
Kaposi’s sarcoma—A rare, malignant
skin tumor that occurs in some AIDS
patients. It can be accompanied by
fever, enlarged lymph nodes and
gastro intestinal problems.
leiomyoma—A benign neoplasm
derived from smooth muscle.
leukemia—A form of cancer in which
abnormally growing white blood cells
are scattered throughout the body and
bone marrow. They can take over the
marrow and prevent it from making
enough normal blood cells (white,
red and platelets), leaving the patient
highly susceptible to serious infections,
anemia and bleeding episodes.
The cells can also spill into the blood,
infiltrating and interfering with the
function of other organs. The four
main types of leukemia are: acute
lympho blastic leukemia (ALL), acute
myeloid leukemia (AML), chronic
lymphocytic leukemia (CLL), and
chronic myeloid leukemia (CML).
The acute types have a rapid onset,
and overwhelming infection or blood
loss can cause death. The chronic
forms progress much more slowly.
lung cancer—The leading cause
of cancer deaths in both men and
G l o s s a r y
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 87
women. There are several types of
lung cancer, the most common being
squamous cell carcinoma, small (oat)
cell carcinoma, adenocarcinoma and
large cell carcinoma. Each has a different
growth pattern and response to
treatment. The squamous cell, small
cell and large cell types are all strongly
associated with tobacco abuse.
lymphoma—Cancers in which the
cells of lymphoid tissue, found mainly
in the lymph nodes and spleen, multiply
unchecked. Lymphomas fall into
two categories: Hodgkin disease,
characterized by a particular kind
of abnormal cell, and non-Hodgkin
lymphomas, which vary in their
malignancy according to the nature
and activity of the abnormal cells.
Mantle cell lymphoma is a type of
non-Hodgkin lymphoma.
macroglobulinemia—A disorder in
which plasma cells produce an
excessive quantity of macroglobulins
(large antibodies) that accumulate in
the blood. It results from a group of
abnormal, cancerous lymphocytes
and plasma cells. Men are affected
more often than women, and the
average age at onset is 65.
mastocytosis—A condition characterized
by infiltration of mast cells
into the tissues of the body. Mast
cells are connective tissue cells
which release chemicals including
histamine that are very irritating and
cause itching, swelling, and fluid
leakage from cells.
medullary—Relating to the medulla
(any soft marrow-like structure, especially
the innermost part) or marrow.
melanoma—A cancer made up of
pigmented (usually brown-colored)
skin cells anywhere in the body.
mesothelioma—A tumor of the lining of
the lung and chest cavity (the pleura).
metastases/metastatic—Areas of
secondary cancer that have spread
from the primary or original cancer
site.
mucositis—The swelling, irritation,
and ulceration of the mucosal cells
that line the digestive tract. Mucositis
can occur anywhere along the digestive
tract from the mouth to the anus.
It can be a very troublesome and
painful side effect of chemotherapy.
multiple myeloma—A malignant
condition of middle to old age,
characterized by the uncontrolled
proliferation and dis ordered function
of plasma cells in the bone marrow.
The condition, which makes the
patient particularly prone to infection,
is rare, with about three new cases
annually per 100,000 population.
myeloablation—A severe form of
myelosuppression, a condition in
which bone marrow activity is
decreased, resulting in fewer red
blood cells, white blood cells, and
platelets. It is a side effect of some
cancer treatments.
myelodysplastic syndromes (MDS)—
Blood disorders that ultimately are
fatal. Patients usually succumb to
infections or bleeding. The term
“preleukemia” has been used to
describe these disorders.
neoadjuvant therapy—Chemo -
therapy, radiation therapy, or hormone
therapy given before the
primary or main treatment. Neo -
adjuvant therapy, like chemotherapy
and radiation therapy, is often given
before surgery to reduce the size of
a tumor or to make surgery less
complicated.
neuroblastoma—A tumor of the
adrenal glands or sympathetic nervous
system (the part of the nervous
system responsible for certain automatic
body functions, such as the
control of heart rate). Neuro blastomas
are the most common extracranial
(outside the skull) solid tumors of
childhood.
osteosarcoma—Cancer of the bone
that occurs predominantly in adolescents
and young adults. It accounts
for 5 percent of cancer in children
peritoneal—Relating to the peritoneum,
the membrane that lines the
abdominal cavity and covers most of
the abdominal organs.
Phase 0—First-in-human trials conducted
in accordance with FDA’s
2006 guidance on exploratory
Investigational New Drug (IND) studies
designed to speed up development
of promising drugs by establishing
very early on whether the agent
behaves in human subjects as was
anticipated from preclinical studies.
Phase I—Safety testing and pharma -
cological profiling of new drugs in
small numbers of humans.
Phase II—Effectiveness testing and
identification of side effects of new
drugs in humans.
Phase III—Extensive clinical trials
in humans to verify effectiveness and
monitor adverse reactions of new drugs.
prolactinoma—A noncancerous
pituitary tumor that produces a hormone
called prolactin, which results
in too much prolactin in the blood.
refractory—Resistant to treatment or
cure.
sarcoma—A malignant tumor that
arises from deep body tissues, such
as muscle, bone or fibrous tissue.
T-cell—One of two main classes of
white blood cells called lymphocytes,
which are important to the body’s
disease-fighting immune system.
thrombocytopenia—A reduction in
the number of platelet cells in the
blood, which causes a tendency to
bleed, especially from the smaller
blood vessels.
thymoma—Although rare, thymomas
are the most common tumor of the
thymus, a small organ located in the
upper chest just below the neck that
produces certain types of white blood
cells (lymphocytes) before birth and
during childhood. Thymomas arise
from thymic epithelial cells, which
make up the covering of the thymus.
Up to 40 percent of thymomas are
invasive. They affect men and women
equally and are usually diagnosed
between the ages of 40 and 60.
Thymomas are uncommon in children.
unresectable—Unable to be
removed (resected) by surgery.
G l o s s a r y
88 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
S E L E C T E D F A C T S A B O U T C A N C E R I N T H E
U N I T E D S T A T E S
New Cancer Cases/Deaths 1
Cancer Type Estimated 2010 New Cases Estimated 2010 Deaths
All Sites 1,529,560 569,490
Male 789,620 299,200
Female 739,940 270,290
Acute Lymphocytic Leukemia 5,330 1,420
Male 3,150 790
Female 2,180 630
Acute Myeloid Leukemia 12,330 8,950
Male 6,590 5,280
Female 5,740 3,670
S E L E C T E D F A C T S A B O U T C A N C E R I N T H E
U N I T E D S T A T E S
Overview1
• In 2010, more than 1.5 million new cancer cases were expected to be diagnosed. The National Cancer Institute
estimates that approximately 11.4 million Americans with a history of cancer were alive in January 2006. The 5-year
relative survival rate for all cancers diagnosed between 1999 and 2005 is 68 percent, up from 50 percent in the
mid-70s.
• Men have a little less than a 1 in 2 lifetime risk of developing cancer, and for women, the risk is a little more than
1 in 3. About 78 percent of all cancers are diagnosed in people ages 55 and older.
• Scientific evidence suggests that about one-third of the cancer deaths expected this year will be related to overweight
or obesity, physical inactivity, and nutrition, and thus could be prevented.
• Cancer is the second leading cause of death by disease—1 of every 4 deaths—in the United States, exceeded only
by heart disease. This year, an estimated 569,490 are expected to die of cancer, more than 1,500 people a day.
Costs1
• The National Institutes of Health estimates overall costs for cancer in 2010 at $263.8 billion: $102.8 billion
for direct medical costs (total of all health expenditures); $20.9 billion for indirect morbidity costs (e.g., cost of
lost productivity due to illness); and $140.1 billion for indirect mortality costs (cost of lost productivity due
to premature death).
Pain
• pain, which can be caused by the disease itself or by treatments, is common in people with cancer, although not
all people with cancer will experience pain. Approximately 30 percent to 50 percent of people with cancer
experience pain while undergoing treatment, and 70 percent to 90 percent of people with advanced cancer
experience pain.2
• Breakthrough cancer pain is common among people with cancer-related pain. It occurs in 50 percent – 90 percent
of oncology inpatient settings, 89 percent of home care and inpatient hospice settings, 74 percent of U.S. pain
clinics, and 33 percent of community-based oncology practices.3
• Breakthrough cancer pain is associated with higher costs for people who suffer from it compared to those who
do not, for exmple, higher hospitalization rates (36.9 percent compared to 22.5 percent) and higher estimated
annual costs of care ($1.7 million compared to $192,000).3
M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011 89
S E L E C T E D F A C T S A B O U T C A N C E R I N T H E
U N I T E D S T A T E S
New Cancer Cases/Deaths 1 (continued)
Cancer Type Estimated 2010 New Cases Estimated 2010 Deaths
Bladder Cancer 70,530 14,680
Male 52,760 10,410
Female 17,770 4,270
Bone Cancer (and joints) 2,650 1,460
Male 1,530 830
Female 1,120 630
Brain Cancer (and other nervous system) 22,020 13,140
Male 11,980 7,420
Female 10,040 5,720
Breast Cancer 209,060 40,230
Male 1,970 390
Female 207,090 39,840
Cervical Cancer/Uterine Cancer 55,670 12,160
Male — —
Female 55,670 12,160
Chronic Lymphocytic Leukemia 14,990 4,390
Male 8,870 2,650
Female 6,120 1,740
Chronic Myeloid Leukemia 4,870 440
Male 2,800 190
Female 2,070 250
Colorectal Cancer 142,570 51,370
Male 72,090 26,580
Female 70,480 24,790
Esophageal Cancer 16,640 14,500
Male 13,130 11,650
Female 3,510 2,850
Kidney Cancer (and renal pelvis) 58,240 13,040
Male 35,370 8,210
Female 22,870 4,830
Leukemia (all types) 43,050 21,840
Male 24,690 12,660
Female 18,360 9,180
Liver Cancer 24,120 18,910
Male 17,430 12,720
Female 6,690 6,190
90 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2011
S E L E C T E D F A C T S A B O U T C A N C E R I N T H E
U N I T E D S T A T E S
New Cancer Cases/Deaths 1 (continued)
Cancer Type Estimated 2010 New Cases Estimated 2010 Deaths
Lung Cancer (and bronchus) 222,520 157,300
Male 116,750 86,220
Female 105,770 71,080
Lymphoma (all types) 74,030 21,530
Male 40,050 11,450
Female 33,980 10,080
Lymphoma (non-Hodgkin’s) 65,540 20,210
Male 35,380 10,710
Female 30,160 9,500
Melanoma-Skin Cancer 68,130 8,700
Male 38,870 5,670
Female 29,260 3,030
Multiple Myeloma 20,180 10,650
Male 11,170 5,760
Female 9,010 4,890
Ovarian Cancer 21,880 13,850
Male — —
Female 21,880 13,850
Pancreatic Cancer 43,140 36,800
Male 21,370 18,770
Female 21,770 18,030
Prostate Cancer 217,730 32,050
Male 217,730 32,050
Female — —
Stomach Cancer 21,000 10,570
Male 12,730 6,350
Female 8,270 4,220 |
